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ABSTRACT OF DISSERTATION

IMPACT OF FEEDING FOODS CONTAINING INDUSTRIAL HEMP-DERIVED
CANNABIDIOL ON CANINE HEALTH AND WELL-BEING
Anecdotal evidence of beneficial behavioral and health effects of cannabidiol
(CBD) use in companion animals has amplified the need to elucidate safety and potential
impacts of CBD use. The purpose of this investigation was to determine the impact of
industrial hemp-derived CBD administration on canine health and well-being. We
hypothesized that CBD would produce beneficial effects on canine behavior without
negatively impacting animal health. Dog treats were formulated to include CBD and
shown to be palatable across a range of CBD inclusion levels. Dogs were supplemented
with CBD treats and subjected to a noise-induced fear response test to assess potential
anxiolytic effect of CBD. Behavioral response to the noise-induced fear response test was
unaffected by CBD and did not support an anxiolytic effect of CBD when supplemented
at 1.4 mg/kg BW/d. Next, triaxial accelerometers were fitted to dogs’ collars to assess the
impact of CBD treats on voluntary daily activity. While voluntary daily activity of
healthy adult dogs was unaffected by 1.8 and 4.5 mg CBD/kg BW/d, a reduction in daily
scratching suggested a potential antipruritic effect of CBD. Potential impacts on canine
health were also assessed by evaluating changes in the canine metabolome, hematology,
and serum chemistry, and immune response upon exposure to a novel antigen. The canine
metabolome, including amine/phenol, carbonyl, carboxyl, and hydroxyl metabolites, was
altered with 4.5 mg CBD/kg BW/d and suggested an impact on glucose, amino acid,
vitamin, and nucleotide metabolism. Hematological and clinical indices of health and
serum immunoglobulins (IgG and IgM) were largely unaffected by 5 mg CBD/kg BW/d;
however, elevated liver enzyme alkaline phosphatase may suggest altered liver function.
These findings may be used to formulate recommendations for CBD use in a clinical
environment, spur investigation into other potential therapeutic effects of CBD, and may
serve as a foundation for the development of regulations on CBD use, all of which are
essential to supporting the health and well-being of companion animals.
KEYWORDS: canine, cannabidiol, noise phobia, voluntary activity, metabolomics,
immunomodulation
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CHAPTER 1. INTRODUCTION
The 2018 amendment to the 2014 Farm Bill removed industrial hemp from the
Controlled Substances Act (CSA) and cannabidiol (CBD) from the Schedule I drug list,
opening up the possibility of expanding the market for and research on CBD products
derived from industrial hemp (Johnson, 2019; Mead, 2017). Just one year later, the mean
acreage devoted to hemp cultivation in the U.S. had increased by 54%, and the market for
industrial hemp-derived CBD products was approximately $1.2 billion. This market is
expected to grow to over $10 billion by 2024 (Hemp Industry Daily, 2019).
Much of this growth can be attributed to public perception of the supposed health
benefits of CBD. In a set of surveys distributed by a research group at Colorado State
University, 60-80% of over 1,500 pet owners said they were currently feeding or had
previously fed hemp or marijuana products to their dogs (Kogan et al., 2016; 2018).
These surveys provide insight on the overwhelmingly favorable perceptions of pet
owners on the safety and efficacy of CBD, though they likely over-estimate CBD use in
dogs and cats due to the surveys being shared primarily within social media groups
dedicated to cannabis use in pets. On the other hand, a survey of over 2,100 veterinarians
indicated that the majority of veterinarians are still hesitant to recommend or prescribe
CBD products to patients, either because they did not feel knowledgeable enough or they
felt that the field needed more research (Kogan et al., 2019a).
If CBD is shown to be safe and effective, it has the potential to improve the health
and well-being of companion animals. Cannabidiol is already being supplemented to
dogs for its potential therapeutic applications including, but not limited to, osteoarthritis,
separation anxiety, noise phobias, glaucoma, and epilepsy (Blessing et al., 2015; Landa et
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al., 2016). However, there is still limited in vivo work in canine models evaluating the
safety of CBD supplementation and its efficacy in generating these beneficial effects. The
literature available evaluating its therapeutic potential in osteoarthritic dogs has focused
primarily on the subjective evaluation of CBD’s effects by owners or veterinarians, with
little quantitative data to support its use (Gamble et al., 2018). Thus, despite the
overwhelming public opinion that CBD is a safe and effective treatment for the
previously mentioned diseases, there remains a substantial gap in scientific literature for
these anecdotal claims.
Therefore, the objective of this dissertation was to examine the potential impact of
oral CBD supplementation on the health and well-being of dogs. The CBD was supplied
in the form of treats, which were first assessed for palatability at increasing inclusion
levels. These treats were then supplemented to assess the potential for CBD to influence
canine behavior in both a normal, daily environment and while subject to fearful stimuli.
Additionally, alteration of the canine metabolome, potential immunomodulatory effects,
and impact on overall health indices by CBD were assessed.
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CHAPTER 2. LITERATURE REVIEW
Cannabidiol: Biosynthesis, History of Use, and Legal Status
Hemp, a variety of Cannabis sativa L., is a dioecious, annual plant that is thought
to be one of the earliest plants to be cultivated (Bonini et al., 2018; Russo et al., 2008). It
is a multi-purpose plant, with its stem a source of both cellulosic and woody fibers that
can be used to make animal bedding, textiles, paper, and more. Additionally, hemp seed
is rich in protein and omega-3 fatty acids, which may make it a valuable feed additive in
livestock and companion animal diets (Gibb et al., 2005; Skřivan et al., 2020; Zhang et
al., 2018). The female flowers produce glandular trichomes, hair-like epidermal
protrusions that cover the leaves, bracts, and stems. These trichomes are responsible for
the production and storage of secondary metabolites, including terpenoids, flavonoids,
and cannabinoids (Bonini et al., 2018; Grof, 2018; Huchelmann et al., 2017).
Cannabidiol is one of more than 100 cannabinoids produced by these glandular
trichomes. It was first isolated in 1940 and its structure was elucidated in 1963 (Adams et
al., 1940; Mechoulam and Shvo, 1963). Both CBD and ∆9-tetrahydrocannabinol (THC) –
the other primary cannabinoid produced by C. sativa – are prenylated polyketides
primarily derived from fatty acids and isoprenoids; however, their biosynthetic pathway
has only recently been elucidated, and several steps in the pathway are still under
investigation (Gagne et al, 2012; Stout et al., 2012; Taura et al., 2007). Within the
polyketide pathway, hexanoyl-CoA is produced from the short-chain fatty acid hexanoate
before being converted into olivetolic acid via polyketide synthase. Geranyl diphosphate
(GPP), a product of the 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway, is added to
olivetolic acid to produce cannabigerolic acid, the precursor for the acid forms of both
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THC and CBD (Stout et al., 2012). The concentration of cannabinoids and other
secondary metabolites produced is dependent on a number of factors, including the
different cultivars of C. sativa, whether or not the female plant has been pollinated, and
environmental conditions like humidity, soil nutrients, and temperature (Bonini et al.,
2018).
Due to both the psychoactive effects of THC and the rise of alternative sources for
industrial fibers, the production, possession, and transfer of C. sativa was first restricted
in the United States by the Marihuana Tax Act of 1937. This law required all hemp
growers to be registered and licensed (Bonini et al., 2018, USDA, 2000). In 1970, hemp
and all its products, including CBD, were classified as illegal, Schedule I drugs under the
CSA, which further restricted access to CBD (Corron and Kight, 2018; Mead, 2017).
These restrictions severely limited the potential for research on CBD and its effects on
mammalian physiological systems.
Restrictions on hemp production first began to loosen at the state level in the early
2000’s, with further federal relaxation of restrictions after the 2014 Farm Bill was
enacted. This allowed research institutions to grow “industrial” hemp for research
purposes, including the use of hemp-derived CBD (Mead, 2017). In order to be
considered industrial hemp rather than marijuana, the plant and all its products must
contain less than 0.3% THC on a dry weight basis (Johnson, 2019). Finally, in a 2018
amendment to the 2014 Farm Bill, industrial hemp was removed from the CSA entirely,
and hemp-derived CBD was removed from the Schedule I drug list of the CSA. But
THC, whether produced from hemp or marijuana, remains a Schedule I drug (Johnson,
2019; UDSA, 2000).
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Despite the relaxation of restrictions on the production and research of industrial
hemp-derived CBD, the Food and Drug Administration (FDA) still considers it illegal to
market food or dietary supplements containing CBD, even if there are no therapeutic
claims on the label (Johnson, 2019). The FDA has published several statements to the
public emphasizing the lack of scientific evidence regarding the safety, proper dosage,
and quality of products containing CBD, and they acknowledge the critical need to bridge
public perception of the therapeutic effects of CBD and the scientific literature that is
currently available (FDA, 2020; Hahn, 2020).
The Endocannabinoid System
The therapeutic potential of CBD is a major reason for the increased interest in its
use, both in humans and companion animals. It has been proposed to induce a plethora of
beneficial health effects through action on the endocannabinoid system (ECS). First
described in the early 1990’s, the ECS signaling system was discovered secondarily to
the elucidation of the structure of THC and the search for its biological target. The
discovery of the G-protein coupled receptor (GPCR) target for THC, dubbed cannabinoid
receptor 1 (CB1), during this investigation quickly led to the identification of a second
cannabinoid receptor (CB2) as well as the major endogenous ligands, or
endocannabinoids, for these receptors: arachidonoyl ethanolamide (AEA; also known as
anandamide) and 2-arachidonoyl glycerol (2-AG) (De Petrocellis and Di Marzo, 2009;
Silver, 2019). These receptors and endocannabinoids, along with the enzymes involved in
their synthesis, degradation, and regulation, make up the ECS. (Lu and Mackie, 2015;
Pacher et al., 2006; Russo et al., 2016). Additional endocannabinoids and receptors like
peroxisome proliferator activated receptors (PPARs) and transient receptor potential

5

(TRP) channels have since been shown to contribute to the widespread actions of the
ECS (De Petrocellis and Di Marzo, 2009).
The ECS has been implicated in a number of physiological processes and is
responsible for regulatory functions throughout the body, including the central nervous
system (CNS), cardiovascular system, and immune system (Burstein, 2015; Russo, 2016;
Silver, 2019). Receptor location and level of expression dictate their function. CB1
receptors, for instance, are most abundant within the CNS, particularly in the cortex,
basal ganglia, hippocampus, and cerebellum. Under normal conditions, CB1 receptors
exert a general protective or pro-homeostatic effect by helping to regulate synaptic
strength of neurons involved in cognitive, affective, and motivational processes (De
Petrocellis and Di Marzo, 2009). However, CB1 receptors are also expressed to a lesser
extent throughout the rest of the body, including, but not limited to, the enteric nervous
system, liver, and thyroid (De Petrocellis and Di Marzo, 2009; Galiazzo et al., 2018;
Pagotto et al., 2006). Conversely, CB2 receptors are primarily expressed in immune cells
like monocytes, macrophages, B-cells, and T-cells, and are in part responsible for the
regulation of cytokine and chemokine release (Vučković et al., 2018). They are also
expressed in the peripheral nervous system, the gastrointestinal tract, skin, and more
(Galiègue et al., 1995; Silver, 2019; Wright et al., 2008).
Phytocannabinoids and the Endocannabinoid System
Plant-based cannabinoids, or phytocannabinoids, like CBD and THC are
exogenous ligands for ECS receptors. For instance, THC is a high-affinity agonist for
CB1, and the psychotropic effects of THC are a result of the abundant expression of CB1
within the CNS (Lu and Mackie, 2015; Pacher et al., 2006). This effect is magnified in
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the canine nervous system as dogs have higher expression of CB1 in the brain than
humans, often leading to adverse reactions like static ataxia when a dog is exposed to
THC (Silver, 2019). Conversely, CBD has low affinity for both CB1 and CB2 receptors,
which explains its lack of psychotropic effects. It is, however, capable of acting as an
antagonist of both cannabinoid receptors when in the presence of THC as well as a noncompetitive negative allosteric modulator of CB1 (Laprairie et al., 2015; Thomas et al.,
2007). In addition to interactions with the primary cannabinoid receptors, CBD is a
known agonist or antagonist for several ECS-associated receptors, including transient
receptor potential (TRP) vanilloid receptors 1 and 2 (TRPV1 and 2), ankyrin 1 (TRPA1),
melastatin 8 (TRPM8), G protein-coupled receptor 55 (GPR55) and more (Wang and
Multhoff, 2021; Vučković et al., 2018). The potential physiological and therapeutic
effects of CBD result from the action of CBD on the various ECS-associated receptors
and interactions with endocannabinoids.
Potential Physiological Effects of Cannabidiol
Analgesic
Several ECS-associated receptors like TRPV1, serotonin (5-HT) 1A, and GPR55
are present throughout peripheral and central nervous system pain pathways (Burston and
Woodhams, 2014; Jesus et al., 2019). Cannabidiol may exert an analgesic effect either
via direct action on these receptors or indirectly by inhibiting the cellular uptake and
degradation of AEA. In rats, repeated administration of CBD was shown to attenuate
both thermal and mechanical hyperalgesia in a dose-dependent manner after either
injection of complete Freund’s adjuvant or injury to the sciatic nerve. The lower doses,
ranging from 2.5 to 10 mg/kg, CBD reduced hyperalgesia whereas the 20 mg/kg dose
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completely abolished hyperalgesia (Costa et al., 2007). As their findings saw no effect of
CB1 and CB2 receptor antagonists, it was suggested that TRPV1 was the molecular target
of this activity – either via direct action by CBD or indirect action through its effects on
AEA (Costa et al., 2004; 2007).
Anandamide is an endocannabinoid produced in response to tissue injury or
excessive pain signaling and acts on receptors to reduce pain and inflammation
(Maccarrone et al., 2015; Vučković et al., 2018). However, AEA is rapidly taken up into
cells via the anandamide membrane transporter (AMT) and degraded via hydrolysis by
fatty acid amide hydrolase (FAAH) (Hillard and Jarrahian, 2000; Ueda et al., 2000).
Cannabidiol is thought to indirectly produce analgesia by inhibiting both cellular uptake
of AEA by AMT and AEA hydrolysis by FAAH, thus prolonging the analgesic effect of
AEA (Bisogno et al., 2001).
Cannabidiol may also exert analgesic effects via activation of serotonin receptors.
Jesus et al. (2019) investigated the potential analgesic effect of intraperitoneal CBD on
pain in diabetic rats. The observed anti-allodynic effect of CBD treatment was not
blocked by selective CB1, CB2, and glycine receptor antagonists; pretreatment with a
selective 5-HT1A antagonist completely prevented the antinociceptive effect. The role of
5-HT1A receptors in the analgesic effect of CBD is supported by in vitro work
demonstrating agonistic effects on 5-HT1A receptors and inhibitory effects on serotonin
reuptake (Rock et al., 2012; Russo et al., 2005).
The analgesic action of CBD may also be modulated via action on GPR55. An
orphan receptor expressed in both central and peripheral nociceptive systems, GPR55 is
believed to help modulate pain receptor excitability (Guerrero-Alba et al., 2019; Ray et
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al., 2018). The activation of GPR55 increases intracellular Ca2+ in large dorsal root
ganglia responsible for the transmission of both proprioceptive and nociceptive peripheral
stimuli (Lauckner et al., 2008). Additionally, GPR55 activation has been shown to
produce mechanical hypersensitivity in mice (Gangadharan et al., 2013). Cannabidiol
may exert analgesic action by blocking the activation of GPR55, which has been
demonstrated both in vitro and in mouse models (Kaplan et al., 2017; Ryberg et al.,
2007).
Collectively, action on these receptors supports the analgesic potential of CBD,
for which there are many possible applications. Its analgesic effect may inhibit
mechanosensitivity of joint nociceptors, which would be useful in the management of
arthritis or other inflammatory conditions (Philpott et al., 2017). Cannabidiol may also
attenuate nociception involved with neuropathic or chronic pain, which could be used to
mitigate the pain associated with conditions like nerve injury, diabetes, or cancer
(Elikottil et al., 2013; Vučković et al., 2018). However, current in vivo work with canine
models have focused primarily on the impact of CBD on symptoms rather than
mechanisms of action (Brioschi et al., 2020; Gamble et al., 2018; Verrico et al., 2020).
Thus, the mechanism by which CBD produces the reported analgesic effects in dogs has
yet to be elucidated.
Anti-Arthritic
Arthritis is a general term encompassing more than 100 conditions in which one
or more joints are inflamed. The most common types of arthritis – osteoarthritis and
rheumatoid arthritis – are degenerative and characterized by chronic pain and
inflammation (McDougall, 2006). The ECS is known to modulate joint homeostasis
9

through CB1, CB2, and TRPV1 (Richardson et al., 2008; Schuelert et al., 2008). These
receptors are thought to be potential targets for the regulation of joint disease like arthritis
(Philpott et al., 2017). To date, there is no evidence of CBD preventing or treating any
form of arthritis. Instead, the so-called “anti-arthritic” effect of CBD is primarily
attributable to its analgesic and anti-inflammatory effects discussed in pertinent sections
of this work.
Anti-Cancer
Cancer is one of the leading causes of worldwide disease-related death; there is a
great need for anti-cancer drugs that are both well-tolerated and highly effective against
cancer cells (Siegel et al., 2020). Several ECS receptors, such as CB2, TRPV1 and 2,
TRPA1, TRPM8, and GPR55, are upregulated in cancer cells and have been shown to
modulate cellular processes involved in tumor cell growth and proliferation (Lee et al.,
2021; Wang and Multhoff, 2021). Therefore, CBD is thought to serve as an anti-cancer
agent through several potential mechanisms, including induction of cell apoptosis,
induction of autophagy, increasing sensitivity to cytotoxic therapies, and the inhibition of
cell growth and proliferation.
Cannabidiol may induce tumor cell apoptosis through several mechanisms,
including the inhibition of AKT/mammalian target of rapamycin (mTOR) signaling,
activation of pro-caspases, and increasing the production of reactive oxygen species
(ROS). Under normal conditions, the mTOR signaling pathway regulates cell growth and
division, but can lead to tumor development when abnormally activated (Zou et al.,
2020). In human breast cancer cells, CBD was shown to induce endoplasmic reticulum
stress, thereby inhibiting AKT and mTOR signaling which led to cell death (Shrivastava
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et al., 2011). In human gastric cancer and glioma cells, CBD has been shown to activate
caspases-3/8/9, which directly trigger apoptosis (Massi et al., 2006; Zhang et al., 2019).
Additionally, CBD has been shown to increase ROS production through both TRPV1 and
TRPV 2 agonism (Kis et al., 2019; Massi et al., 2006; Wang and Multhoff, 2021).
Increased ROS generation disrupts mitochondrial membrane potential, which leads to a
release of cytochrome c, another pro-apoptotic factor (Olivas-Aguirre et al., 2019;
Shrivastava et al., 2011). Remarkably, CBD did not impair normal primary glial cells
under the same conditions (Massi et al., 2006).
In addition to inducing apoptosis, CBD is also thought to exert anti-cancer effects
through the induction of autophagy. Autophagy is an intracellular degradation process
that removes misfolded or aggregated proteins and damaged organelles from cells (Lee et
al., 2021). Under normal conditions, autophagy helps maintain homeostasis, but can serve
as a tumor suppressant in the early stages of cancer development or a tumor promoter in
later stages (Amaravadi et al., 2019; Lee et al., 2021). Cannabidiol has been shown to
induce autophagy in both human breast cancer and glioma cells through action on
TRPA1 and TRPV2 (Nabissi et al., 2015; Shrivastava et al., 2011; Wang and Multhoff,
2021). Additionally, when combined with traditional cytotoxic cancer treatments,
cannabinoids have been shown to enhance autophagy and increase the uptake of those
chemotherapeutic compounds into cancer cells, suggesting a potential benefit of
combining CBD with conventional treatments (Torres et al., 2011).
Lastly, CBD may exert anti-cancer effects by inhibiting tumor cell growth and
proliferation. One potential mechanism for this antiproliferative effect is the antagonistic
action of CBD on GPR55, which is known to activate downstream proliferation pathways
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and is implicated in tumor migratory behavior (Kargl et al., 2016; Kis et al., 2019; Lee et
al., 2021). Treatment of mice pancreatic cancer cells with GPR55 antagonists, including
CBD, prevented MAPK signaling, cell growth, and cell cycle progression (Ferro et al.,
2018; Lee et al., 2021). In male mice, treatment with 1 mg/kg CBD was shown to inhibit
colon cancer cell growth (Aviello et al., 2012). In prostate cancer cell lines, CBD was
also shown to inhibit cancer cell growth, potentially due to pro-apoptotic activity
(Sharma et al., 2014; Sreevalsan et al., 2011). Another potential mechanism is CBD’s
anti-angiogenic properties. Angiogenesis, or the process of forming new blood vessels
from pre-existing ones, is essential for tumor growth and metastasis (Kis et al., 2019).
Cannabidiol has been shown to reduce growth, migration, and invasion of human
umbilical vein endothelial cells (HUVEC), a cell line commonly used for proliferation
assays as well as glioma cells in vitro (Solinas et al., 2012; 2013).
All this work points to the potential for CBD to be a potent anticancer agent.
Currently, CBD is most commonly used to alleviate symptoms of cancer treatment.
Tumor-related adverse effects were shown to be alleviated by 50-600 mg CBD/d in a
human phase I clinical trial (Good et al., 2019), and a THC/CBD combination helped
reduce pain intensity, nausea, and vomiting in patients undergoing chemotherapy
(Johnson et al., 2010). However, there is currently little clinical evidence of anticancer
effects of CBD outside of preclinical studies in cell lines and animal models, and more in
vivo research with larger samples sizes is needed.
Anti-Epileptic
Epilepsy is a chronic neurological disease characterized by the occurrence of
repeated and spontaneous seizures. In many cases, epilepsy can cause several
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comorbidities that reduce a patient’s quality of life, including cognitive deficits,
psychiatric disorders, anxiety, and depression (Boleti et al., 2020). While many forms of
epilepsy can be controlled with conventional antiepileptic medications, an estimated onethird of epileptic patients still suffer persistent seizures (Chen et al., 2018). Thus,
investigation into alternative therapies such as CBD has increased substantially in recent
years, culminating in the FDA approval of a CBD-based medication, Epidiolex®, for the
treatment of seizures associated with Dravet and Lennox-Gastaut syndromes (Boleti et
al., 2020).
There are several potential targets of CBD that may contribute to its anti-epileptic
effect. The activation of TRPV1 has been implicated in the induction of epileptic seizures
as it prompts a release of glutamate and an increase in Ca2+, resulting in neuronal
excitability (Nazıroğlu, 2015). While CBD is a known agonist of TRPV1, it acts more as
a functional antagonist, desensitizing the receptor and preventing further release of
glutamate and Ca2+ (Boleti et al., 2020; Silvestro et al., 2019). A similar mechanism of
action has been postulated for the functional antagonism of GPR55 by CBD (Gray and
Whalley, 2020; Rosenberg et al., 2015). Additionally, agonism of 5-HT1A by CBD has
been suggested to play a role through its inhibition of serotonergic neurons (Silvestro et
al., 2019; Theodore, 2003). The antiseizure effect may also involve CBD’s action on
adenosine receptors A1 and A2A. Adenosine is an endogenous compound known to
modulate neuronal excitability and is considered an endogenous anti-convulsant (Weltha
et al., 2019). Activation of adenosine receptors by either adenosine or CBD inhibit the
presynaptic influx of Ca2+, thus preventing hyperpolarization (Boleti et al., 2020; Gray
and Whalley, 2020).
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Several human clinical trials have been completed evaluating the safety and
efficacy of CBD for use in patients with epilepsy. Cannabidiol doses ranging from 5 to 50
mg CBD/kg/d have been shown to reduce seizure frequency and improve subjective
quality of life in patients ranging from infants to adults suffering from a variety of
seizure-related disorders (reviewed extensively in Silvestro et al., 2019). While CBD has
been extensively studied in these clinical trials for safety and preliminary efficacy, work
is ongoing to determine proper dosing and potential long-term psychiatric and cognitive
effects. Adverse events are also of concern considering severe adverse events were
reported in a number of these clinical trials as well as the possibility of interactions with
other anti-seizure medication (Devinsky et al., 2018; Lattanzi et al., 2020). Altogether,
CBD appears to be a promising prospect for the management of epileptic disorders.
Anti-Inflammatory and Immunomodulatory
One of the most common reasons for CBD use is its suspected anti-inflammatory
effect (Kogan et al., 2016). Inflammation is a normal but complex physiological process
in which the body responds to the presence of foreign bodies or damage by recruiting the
immune system to eliminate the threat or repair the damage. In some chronic
inflammatory disorders like osteoarthritis and rheumatoid arthritis, however, the immune
system remains active, resulting in prolonged inflammation that can eventually be
harmful to the body (Pahwa et al., 2020). Chronic inflammation is often marked by
elevated production of pro-inflammatory cytokines such as IL-1β, IL-6, IL-8, and TNFα
as well as high-sensitivity C-reactive protein and NF-κB that are produced by immune
cells as part of the immune response (Albensi, 2019; Zhang and An, 2007).
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Cannabidiol is thought to exert anti-inflammatory effects through several
mechanisms, including the reduction of pro-inflammatory cytokine production, alteration
of T cell proliferation, activation of PPARγ, and more. Activation of ECS receptors like
CB1 have been shown to stimulate the pro-inflammatory response; as a negative allosteric
modulator of CB1, CBD may inhibit their activation and downstream inflammatory
cascade (Han et al., 2009). Conversely, CBD can act as both a weak agonist and indirect
agonist of CB2 that, when activated, has been shown to decrease TNFα (Han et al., 2009;
Muller et al., 2019; Pertwee, 2008). The indirect actions of CBD on both CB1 and CB2
may thus be a mechanism by which it produced anti-inflammatory effects. Decreased
production of TNFα and other pro-inflammatory cytokines by CBD has also been shown
to be mediated by its activation of A2A receptors (Liou et al., 2008; Sunda and Arwolo,
2020), which may protect tissues from inflammation by down regulating over-reactive
immune cells (Carrier et al., 2006; Ohta and Sitkovsky, 2001). Antagonism of GPR55
(Lanuti et al., 2015) and TRP channels (Atalay et al., 2020; Bujak et al., 2019; Minke,
2006) have also been suggested to facilitate the anti-inflammatory effect, though less
studied. The anti-inflammatory effect of CBD may also be mediated by PPARγ activation
as CBD has been shown to bind to and activate PPARγ (O’Sullivan, 2016). The
inhibition of several cytokines by CBD has been shown to be PPARγ-mediated
(Rockwell and Kaminski, 2004) along with the inhibition of myeloid‐derived suppressor
cell induction (Hegde et al., 2015) and reduced expression of inflammatory proteins in
enteric glial cells (De Filippis et al., 2011), all of which may contribute to an antiinflammatory effect. Cannabidiol has also been shown in vitro to modulate T cell
proliferation through several mechanisms. Transcription of T-cell co-inhibitory
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molecules – which are known to interfere with the interaction of T cells and antigen
presenting cells required for differentiation – was enhanced by CBD treatment in
encephalitogenic memory T cells (Kozela et al., 2011; 2016). Conversely, CBD has been
shown to induce functional Tregs, which are a specialized population of T cells that
suppress the immune response (Dhital et al., 2017).
The potential anti-inflammatory effect of CBD has been demonstrated in a limited
number of studies in rats and humans. Rats with sodium monoiodoacetate-induced
osteoarthritis demonstrated reduced joint inflammation when treated with localized CBD,
and prophylactic CBD administration prevented the later development of pain and nerve
damage from osteoarthritis induction (Philpott et al., 2017). Similarly, oral CBD
administration reduced overexpression of prostaglandin E2 and nitric oxide in rats with
induced unilateral neuropathy, though NF-κB and TNFα were unaffected (Costa et al.,
2007). In a human pilot study, a single dose of oral CBD was administered, and blood
drawn over the course of 6 hours. When human peripheral blood mononuclear cells
(PBMCs) were isolated and stimulated by lipopolysaccharide, TNFα was decreased
(Hobbs et al., 2020). However, this was a small study using only a single dose and
administration of CBD. Other retrospective studies have been performed to evaluate
current use of CBD and other cannabinoids for orthopedic issues (Gusho and Court,
2020) but no other controlled clinical trials have been published regarding the use of
CBD for its anti-inflammatory effect.
While the anti-inflammatory effect of CBD has been pursued for potential
treatments against chronic inflammatory conditions like multiple sclerosis and
osteoarthritis, there is also evidence from in vitro work suggesting CBD may negatively
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impact other functions of the immune system. Notably, CBD has been shown to inhibit
IL-2, IL-10, and IFNγ production in mice (Condie et al., 1996; Jan et al., 2007). IL-2 is
an essential cytokine for the activation and differentiation of T cells as well as the
maintenance of peripheral tolerance, which is one mechanism for the regulation of selfreactive immune cells (Arenas-Ramirez et al., 2015). T cell activation is an essential
component of the T cell-dependent B cell response to antigen encounter. Without proper
levels of IL-2, T cells cannot be activated, and thus B cells are unable to undergo somatic
hypermutation and isotype switching, the processes that generate high affinity antibodies
to bind antigens (Jeurissen et al., 2004). This suppression of antigen-specific antibody
production has been observed in mice after a single intraperitoneal dose of CBD (Jan et
al., 2007).
There is also conflicting evidence regarding anti-inflammatory and
immunomodulatory effects of CBD. Several studies have demonstrated an increase in IL2 secretion through enhancement of gene transcription in activated T cells by CBD and
other cannabinoids (Chen et al., 2012; Jan et al., 2002). Jenny et al. (2009) reported a
biphasic response in human PBMCs, with CBD exhibiting a stimulatory effect at lower
doses and inhibitory effects at higher doses. Cannabidiol has also been shown, under
certain conditions, to enhance production of pro-inflammatory cytokine mRNA, thus
exacerbating lipopolysaccharide-induced inflammation in mice (Karmaus et al., 2013).
These discrepancies between responses may be dependent upon age, cell type, CBD dose,
mode of administration, magnitude of cellular activation, or other unknown factors (Chen
et al., 2012; Karamus et al., 2013). Although these immunomodulatory effects may be
beneficial in some conditions, they may also be detrimental, particularly regarding
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immune responses to antigen encounters. Continued investigation is essential to better
understand these mechanisms and to elucidate potential risks to health especially because
of the lack of in vivo studies and clinical trials.
Anti-Nausea and Anti-Emetic
Hemp has been used for centuries for its anti-nausea and anti-emetic effects
(Russo, 2007), and has recently been suggested as a management strategy for
chemotherapy-induced nausea and vomiting in cancer patients (Smith et al., 2015;
Whitling et al., 2015). Cannabidiol is believed to exert a biphasic effect on nausea and
vomiting. Low doses (2.5-20 mg/kg) of CBD have been shown to suppress toxin-induced
vomiting while higher doses (40 mg/kg) exacerbated toxin-induced vomiting in musk
shrews (Parker et al., 2004; Rock et al., 2020). One potential mechanism of action may be
reduction of the firing rate of 5-HT afferents to the terminal forebrain regions via
agonism of 5-HT1A receptors, which has been demonstrated in musk shrews and rats
(Rock et al., 2012). Alternatively, allosteric inhibition of 5-HT3A receptors may be
another mechanism of this effect. 5-HT3A antagonists are known to be highly effective
anti-nausea and anti-emetic drugs (Kaiser et al., 2004), and CBD has been shown to act
as an allosteric inhibitor of 5-HT3A receptors (Yang et al., 2010).
While there have been many clinical trials evaluating the use of cannabinoids or
synthetic cannabinoids, either by themselves or in combination with other treatments, for
nausea and vomiting, there have been no human clinical trials looking specifically at
CBD. There have been a few phase I and II safety and efficacy studies using THC:CBD
combinations (Duran et al., 2010; Mersiades et al., 2018) suggesting the combination is
well-tolerated and may help reduce chemotherapy-induced nausea and vomiting. One
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small phase II/III trial reported an association of oral THC:CBD with reduced nausea and
vomiting, though approximately one-third of the participants experienced moderate to
severe cannabinoid-related adverse events (Grimison et al., 2020). While this work is
promising, additional investigation is necessary to elucidate what role CBD may play in
this effect.
Anti-Obesity
The ECS plays a well-established role in glucose and energy metabolism.
Activation of ECS receptors have been shown to increase food intake, to activate
anabolic metabolic pathways in peripheral organs that favor energy storage, and to
enhance triglyceride accumulation in adipocytes (Boon et al., 2014; Gruden et al., 2016;
Kunos and Tam, 2011). The ECS is also known to be up regulated in metabolic disorders
like insulin resistance and type 2 diabetes and its dysregulation is thought to contribute to
the development of these disorders (Bielawiec et al., 2020; Silvestri and Di Marzo, 2013).
Consequently, cannabinoids like CBD and THC are thought to possess therapeutic
potential for these disorders.
The mechanisms by which CBD may exert an anti-obesity effect is unclear. It is
possible that CBD may exert this effect through action on PPARγ or TRPV1.
Cannabidiol is a known ligand for PPARγ, which plays an essential role in regulating
glucose homeostasis and lipoprotein metabolism (Bielawiec et al., 2020; O’Sullivan,
2016). Stimulation of PPARγ has been shown to improve glucose tolerance, insulin
sensitivity (Picard and Auwerx, 2002), and treatment with a PPARγ ligand reduced
triglyceride levels by increasing the fractional clearance rate of triglycerides from very
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low-density lipoproteins (Nagashima et al., 2005). Thus, the action of CBD on PPARγ
may play a role in its suspected anti-obesity effect; however, this effect has not been
directly investigated. TRPV1 is highly expressed on sensory nerve fibers in the pancreas
and has been implicated in diabetes and obesity. Ablation of TRPV1-positive fibers by
capsaicin has been shown to improve glucose tolerance in rat models of type 2 diabetes
and prevented immune-mediated destruction of pancreatic β-cells in mice (Gram et al.,
2007; Razavi et al., 2006). Silvestri et al. (2015), on the other hand, demonstrated a doseand time-dependent reduction in hepatocyte lipid content in vitro that was shown to be
independent of TRPV1, but their work was not able to identify a potential receptor
responsible for the effect. They do suggest that the effect may have been a result of posttranslational modifications as the expression of several proteins involved in lipid
metabolism were upregulated (Silvestro et al., 2015). Thus, mechanisms by which CBD
may exert a direct anti-obesity effect are currently unclear, and continued investigation is
necessary.
Both CBD and THC have been shown to reduce hyperglycemia and increase
insulin production in diabetic rats (Zorzenon et al., 2019). In a human pilot study, patients
with type 2 diabetes receiving 100 mg CBD daily for 13 weeks had reduced resistin – a
hormone linked to obesity and insulin resistance – compared to baseline, but there were
no other changes in response to CBD treatment (Jadoon et al., 2016). However, it is
possible these benefits of CBD may be attributable to its antioxidant and antiinflammatory effects rather than a specific anti-obesity effect. In mice with induced type I
diabetes, treatment with CBD reduced markers of inflammation in the microcirculation of
the pancreas and reduced leukocyte activation, suggesting the influence of CBD on
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diabetes and obesity may be attributed to its anti-inflammatory effect (Lehmann et al.,
2016). Additionally, in a mouse model of type I diabetic cardiomyopathy, CBD
attenuated the high glucose-induced increase in reactive oxygen species, cardiac fibrosis,
and NF-κB activation (Rajesh et al., 2010). Collectively, current evidence points to CBD
being beneficial for the management of complications associated with obesity and
diabetes, though direct evidence of an anti-obesity effect remains elusive.
Antioxidant
Closely associated with the anti-inflammatory effect of CBD is its action as an
antioxidant. Production of free radicals through aerobic metabolism is a normal
physiological process tightly controlled by a complex network of antioxidant enzymes
and molecules that remove ROS before they can damage a cell (Vertuani et al., 2004).
During periods of oxidative stress, however, ROS production exceeds removal or damage
repair by antioxidants, which can lead to permanent damage of cellular components like
DNA, lipid peroxidation, and eventually cell death (Evans and Cooke, 2004).
Cannabidiol has been shown to be a powerful antioxidant acting through direct and
indirect mechanisms.
At the most basic level, CBD acts as an antioxidant by directly interrupting free
radical chain reactions. Free radicals can be scavenged by the hydroxyl group on CBD’s
phenol ring, which then prevents further free radical propagation (Atalay et al., 2020;
Borges et al., 2013). Cannabidiol can also directly reduce ROS generation by chelating
transition metal ions involved in the production of free radicals by the Fenton reaction
(Campos et al., 2016; Hamelink et al., 2005). Lastly, CBD prevents ROS production by
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inhibiting pro-oxidant enzymes like xanthine oxidase, nitric oxide synthase, NADPH
oxidases (Costa et al., 2007; Pan et al., 2009; Rajesh et al., 2007).
Indirect mechanisms by which CBD acts as an antioxidant include activation of
PPARγ, reduction in lipid peroxidation, and enhanced expression and activity of
antioxidant enzymes. Activation of PPARγ has been shown to inhibit cyclooxygenase 2,
TNFα, IL-1, and IL-6 gene expression, and as CBD is a PPARγ agonist, it can indirectly
exert antioxidant effects through this mechanism (Atalay et al., 2020; Hou et al., 2012).
Administration of CBD also reduces lipid peroxidation, likely through its reduction of
ROS production. Reduction of lipid peroxidation by CBD has been shown in both in vitro
and rodent models by measuring malonodialdehyde (MDA) levels, which is a product of
oxidative fragmentation of lipids (Ayala et al., 2014; Sun et al., 2017). Lastly, CBD has
been shown to activate the redox-sensitive transcription factor nuclear erythroid 2-related
factor (Nrf2), which regulates transcription of antioxidant genes (Atalay et al., 2020;
Juknat et al., 2013). This activation leads to increased transcription of antioxidant
enzymes like glutathione S-transferase and superoxide dismutase (SOD), whose activity
is also increased by CBD (Jastrząb et al., 2019; Rajesh et al., 2010).
The antioxidant potential of CBD is one of the best studied. In combination with
its potential effects on inflammation, the antioxidant effects of CBD make it a strong
candidate for therapeutic use in diseases associated with oxidative stress and
inflammation such as cancer, Alzheimer’s, and diabetes mellitus. However, most of this
work has been in vitro or in rodent models. Additional work in humans and companion
animals is needed to determine if these effects translate to in vivo models and clinical
trials.
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Anti-Pruritic
Dermatologic conditions like allergic contact dermatitis, atopic dermatitis, and
psoriasis are common medical problems for both humans and companion animals. In
dogs, atopic dermatitis is one of the primary causes of pruritis and is associated with
immune and skin barrier dysfunction (Brément et al., 2019). Emerging evidence suggests
a protective role of the ECS in the skin. For instance, Campora et al. (2012) reported
elevated ECS receptor immunoreactivity in dogs with atopic dermatitis compared to
clinically normal dogs, suggesting an upregulation of these receptors due to
inflammation. While the antipruritic effect of cannabinoids has been observed in humans
and mice (Dvorak et al., 2003; Visse et al., 2017; Yuan et al., 2014), none of these studies
have evaluated CBD in vivo. Palmitoylethanolamide (PEA), for example, has been shown
to reduce itch and inflammation in mice (Vaia et al., 2016) and topical THC decreased
contact allergic swelling and myeloid immune cell infiltration in a mouse model of
allergic contact dermatitis (Gaffal et al., 2013).
While CBD has little affinity for CB1 and CB2 ECS receptors, it is a known
agonist for the TRPV family of receptors (TRPV1-4), known ECS receptors widely
expressed in the skin that are involved in itch sensation (Avila et al., 2020; Bisogno et al.,
2001; Caterina and Pang, 2016; Tóth et al., 2019). As TRPV1 is rapidly desensitized after
activation, it is thought that CBD may exert antipruritic effects by keeping TRPV1
desensitized, thus preventing neuronal activation by irritants (Imamachi et al., 2009;
Muller et al., 2019; Xie and Hu, 2018). This potential mechanism is supported by an in
vitro model of allergic contact dermatitis in which CBD elevated AEA and dose-
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dependently inhibited the release of pro-inflammatory IL-6, IL-8, and TNFα, an effect
that was reversed by both CB2 and TRPV1 antagonists (Petrosino et al., 2018).
Other potential mechanisms include action on other receptors or through genetic
regulation. CBD has been shown to be an antagonist for transient receptor potential
melastatin 8 (TRPM8) receptors (De Petrocellis et al., 2008; Muller et al., 2019). In the
skin, TRPM8 is responsible for environmental cold detection and has been suggested to
contribute to the perception of pain and itch, which may indicate it is another target for
the potential antipruritic effect of CBD (Caterina and Pang, 2016; Jankowski et al.,
2017). In an in vitro model using canine keratinocytes, CBD downregulated several genes
associated with inflammatory pathways though increased DNA methylation of key sites
(Massimini et al., 2021), which may indicate that CBD is affecting gene transcription in
addition to action on receptors. However, as this effect has not been evaluated in vivo,
more research is needed to determine if any of these mechanisms produce a
physiologically relevant response.
Anxiolytic and Antipsychotic
Cannabis has been used for centuries to treat anxiety and to improve mood
(Graczyk et al., 2021), and the ECS is known to play an essential role in the regulation of
cognitive abilities, stress, sleep, and mood (Hill et al., 2013; Morena et al., 2016). While
THC induces psychotic symptoms through its action on CB1 (D'Souza et al., 2004;
Morrison et al., 2011), CBD is a non-psychotropic that can inhibit anxiety and psychoticlike symptoms produced by THC use (Englund et al., 2013; Klein et al., 2011). Because
of this, CBD has been investigated for its therapeutic potential for a wide range of
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medical conditions, including psychiatric disorders like anxiety, schizophrenia, and
depression.
One possible mechanism by which CBD exerts antipsychotic effects is through
the inhibition of FAAH and subsequent increase in AEA. Elevated AEA is associated
with psychiatric symptom improvement (Giuffrida et al., 2004; Leweke et al., 2012), so
CBD may indirectly produce an antipsychotic effect by inhibiting AEA breakdown by
FAAH (Bisogno et al., 2001). Additionally, both CBD and AEA are agonists of TRPV1,
which plays a role in emotional and cognitive responses in the brain in addition to pain
detection (Campos et al., 2012; Nazıroğlu and Demirdaş, 2015). Anxiety was reduced in
TRPV1 knockout mice, and the desensitization of TRPV1 by either CBD or AEA may
produce a similar response (Marsch et al., 2007). The antipsychotic effect of CBD may
alternatively be a result of its action on 5-HT1A receptors (Bonaccorso et al., 2019). A 5HT1A antagonist was shown to attenuate the reduction in anxiety by CBD in rats using
contextual fear conditioning, elevated plus maze, and Vogel conflict test models (Campos
et al., 2008; Gomes et al., 2012).
In addition to the work examining CBD use as an anxiolytic and antipsychotic in
rodent models, there is also considerable evidence of this effect in humans. In human
studies evaluating the impact of CBD/THC ratios in cannabis on psychosis measures,
CBD content was inversely related to psychosis symptoms like memory impairment,
depression, and anxiety (Morgan et al., 2010; 2012) as well as age of onset of psychiatric
disorders (Di Forti et al., 2014; Iseger and Bossong, 2015). In a study of patients with
Parkinson’s disease, CBD improved psychosis scores and did not alter motor function
(Zuardi et al., 2008). In a clinical trial of CBD versus a conventional antipsychotic, CBD
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was as effective as the conventional medication in improving symptoms of schizophrenia
and displayed less side effects (Leweke et al., 2012). Additionally, CBD supplementation
was reported to attenuate the cortisol decrease associated with the circadian rhythm of the
hormone in humans (Appiah-Kusi et al., 2020; Zuardi et al., 1993), which may also
contribute to anxiolytic effects outside of its effects on cognition. Despite these
promising clinical trials, larger scale, long-term, placebo-controlled studies still need to
be conducted in the future, especially considering CBD has been proposed for use in
psychiatric issues that have not been investigated, like depression or post-traumatic stress
disorder
Sedative
The ECS has been implicated in the regulation of the circadian sleep–wake cycle
(Sanford et al., 2008; Vaughn et al., 2010) and has been suggested to be the link between
the superchiasmatic nucleus – which regulates circadian regulation systems – and
associated behavioral and physiological processes like sleep (Babson et al., 2017).
Considering approximately 10% of adults suffer from chronic insomnia and the resulting
decrease in productivity (Kuhathasan et al., 2019), the potential sedative effect of CBD
may be a therapeutic benefit if shown to aid in treatment of sleep disorders through its
actions on the ECS.
The primary mechanism by which CBD is thought to exert a sedative effect is
through inhibition of AEA transport and breakdown. Cannabidiol is thought to indirectly
enhance AEA signaling through both the inhibition of AEA uptake via anandamide
membrane transporters and prevention of AEA degradation via FAAH inhibition
(Bisogno et al., 2001; Rakhshan et al., 2000; Leweke et al, 2012). Anandamide is thought
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to promote sleep through both action on the CB1 receptor and an increase in adenosine,
which is a sleep-inducing molecule (Murillo-Rodriguez, 2008; Murillo-Rodriguez et al.,
2003; 2016). Thus, the delayed transport and degradation of AEA may result in a sedative
effect of CBD indirectly by elevating AEA levels in the brain.
Cannabidiol has been shown to have differential effects on sedation and sleep –
larger doses exerting sedative effects and low doses increasing wakefulness. In humans
and rats, CBD doses ranging from 2 to 40 mg/kg BW/d have been reported to induce
sedative effects, improve sleep quality, and increase total sleep time (Chagas et al., 2013;
Hsiao et al., 2012; Zuardi et al., 1993). In 15 patients with insomnia, 160 mg CBD/d
increased total sleep time and decreased the frequency of arousals during the night,
(Carlini and Cunha, 1981), and a long-term study assessing the effect of CBD on sleep
quality in adults found a modest improvement in sleep (Shannon et al., 2019). However,
some work has demonstrated no influence of CBD on the sleep cycle in humans (Linares
et al., 2018), and others report that CBD promotes alertness and wakefulness rather than
sedation. Nicholson et al. (2004) reported that 15 mg CBD increased wakefulness of
young adults during sleeping time, and increased alertness has been observed in rats
following CBD administration (Murillo-Rodríguez et al., 2006; 2008; 2014). These
discrepancies may be due to differences in length of CBD supplementation, small sample
sizes, route of administration, vehicle used, CBD dose, combination of CBD with other
cannabinoids, or subject species. Based on the numerous conflicting reports on the
potential sedative or wakefulness effects of CBD, it is clear that additional research is
needed in the area of CBD use for sleep disorders.
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Bioavailability, Pharmacokinetics, and Metabolism of Cannabidiol
Compared to intravenous or inhalation administration, the bioavailability of oral
CBD by itself is low, ranging from 5% to 19% due to factors such as low absorption rate
and extensive first-pass metabolism in the liver (Lim et al., 2020; Samara et al., 1988).
Variable increases in bioavailability of oral CBD have been demonstrated when
administered in lipid formulations, such as infused in oil, encapsulated, or formulated
into a chew or treat (Atsmon et al., 2018; Bartner et al., 2018; Deabold et al., 2019).
Administering CBD with a fat meal may also contribute to increased bioavailability by
increasing bile release while slowing gastric emptying and gastrointestinal motility,
which increases the time available for CBD dissolution and absorption (Lim et al., 2020;
Welling, 1996). The increase in oral bioavailability when combined with lipids may also
be a result of intestinal lymphatic absorption and transport. A study in rats demonstrated
an almost 3-fold increase in the bioavailability of oral CBD when administered in a lipidbased formulation compared to a lipid-free vehicle (Zgair et al., 2016).
Pharmacokinetic data from oral CBD administration suggests, in both human and
canine models, that the half-life of elimination (t1/2) ranges from 1 to 4 hours while the
maximal concentration (Cmax) and area under the curve (AUC) vary considerably
depending on the dose and whether the CBD was administered with food (Bartner et al.,
2018; Deabold et al., 2019; Gamble et al., 2018; Hobbs et al., 2020; Millar et al., 2018).
Major elimination pathways of CBD may include both urinary excretion and fecal
excretion via biliary secretion. In dogs, unmetabolized CBD is the predominant
compound excreted within the first several hours after administration (Samara et al.,
1990a). Once absorbed, CBD undergoes extensive metabolism in the liver by various
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cytochrome P450 enzymes, involving hydroxylation, oxidation, side-chain degradation,
and conjugation (Jiang et al., 2011; Samara et al., 1990a). Metabolites produced during
these processes differ considerably between species. In humans, major routes of
transformation include 7-hydroxylation, oxidation of C9 to the alcohol and carboxylic
acid, and side-chain oxidation (Harvey et al., 1991a, b; Huestis, 2007). In mice and rats,
hydroxylation at C2 is a major route of biotransformation alongside acid products of
beta-oxidation (Harvey et al., 1991b; Samara et al., 1991). In dogs, 6β-hydroxylation and
oxidation of resulting alcohol is the dominant oxidative pathway compared to the 7hydroxylation in humans. Additionally, side-chain hydroxylation is less extensive in dogs
than in humans (Samara et al., 1990b). Canine and human CBD metabolite production is
similar in the production of glucoside conjugates, like 6-oxo CBD, while similar
conjugates are not found in rat urine (Harvey et al., 1991a; Samara et al., 1990a). Rats
and dogs are similar in the production of acids via beta-oxidation whereas acids formed
in humans are primarily derived from side-chain degradation and 3” hydroxylation
(Harvey et al., 1991a).
Cannabidiol Use in Dogs
Cannabidiol is currently supplemented to dogs for its potential therapeutic
applications including osteoarthritis, separation anxiety, noise phobias, and epilepsy
(Kogan et al., 2018; Landa et al., 2016). Several studies have evaluated its effectiveness
in dogs with osteoarthritis (Brioschi et al., 2020; Gamble et al, 2018; Verrico et al.,
2020), behavior (Corsetti et al., 2021) and epilepsy (McGrath et al., 2019) with mixed
results. Considerable work has also been done investigating pharmacokinetics (Bartner et
al., 2018; Deabold et al., 2019; Gamble et al., 2018; Wakshlag et al., 2020) of oral CBD
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administration. However, there is still limited in vivo work in canine models evaluating
long-term safety of CBD supplementation and its efficacy in generating these beneficial
effects.
A preliminary investigation of the safety of escalating CBD doses in 20 healthy
dogs reported mild constitutional adverse events recorded for dogs receiving 1.7-64.7
mg/kg CBD oil, which included both lethargy and hyperesthesia (Vaughn et al., 2020). A
similar investigation into the safety of a 1:20 THC:CBD herbal extract reported mild
neurological adverse events, like ataxia and delayed hopping, after single and multiple
oral doses of 2 and 5 mg/kg CBD extract (Chicoine et al., 2020). While adverse events in
both studies were mild and rare, they do highlight the potential for CBD to cause
undesirable side effects as well as the need for continuing research evaluating the safety
and efficacy of CBD use in dogs.
The literature available evaluating the therapeutic potential of CBD in dogs is
sparce. Work in osteoarthritic dogs has focused primarily on the subjective evaluation of
CBD’s effects by owners or veterinarians, with little quantitative data to support its use.
In those studies, administration of either oral or transmucosal CBD oil at 2 mg/kg
increased canine brief pain inventory (CBPI) and Hudson scores in dogs with
osteoarthritis (Brioschi et al., 2020; Gamble et al., 2018), suggesting an increase in
activity and comfort with CBD use. Before this work, only one other study evaluated
behavioral effects of CBD, in which the effect of a CBD-predominant hemp extract on
aggressive behaviors was assessed in shelter dogs. Authors reported a reduction in
aggressive behaviors in dogs towards humans after treatment but no differences between
CBD and placebo, suggesting acclimation of animals to humans and the environment
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rather than a result of CBD (Corsetti et al., 2021). McGrath et al. (2019) reports the first
randomized, blinded clinical trial assessing the addition of CBD to conventional
antiepileptic treatment in dogs with epilepsy. Treatment with 2.5 mg CBD/kg reduced
seizure frequency compared to placebo, but the proportion of responders to treatment was
similar between groups. Lastly, an in vitro model of canine atopic dermatitis, a primary
cause of pruritus in dogs, demonstrated the potential for a combination of CBD and
polyphenols to modulate transcription of inflammatory genes related to atopic dermatitis
(Massimini et al., 2021).
Despite this lack of scientific evidence, use of CBD by dog owners is gaining in
popularity due to the possibility of therapeutic benefits. Some owners have turned to
hemp products because it is from a natural source versus conventional medications while
others believe hemp products to be better at managing specific symptoms than
conventional medicine (Wallace et al., 2020). Kogan et al. (2016; 2018) reported that of
dog owners who gave hemp products to their pets, most said they perceived the products
to be helpful in the reduction of symptoms associated with pain, anxiety, nausea and
vomiting, noise phobias, and more. A survey of Canadian dog owners reported that
owners generally perceived the cannabis products to be equally or more effective than
conventional medications for similar issues (Kogan et al., 2019b). Veterinarians, on the
other hand, are more hesitant to use or recommend hemp products. While the majority of
veterinarians and veterinary students responding to surveys report their hesitancy is due
to awareness of the lack of research, they still expressed positive views on the potential
benefit of the use of hemp products in animals and overwhelmingly supported continued
research in animals (Kogan et al., 2019a; Vogt et al., 2019).
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Conclusions
Despite centuries of cannabis use and favorable public opinion of CBD use for a
variety of ailments, there is limited evidence of safety or efficacy of CBD in both humans
and companion animals. While investigations into CBD effects have increased since its
removal from the CSA in 2018, evidence supporting its use is largely limited to in vitro
work, rodent models, or under-powered clinical trials. Regardless of desired effect, more
research is necessary to clarify safety of use, proper dosing, and which, if any, actions of
CBD have physiological relevance in dogs.
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CHAPTER 3. PALATABILITY OF CANNABIDIOL-CONTAINING DOG TREATS
Introduction
Palatability is the capacity of a food or ingredient to stimulate the appetite to
encourage eating and satiety. It is dependent on several factors, including formulation of
ingredients, processing method, texture, and the freshness and stability of raw materials
(Aldrich and Koppel, 2015). Additionally, palatability can be difficult to quantify as it is
individually perceived and therefore highly subjective (Tobie et al., 2015). Despite the
difficulty, assessment of food palatability is essential in the development of any new
product. It does not matter how well a product is formulated if animals will not consume
it.
In the case of CBD, there are reports of human oromucosal sprays like Sativex®
having an unpleasant taste (Lus et al., 2018). However, there is no literature available
regarding the palatability of CBD-containing canine products like treats nor their
potential effect on daily diet consumption. Therefore, the objective of this study was to
determine the palatability of dog treats formulated with increasing amounts of industrial
hemp-derived CBD and to examine the potential for CBD inclusion in treats to alter daily
food consumption. The underlying hypothesis was that inclusion of CBD in treats would
not alter food consumption nor treat consumption compared to control.
Materials and Methods
This study was approved by the Lincoln Memorial University (LMU) Institutional
Animal Care and Use Committee (IACUC) (protocol 1801-RES) before the start of the
study. All housing and husbandry received were in accordance with the Animal Welfare
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Act, the Guide for the Care and Use of Laboratory Animals (8th ed.), and all applicable
LMU standard operating procedures (SOPs).
Subjects and Housing
Twenty-four dogs (12 male, 12 female, 16.0 ± 3.6 kg BW) were received from a
local shelter for inclusion in this study. The shelter was asked to provide dogs weighing
16 ± 4 kg. Additionally, the shelter was informed and gave consent for the use of the
dogs for research purposes prior to their arrival. Prior to beginning the experiment, each
dog had a complete blood count (CBC) and serum chemistry analysis (IDEXX
Laboratories, Inc., Westbrook, ME) performed, along with physical evaluation by a
veterinarian and a fecal examination to rule out any underlying disease that might
preclude enrollment. Dogs were excluded if they demonstrated serious behavioral issues,
such as aggression that would endanger research personnel, were severely emaciated,
classified as a body condition score < 3.5 or > 7.5 on a 9-point scale (where 1 is
emaciated and 9 is obese; Laflamme, 1997), or if their initial evaluations revealed an
underlying disease that required more than routine treatments (such as heartworm
positive dogs). Three dogs were excluded for being spayed and one dog was excluded for
behavioral issues. Dogs were individually housed in 1.2 x 1.8 m kennels within one of
two dog wards at the LMU DeBusk Veterinary Teaching Center (DVTC, Ewing, VA).
Dogs were stratified by treatment and sex and evenly distributed between the two wards.
Treatments and Diets
Twenty dogs were included in this study (10 male, 10 female, 16.1 ± 3.8 kg BW)
and were stratified by weight and sex before being randomized into four treatment groups
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(n = 5 per treatment). The treatments consisted of 0, 5, 10, or 25 mg CBD/d. The CBD
was the primary constituent of a proprietary industrial hemp isolate (AgTech Scientific,
Paris, KY) that was incorporated into treats and administered in the form of 1 treat twice
daily with each treat containing half the daily dose. Treats were offered as a reward
within 30 min of a meal upon kennel re-entry following twice daily exercise, with
consumption scored for five days. Based on an average body weight, dogs received
approximately 0, 0.313, 0.625, or 1.563 mg CBD/kg BW/d.
Dogs were fed Purina Pro Plan EN Gastroenteric Dry Dog Food (Nestle Purina,
Inc., St. Louis, MO) during the initial measure and Purina Pro Plan EN Gastroenteric Wet
Dog Food during the final as these foods provide a large difference in palatability of the
basal diet. Both foods were fed to meet the daily metabolizable energy requirements of
intact adult dogs at maintenance, calculated as (70 * BW0.75) * 1.8 and split into two
meals per day.
Data Collection
Prior to scoring treat consumption for 5 days (Treatment Period), dogs were
adapted to each test food for 5 days (Adaptation Period). Daily intake of the basal food
was monitored to determine if treat consumption affected food intake. The dogs were
then adapted to the second commercial food (the canned food) for 5 days before offering
the treatment treats for 5 days and again scoring consumption.
Palatability was scored based on their consumption of each treat: Rapid, Hesitant or
No consumption. Consumption was considered “rapid” if the treat was consumed within
5 seconds of being offered and was given a numerical score of 2 for statistical analysis.
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Consumption was considered “hesitant” if the treat was consumed between 5-10 seconds
of being offered, where it was then given a numerical score of 1. Lastly, “no
consumption” was recorded if the treat was not consumed within 10 seconds of being
offered, in which case the numerical score was 0. If the treat was not consumed within 10
seconds, it was left in the dog’s food bowl until the next feeding. If the treat was still
present before the next feeding, its presence was noted, and the treat was removed prior
to receiving the next meal. Persons administering the treats were blinded as to the actual
IHE content.
Statistical Analysis
Food intake and treat consumption were analyzed using the MIXED procedure in
SAS 9.4 (SAS Institute, Cary, NC) including the fixed effects of treatment (CBD), period
(Adaptation and Treatment), and treatment by period interaction. Food intake was
assessed as mean intake per kg of metabolic body weight per day (g/kg BW0.75/d) over
each 5-d period. Treat consumption was analyzed as the mean numerical treat
consumption score (range of 0-2) over each 5-d period. Results are presented as the mean
± SE and effects were considered significant when P ≤ 0.05.
Results
Food intake was unaffected by treatment when dogs were fed either dry (31.4 ±
0.66 g/kg BW0.75/d) or wet dog food (102.9 ± 3.94 g/kg BW0.75/d; Figure 3.1; P = 0.280
and 0.669, respectively). Similarly, food intake did not differ between adaptation and
treatment periods for either the dry or wet foods (P = 0.968 and 0.500, respectively).
Cannabidiol inclusion had no effect on the consumption of treats when fed either a dry or
wet dog food (P = 0.308 and 0.571, respectively). Similarly, treat consumption did not
36

differ between adaptation and treatment periods when dogs were fed wet food (P =
0.171). However, when fed dry dog food, treat consumption was increased during the
Treatment period compared to the Adaptation period (Figure 3.2; P = 0.005).
Discussion
During the first adaptation phase of this study, when the dogs were being adapted to
the dry food diet, the control treats offered were a commercially available treat (Purina
Pro Plan Gentle Snackers). During the remainder of the study, the control treats were the
test treats prepared for the study (0 mg CBD) and were given during the Adaptation
period. The test treats were quite different from the commercial treats in smell, texture,
and taste and were extremely palatable. The consumption of the commercial treats during
the dry food adaptation phase was lower than the consumption of the test treats during the
treatment period because of the differences in the treats. There were several dogs who
refused to eat a single commercial treat but consumed every single test treat without
hesitation. During the second adaptation phase, when dogs were being adapted to the wet
food diet, the test treats were offered and no difference was found between those control
treats and the treatment treats. Additionally, as there were no differences between
treatments, there was no apparent effect of increasing levels of CBD on the palatability of
the treats when included at up to 25 mg CBD per day.
The presence of CBD in these treats also did not alter daily intake. There were no
differences in intake on a metabolic body weight basis between the different treatments,
or between the adaptation and treatment periods for both dry and wet food diets. Intake
was greater when dogs were fed wet food; however, this was likely due to the increased
intake required to meet daily dietary maintenance requirements. Wet dog foods have a
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much lower caloric density than dry dog food because of the high-water content, and as
such, larger amounts needed to be offered each day to meet requirements. Since intake
did not differ between the adaptation and treatment periods while dogs were on wet
foods, individual dog preference was potentially a more important factor affecting daily
food intake. The majority of dogs displayed no hesitation in the consumption of their
twice daily meals. A few of the dogs were picky eaters, and those few dogs were the
primary source of refusals for their treatment groups during both adaptation and treatment
periods.
It is worth noting, however, that all dogs exhibited loose stools when switched to
the strictly wet food diet, regardless of treatment. The wet dog food fed was much lower
in fiber than the dry dog food, despite being the same brand and type of food, indicating a
much more gradual adaptation to the wet food would be needed for all dogs. There were
no recorded reports of diarrhea while the dogs were receiving test treats during the dry
food treatment period, and diarrhea presented during the adaptation to the wet food
before the test treats were being administered. As such, it is unlikely that this
gastrointestinal upset was a result of the CBD supplemented in the treatment treats. It
does, however, reinforce that any change in diet should take place over a longer period of
time and should involve a slow transition from one food to another.
Conclusions
These results suggest the palatability of CBD-containing treats is comparable to
treats without CBD, and that the presence of CBD does not affect daily feed intake when
supplemented up to 25 mg CBD per day. Future studies can utilize these treats to
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examine any potential effects of CBD on various physiological processes in a canine
model.
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Tables and Figures

Figure 3.1. Mean intake (g/kg BW0.75/d) of all animals across all treatments during each
5-d adaptation and treatment period for both dry and wet food diets. Error bars represent
the standard error of the treatment mean (SEM).
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Figure 3.2. Mean treat consumption for animals across all treatments during each 5-d
adaptation and treatment period for both dry and wet food diets. Scores of 2, 1, or 0 were
assigned to each treat offering based on rapid, hesitant, or no consumption of the treat.
Asterisks above bars represent a difference in treat consumption between periods (P ≤
0.05). Error bars represent the standard error of the treatment mean (SEM).
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CHAPTER 4. THE IMPACT OF FEEDING CANNABIDIOL CONTAINING TREATS
ON CANINE RESPONSE TO A NOISE-INDUCED FEAR RESPONSE TEST
Frontiers in Veterinary Science, 2020, 7:569565
Introduction
Noise aversion or reactivity is one of the most common fearful behaviors in dogs,
with 40 to 50% of dogs demonstrating at least one fearful behavior in response to noise
exposure (Blackwell et al., 2013; Tiira et al., 2016). There is, however, considerable
variation in the behavioral responses to noise. Some dogs will reduce activity while
others become hyperactive. Some behavioral changes, such as panting and hiding, are
mild, while others, like destructiveness and self-trauma, are more extreme and potentially
hazardous to the health and well-being of both dog and owner (Sherman and Mills,
2008). Such extreme and detrimental stress associated with fear reduces overall health
and lifespan (Dreschel, 2010; Dreschel and Granger, 2005).
Despite the prevalence of noise aversion behaviors in dogs, they frequently go
untreated with less than one-third of dog owners reporting that they would seek advice
for the treatment of noise aversion (Blackwell et al., 2013). Potential treatment regimens
for various noise aversion behaviors include systematic desensitization with a compact
disk-based training system and administration of medications or natural products
(Sherman and Mills, 2008). There are several commonly prescribed drugs for the
treatment of canine behavior disorders associated with fear and anxiety, including but not
limited to benzodiazepines, selective serotonin reuptake inhibitors, and tricyclic antidepressants (Overall, 2013; Gruen et al., 2014). However, some owners may be hesitant
to administer such medications, whether due to the possibility of undesirable side effects,
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personal bias against drug use, or cost. This has led to increased interest in the use of
natural extract products to alter fearful behaviors, like dog-appeasing pheromones or oral
supplementations such as L-theanine, a tryptic hydrolysate of milk protein and fish
hydrolysate (Araujo et al., 2010; Landsberg et al., 2015; Mills et al., 2006; Palestrini et
al., 2010; Sheppard and Mills, 2003). Additionally, there has been renewed interest in the
use of cannabinoids, CBD in particular, to regulate anxiety disorders in both humans and
companion animals (Tambaro and Bortolato, 2012).
The potential anxiolytic effects of CBD have been attributed to several
mechanisms, including its activation of 5-HT1A receptors and its ability to indirectly
activate cannabinoid receptors by inhibiting the metabolism of the endocannabinoid
anandamide (Blessing et al., 2015; Lee et al., 2011). This has produced great interest in
using CBD as a potential alternative to conventional therapies to reduce anxiety. While
there is considerable work examining its use as an anxiolytic in human and rodent models
(reviewed extensively in Lee et al., 2017), this effect has yet to be examined in a canine
model. But despite the lack of evidence, canine anxiety and noise aversion are some of
the most common reasons that pet owners seek information on and administer CBD to
their pets (Kogan et al., 2019a).
The objective of this study was to evaluate the influence of CBD on behavioral
responses to fear-inducing stimuli in dogs, with the underlying hypothesis was that CBD
would reduce fearful and anxious responses. This hypothesis was tested using a fireworks
model of noise-induced fear and anxiety in which the effectiveness of CBD was assessed
by comparing CBD to both a positive and negative control and to the combination of
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CBD with the positive control. All treatments were expected to reduce fearful and
anxious responses compared to the negative control.
Materials and Methods
This study was reviewed and approved by the LMU IACUC (protocol 1811-RES)
prior to the start of the study. All housing and husbandry received were in accordance
with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals (8th
ed.), and all applicable LMU SOPs.
Subjects and Housing
Twenty-four intact, adult dogs (12 male, 12 female; 1 to 5 years old; 17.7 ± 3.9
kg) of various mixed breeds, including cur, Labrador, hound, Boxer, shepherd, dane,
Schipperkee, Springer Spaniel, and terrier mixes were received from a local shelter for
inclusion in this study. The shelter was asked to provide dogs weighing 16 ± 4 kg.
Additionally, the shelter was informed and gave consent for the use of the dogs for
research purposes prior to their arrival. Prior to beginning the experiment, each dog had a
CBC and serum chemistry analysis (IDEXX Laboratories, Inc., Westbrook, ME)
performed, along with physical evaluation by a veterinarian and a fecal examination to
rule out any underlying disease that might preclude enrollment. Dogs were excluded if
they demonstrated serious behavioral issues, such as aggression that would endanger
research personnel, were severely emaciated, classified as a body condition score < 3.5 or
> 7.5 on a 9-point scale (where 1 is emaciated and 9 is obese; Laflamme, 1997), or if
their initial evaluations revealed an underlying disease that required more than routine
treatments (such as heartworm positive dogs). Two dogs were excluded from the
experiment due to positive heartworm tests and 4 additional dogs were excluded due to
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other health or behavioral concerns. Dogs were individually housed in 1.2 x 1.8 m
kennels within one of two dog wards at the LMU DeBusk Veterinary Teaching Center.
Dogs were stratified by sex and evenly distributed between the two wards.
Diets and Treatments
Dogs were fed Purina Pro Plan EN Gastroenteric Dry Dog Food (Nestle Purina
Inc., St. Louis, MO) to meet the daily metabolizable energy requirements of intact adult
dogs at maintenance, calculated as (70 * BW0.75) * 1.8 and split into two meals fed at
approximately 0730 and 1830 h each day. Dogs were weighed and body condition scored
(5-point scale) weekly and diets adjusted accordingly. Treatments were arranged in a 2 x
2 factorial and consisted of 1) control (placebo treats), 2) 25.2 mg CBD/d, 3) Trazodone
+ 0 mg CBD, and 4) 25.2 mg CBD/d + Trazodone. Trazodone, a serotonin antagonist and
reuptake inhibitor, was dosed at 100 mg for dogs weighing 10.0-20.0 kg and at 200 mg
for dogs weighing 20.1-40 kg as recommended by the veterinarian and based on previous
work (Jay et al., 2013). Because trazodone does not require an extensive adaptation
period, trazodone tablets were dosed via a Pill Pocket (Mars Petcare US, Franklin, TN)
the evening prior and morning of the behavioral assessment.
The CBD was the primary constituent of a proprietary industrial hemp isolate
(AgTech Scientific, Paris, KY) that was incorporated into treats and administered in the
form of 2 treats daily, with each treat containing half the daily dose. Groups not receiving
CBD treatment received control treats (0 mg CBD). Both control and CBD treats were
composed of the following ingredients: chicken, chicken liver, Asian carp, catfish, and in
the case of the CBD treats, industrial hemp extract. Dosage of CBD was selected based
on previous work utilizing oral CBD in dogs (Gamble et al., 2018). CBD was the primary
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constituent of the industrial hemp extract (12.6 ± 1.2 mg/treat); no other cannabinoids
were detected in the treats. Treats were formulated to target CBD at 2 mg/kg BW/d based
on an estimation that dogs would weigh an average of 16 kg. However, based on the
mean weight of dogs included on the study, actual dosage of CBD was 1.4 mg/kg BW/d.
Treats were offered solely as a reward upon kennel re-entry following twice daily
exercise at approximately 0700 and 1800 h each day. Trazodone tablets hidden in Pill
Pockets were administered at approximately 1830 h the evening before and 1000 h the
morning of each noise-induced fear response test. Empty Pill Pockets were administered
to the control and CBD treatment groups on those days to ensure that research personnel
administering the treats were blinded as to the treatments administered.
Testing Room and Equipment
The testing room was an approximately 2.72 x 3.38 m isolation room located on
the opposite side of the building relative to where dogs were housed. The room contained
a wall-mounted table and cabinets, a set of closed metal kennels, and a cloth dog bed.
The dogs could interact with these objects, but none obstructed the dogs from view of the
cameras. Two recording cameras (Model BRC-Z700, Sony Co., New York, NY and
Model B07DQPS3KY, QallExpress International, China) were secured on opposite sides
of the room near the ceiling – approximately 2 m from the floor – to ensure the dogs
would be within sight at all times. Dogs were isolated in the testing room; handlers
monitored the dogs from the adjacent room via the cameras and could not be seen by
dogs. Two Bluetooth speakers (Bose Co., Framingham, MA) were placed on opposite
sides of the room near the cameras to create a surround-sound effect during the noise
tests. Between each dog’s test, the room was cleaned with Rescue™ Concentrate (Virox
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Animal Health, Oakville, ON, Canada), an accelerated hydrogen peroxide-based
disinfectant.
Acclimation
After intake and entrance into the study, all dogs were adapted to their
environment, diet, daily routine, and the testing room for 3 d (Table 4.1), in which the
dogs spent 6 minutes in the testing room where behavior was monitored, but not scored.
A baseline open field test followed the 3-d adaptation, where dogs were placed in the
testing room, behavior was scored, but no noise track was played (described below). The
next day, a 6-min baseline fireworks test was conducted (described below). Both the open
field test and baseline fireworks test were used solely to select dogs for inclusion in the
study. Dogs not exhibiting at least one behavioral change between the open field test and
the fireworks test, behaviors such as cowering, shaking, vocalization, destructiveness, or
tail tucking, were excluded from the study. Dogs included in the study spent 6 min in the
test room every day throughout the experiment to eliminate the possibility of behavioral
changes due to the novel environment of the test room. In order to acclimate dogs to the
testing procedure, heart rate monitors bands were placed on the dogs for each adaptation
to the test room. Additionally, blood draws were simulated on non-testing days by
restraining dogs and holding off cephalic and jugular veins prior to placing them in the
testing room. The fireworks test was conducted on the last day of each 7-d period (Table
4.1).
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Open Field and Fireworks Tests
A fireworks model of noise-induced fear and anxiety was utilized to assess the
effectiveness of the treatments. All dogs received from the shelter (n = 24) received 1
open field test and 1 baseline fireworks test. All dogs included on the study (n = 16) also
received 1 fireworks test per 7-d period (5 total fireworks tests), each lasting 6 min.
During the open field test, the dogs were placed in the testing room and their behavior
was recorded in two 3-min blocks where no fireworks track was played in order to assess
baseline behavior of dogs in the testing room. During the fireworks tests, the first 3-min
block was the same as the open field test where no noise was played (Pre-Noise), and the
fireworks track was played over a stereo speaker system (mean) during the second 3-min
block (Noise).
In previous work using this model, a thunderstorm track was utilized to test the
noise-induced fear response in dogs (Araujo et al., 2013; Landsberg et al., 2015).
However, a fireworks video (https://www.youtube.com/watch?v=5eLcHJLDlI8) was
used according to Blackwell et al. (2013) that reported a larger percentage of dogs
respond to fireworks than to thunderstorms. This noise-induced fear response test used in
this study was a modified version of the one developed and validated by Araujo et al.
(2013). They utilized a 9-min test that included a “before,” “during,” and “after”
thunderstorm time points. Because they saw no behavioral differences (i.e. near door
duration, inactivity duration) between the “during” and “after” thunder time points, the
test for this study was shortened to 6 min, ending immediately after the fireworks track
(Noise time point) ended. This allowed for the immediate post-test blood sample
collection to be obtained more quickly after the fireworks test. The mean of 90 dB was
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selected based on previous work (Araujo et al., 2013; Landsberg et al., 2015) that were
both successful in generating a response using equal or lesser decibel thunderstorm track.
Behaviors in each 3-min time block were recorded and analyzed as separate time points
(Pre-Noise and Noise).
Experimental Design
Sixteen dogs were included in this study (7 male, 9 female; 1 to 4 years old, mean
BW 18.1 ± 0.2 kg). Dogs were selected based on their behavioral response to the baseline
noise-induced fear test (described above), in which behaviors such as cowering, shaking,
vocalization, destructiveness, and tucking tail upon the start of the fireworks track
indicated the dog was reactive to noise. These behaviors were selected as they have been
previously used to assess noise reactivity (Franzini de Souza et al., 2017; Landsberg et
al., 2015; Sheppard and Mills, 2003). Included dogs were then arranged in a multiple
square, replicated 4 x 4 Latin Square design in which dogs within each square (4 dogs per
square) were randomly assigned to receive one of the four treatments each week (Periods
1 – 4). Each square was tested on successive days for scheduling purposes. Dogs received
each treatment for a 7-d period prior to each of the noise-induced fear response tests
(Table 4.1).
On testing days, all experimental procedures started at 1200 h. CBD treats were
administered approximately 4 to 6 hours prior to the test, and the morning dose of
trazodone was administered approximately 2 to 4 hours prior to the test. At the time of
the completion of this study (July 2018), there was little literature available on the
pharmacokinetics of oral CBD administration. Samara et al. (1988) reported that the halflife of IV CBD administration was 6 to 9 hours but had no estimate for an oral dose. For a
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similar dose of trazodone, Jay et al. (2013) reported a mean half-life of elimination of 166
min. No washout period was included between treatment periods. From the reported halflives of both CBD and trazodone, it was decided that the 7-d treatment period would be
sufficient to allow for elimination of previous treatments prior to the next test while also
allowing for acclimation to the next treatment. Additionally, time constraints on the
availability of the kennels in which the dogs were housed prevented the inclusion of
washout periods. Dogs received the test at the same time each week.
Because of scheduling constraints, the test started as soon as the dogs entered the
testing room on testing days. This did not allow for either HRV or behavior to return to
normal after movement from kennel to testing room. To account for this, only data from
the last minute of the Pre-Noise time point was utilized to represent the behavior and
HRV of dogs during that time point, which served as a reference of their normal behavior
prior to the fireworks track starting. Additionally, only the first minute of the Noise time
point was utilized to represent the dogs’ behavior and HRV during that time point in
order to assess the dogs’ initial reaction to the fireworks track.
Data Collection
Consumption of food and treats, consistency of stool, frequency of elimination,
activity during exercise, mucus membrane color, and other indicators of general health
status were monitored twice daily by research personnel. Evidence of any adverse event –
defined as any symptom occurrence that would not be expected in normal dogs – was
also monitored. However, no adverse events were observed in any dogs following the
administration of CBD treats during this study.
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On the day of each fireworks test, blood samples (5 mL) were collected via
jugular or cephalic venipuncture 1 h prior to testing, immediately after testing (5-10 min
after cessation of noise exposure), and again 1 h post testing for cortisol analysis. Blood
samples were collected into EDTA plasma tubes, centrifuged at 1645 x g, and stored at 80°C for later analysis. Plasma samples were analyzed in duplicate for cortisol using a
commercial radioimmunoassay kit (MP Biomedicals, LLC, Solon, OH). The sensitivity
reported for the radioimmunoassay was 1.7 ng/mL, and the intra- and inter-assay
coefficients of variation were 5.3-8.9% and 7.5-9.3%, respectively.
Polar H10 (Polar Electro Inc., Bethpage, NY) heart rate sensors were used for the
collection of heart rate (HR) and heart rate variability (HRV) parameters via Bluetooth
connection to an iPhone app (Heart Rate Variability Logger, Marco Altini). Parameters
measured are defined in Table 4.2. In general, HR will increase and HRV will decrease in
response to stressful stimuli as a result of an increase in sympathetic nervous system
activity (Kim et al., 2018). Thus, an effective treatment would be expected to decrease
HR and increase HRV, indicating higher parasympathetic activity. Just prior to the open
field and fireworks tests, the heart rate monitor bands were placed around the chest of the
dogs immediately behind the front legs, with the rubberized surface placed ventrally
immediately behind the left front leg. Electrode gel was applied liberally to the
rubberized surface of the transmitter band to promote conductivity. Due to all dogs
having short hair and the use of electrode gel, dogs did not have to be shaved to promote
conductivity.
Two cameras mounted approximately 2 m from the floor on opposite corners of
the testing room continuously recorded all video and audio data for each test. The
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duration of behaviors given in Table 4.3 were logged by a single trained observer who
was blinded to treatments using The Observer XT software (Noldus Information
Technology Inc., Leesburg, VA). Three of the dogs included on the study had docked
tails, and as such had no data on tail posture. The behaviors assessed were selected based
on behavioral measures used in previous work evaluating canine anxiety and fear
(Dreschel and Granger, 2005; Franzini de Souza et al., 2017; Korpivaara et al., 2017).
Based on these previous studies, duration of fearful behaviors such as panting, cowering,
and tail tuck were expected to increase during the fireworks test. Thus, an effective
treatment was expected to decrease the duration of such fearful behaviors. Behaviors in
different behavioral categories (i.e. Movement vs. Tail Posture) were not mutually
exclusive, whereas behaviors within a behavioral category were mutually exclusive.
Statistical Analysis
The normality of data distribution was tested using the UNIVARIATE procedure
in SAS 9.4 (SAS Institute, Cary, NC) on the residual of the data. In instances where data
did not meet normality assumptions, statistical analysis was performed on the natural
logarithm transformation of the data. However, data were then back transformed for
reporting purposes. The standard error of the back transformed data was calculated from
the confidence limits of the transformed data as follows: SEM = (back-transformed upper
limit – back-transformed lower limit)/3.92. The denominator relates to the Z-value of a
95% confidence interval (± 1.96). Cowering, pacing, destruction, tail wagging, tail
tucked, and all muzzle behaviors could not be analyzed due to insufficient occurrences
that prevented data from meeting normality assumptions. With the exception of HR,
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pNN50, and HF, parameters were not normally distributed and were analyzed using the
natural logarithm of the data.
Blood cortisol was then analyzed using the MIXED procedure in SAS including
the fixed effects of CBD, trazodone, period (Weeks 1 – 4), time (-60, 0, and 60 min), the
interaction of CBD and trazodone, and the interaction of CBD by trazodone by time.
Random effects included square and dog nested within square and repeated effect of time.
All behavioral and HRV data from the 1-min immediately prior to (Pre-Noise) and the
first min of the noise-induced fear response test (Noise) were also analyzed using the
MIXED procedure in SAS including the fixed effects of CBD, trazodone, period (Weeks
1 – 4), time (Pre-Noise and Noise), and all accompanying interactions. Random effects
included square and dog nested within square and repeated effect of time. Effects were
considered significant when P ≤ 0.05 and considered a tendency when P ≤ 0.10.
Results
Blood Cortisol
There was an overall effect of period on blood cortisol (P = 0.024). Blood cortisol
was reduced in period 1 compared to both periods 3 and 4 (P = 0.003 and 0.003,
respectively), but was similar across all other periods (P > 0.05). Blood cortisol was
unaffected by time of collection and CBD (P = 0.189, 0.104, respectively). Similarly,
neither the CBD x trazodone, time x CBD, time x trazodone, nor the time x CBD x
trazodone interactions affected blood cortisol (P = 0.238 0.772, 0.667, and 0.812,
respectively). However, trazodone lowered overall blood cortisol concentrations (Figure
4.1; P < 0.0001).
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Heart Rate and Heart Rate Variability
There was a period effect on both HR and AVNN (Table 4.4; P = 0.005 and
0.046, respectively). Heart rate in period 4 tended to be lower than in period 1 (P =
0.075) and was lower than in periods 2 and 3 (P = 0.004 and 0.001, respectively). Heart
rate was similar between periods 1, 2, and 3 (P > 0.05). The mean beat-to-beat intervals
(AVNN) was increased in period 4 compared to all other periods (P = 0.021, 0.018, and
0.030, respectively), but was similar between all other periods (P > 0.05). All other HR
and HRV variables were unaffected by period (P > 0.05).
With the exception of SDNN and RMSSD, HR and all other HRV variables were
affected by the time point (Pre-Noise vs. Noise) (Table 4.4; P < 0.05). HR was lower
during the Pre-Noise time point compared to the Noise time point (P < 0.001), while
HRV parameters affected by time – AVNN, pNN50, LF, and HF – were all higher during
the Pre-Noise time point than the Noise time point (P < 0.05). The LF/HF ratio tended (P
= 0.053) to be higher in the Pre-Noise time point compared to the Noise time point.
CBD tended to increase overall HR (Table 4.4; P = 0.093) and decreased LF
regardless of time point (P = 0.011). All treatments reduced HF compared to control (P <
0.05). AVNN, SDNN, RMSSD, and pNN50 were unaltered by CBD and trazodone (P <
0.05). No HRV variables were affected by the CBD by time nor the trazodone by time
interaction (P > 0.05). The CBD by trazodone by time interaction influenced the LF/HF
ratio (P = 0.039). During the Pre-Noise time point, trazodone tended (P = 0.061) to
increase the LF/HF ratio compared to control and increased the LF/HF ratio compared to
the combination of CBD and trazodone (P = 0.038). During the Noise time point, the
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combination of CBD and trazodone tended (P = 0.083) to reduce the LF/HF ratio
compared to control.
Behavior
There were no period effects on any behavioral variables (Table 4.5; P > 0.05).
With the exception of Facing Door and Tail Relaxed, all other behaviors were affected by
time point (Pre-Noise vs. Noise; P < 0.05). During the Noise time point, duration of
inactivity (P = 0.011), Glancing Around (P < 0.001), and Ears Moving (P < 0.001) were
increased compared to their duration during the Pre-Noise time point. Conversely, the
duration of Other Eyes, Ears Relaxed, Ears Erect, and Tail Stiff were reduced during the
Noise time point compared to the Pre-Noise time point (P < 0.05). Across both time
points, dogs fed CBD tended (P = 0.072) to spend less time focused on something in the
room (Other Eyes). Conversely, trazodone increased overall duration of Other Eyes (P =
0.044) and time spent with Tail Relaxed (P = 0.001), but CBD did not alter tail posture (P
= 0.753). No behavioral variables were affected by the CBD by time nor the trazodone by
time interaction (P > 0.05).
These changes between the Pre-Noise and Noise time points may indicate that the
fireworks test generated the desired fearful behavioral response. However, the behaviors
Glancing Around and Ears Moving could be considered a normal response to hearing a
loud noise and may not necessarily indicate a fearful response to the noise. However,
since the common fearful behaviors measured – cowering, pacing, vocalizations, etc. –
could not be analyzed due to insufficient occurrences, it is difficult to determine if the
fireworks test was severe enough to generate a fearful response.

55

Discussion
Since the passage of the Agriculture Improvement Act of 2018, which removed
industrial hemp from the Controlled Substances Act and removed CBD from the
Schedule I drug list, the market for industrial hemp-derived CBD has be able to expand
considerably (Johnson, 2019). Just one year after the act passed, the market was
estimated to be $1.2 billion and is expected to grow to over $10 billion by 2024 (Hemp
Industry Daily, 2019). Much of this growth can be attributed to public perception of the
supposed health benefits of CBD, including analgesic, antioxidant, anti-inflammatory,
and anti-anxiety effects. However, despite general public opinion that CBD is a safe and
effective treatment for these conditions, the lack of scientific clarity on the safety, dosage,
and efficacy of CBD makes it critical for continued research in both humans and
companion animals.
The present study is one of the first to describe the effect of CBD on the fear and
anxiety response of dogs. The fear-response test was developed and validated by Araujo
et al. (2013), in which dogs were placed in the test room for 9 min and a thunderstorm
track was played from 3-6 min. A modified version of this test was used in the current
study, with a fireworks track being used instead of a thunderstorm track as previous
literature has shown a greater percentage of dogs to be fearful of fireworks than of
thunderstorms (Blackwell et al., 2013). Additionally, because Araujo et al. (2013) saw no
behavioral differences during the “after thunder” time period, the test for this study was
shortened to 6 min, ending immediately after the fireworks track ended. This allowed for
the immediate post-test blood sample collection to be obtained within 10 min of the end
of the fireworks test.

56

If cortisol concentrations had decreased with each subsequent period of the
experiment, it would have been an indication that the dogs were adapting to the sound
stimulus. While there was a period effect on cortisol, it was due to cortisol in periods 3
and 4 being increased compared to period 1. This may indicate a heightened response to
the sound stimulus upon repeated exposure, which suggests that the dogs were being
conditioned to be stressed in the testing room despite being placed in the room on nontesting days to avoid such conditioning. The potential for conditioned place aversion is a
limitation of the crossover design used in this study. It may be beneficial in future work
to either include washout periods or utilize a different design to reduce the number of
tests administered to each dog to prevent this conditioning; however, the latter would
require a larger sample size than is needed when using a Latin Square design.
The lack of a time effect on blood cortisol concentration was also unexpected. It
is possible that cortisol concentrations did not change because the fireworks test may not
have produced a sufficient change in fear or stress in these dogs. However, Landsberg et
al. (2015) demonstrated that the use of a thunderstorm noise-induced fear response test –
also averaging 90 dB – resulted in a time-dependent change in blood cortisol, with higher
concentrations 5 min post-test compared to 1 hour pre- and post-test samples. This time
effect was not replicated in this study. Instead, cortisol concentrations decreased at each
subsequent timepoint, though not enough to produce an overall effect of time. Other
studies have also demonstrated that blood and saliva cortisol concentrations peak
between 5 and 20 minutes after noise exposure and begin to decline as early as 30
minutes post-exposure (Franzini de Souza et al., 2017; 2018; Hydbring-Sandberg et al.,
2004). For this study, while the blood sample taken immediately after the test was taken
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within this window, it is possible that cortisol levels had not yet peaked after noise
exposure. It would be beneficial in future work to take additional blood samples
throughout the first hour after noise exposure to better show cortisol changes after noise
exposure. Alternatively, it is also possible that the lack of time effect on cortisol may
have been due to elevated initial stress due to the use of shelter animals. Franzini de
Souza et al. (2017) demonstrated differences in endocrine and behavioral responses
between laboratory and companion dogs in response to sound stimuli. While shelter
animals were not represented in that study, it is possible that increased stress from the
shelter environment, transport, and new environment could impact cortisol concentrations
and warrants further investigation.
It is also possible that the time of testing influenced cortisol concentrations.
Kolevská et al. (2003) showed that dogs not undergoing an exercise regimen had the
highest blood cortisol concentrations between 1000 h and 1300 h and the lowest
concentrations between 1600 h and 1900 h. A similar pattern was seen in this experiment,
with the highest cortisol concentrations at the 60-min pre-test sample, which would have
been taken between 1200 h and 1400 h, and the lowest concentrations at the 60-min posttest sample period, which would have been taken between 1400 h and 1600 h. While
blood cortisol concentrations in samples taken from 1300 h to 1600 h were lower than
those taken between 1000 h and 1300 h (Kolevská et al., 2003), that effect was not seen
in this study. This could indicate that the noise-induced fear response test did in fact
affect blood cortisol concentrations, maintaining the elevated levels through the afternoon
rather than the normal drop expected from the circadian rhythm of the hormone. These
results warrant further investigation, and future work should consider administering the
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noise test earlier in the day to account for possible influence of the circadian rhythm of
cortisol.
In humans, trazodone has been shown to decrease plasma cortisol concentrations
compared with placebo and is commonly prescribed for the treatment of anxiety,
depression, and to facilitate sleep (Gruen et al., 2014; Monteleone, 1991). While
trazodone is not currently labeled for use in dogs, off-label use of trazodone is common
for the treatment of anxiety disorders as well as to reduce the agitation and distress
associated with post-surgery confinement and reduced exercise (Chea and Giorgi, 2017;
Gruen and Sherman, 2008). In this experiment, treatment with trazodone lowered blood
cortisol concentrations compared to all other treatments. On the other hand, CBD did not
alter plasma cortisol concentrations compared to control in this experiment. In humans,
CBD administration has been shown to attenuate the cortisol decrease associated with the
circadian rhythm of the hormone (Appiah-Kusi et al., 2020; Zuardi et al., 1993). While
other anxiolytic supplements seem to reduce anxiety in dogs at least in part by reducing
the cortisol response to stressors (Landsberg et al., 2015), the results of this study may
suggest that CBD does not exert an anti-anxiety effect by lowering blood cortisol
concentrations. However, Hurd et al. (2019) demonstrated a decrease in salivary cortisol
when CBD was dosed to humans at ~5 and 10 mg/kg BW, which may indicate that the
CBD dosage selected for this study (1.4 mg/kg BW) was too low to exert an effect on
cortisol.
Another possibility is that CBD was administered too early the day of the
fireworks test. Recent work with other oral CBD products with similar dosages to this
study demonstrated the time of maximum CBD concentration to be around 1.5 hours after
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administration and the half-life of elimination to be between 1 and 4 hours (Bartner et al.,
2018; Deabold et al., 2019; Gamble et al., 2018). However, at the time this study was
completed (July 2018), these works on CBD pharmacokinetics had not yet been
published, and earlier literature (Samara et al., 1988) reported much longer half-life for
IV administration of CBD. This resulted in CBD treats being administered between 4 and
6 hours prior to the test in this study. In the future, it may be necessary to administer
treatments within 2 hours of the noise test in order for CBD to have the greatest effect.
This was accounted for in the administration of trazodone, as Jay et al. (2013) reported
that the same dose of oral trazodone had a mean half-life of 166 min in dogs.
Even if CBD was administered too early to exert an anxiolytic effect, CBD did
appear to inhibit the ability of trazodone to lower blood cortisol in the combination
treatment compared with trazodone alone. This observation may support previous work
that shows CBD to be a potent inhibitor of the cytochrome P450 family of enzymes,
which is responsible for the metabolism of trazodone to its active metabolite, mchlorophenylpiperazine, in the liver (Rotzinger et al., 1998; Yamaori et al., 2011).
Several studies have highlighted these potential CBD-drug interactions as well as the lack
of information regarding CBD doses that can be deemed safe for use – whether
administered alone or in combination with other medications (Ewing et al., 2019; Foster
et al., 2019; Iffland and Grotenhermen, 2017; Zendulka et al., 2016). The potential
interaction between CBD and trazodone demonstrated in this study lends support to these
concerns. While there has been some work investigating specific CBD-drug interactions
(Manini et al., 2015), it may be inadvisable to administer CBD concomitantly with other
products or medications until these interactions are more fully elucidated.
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In agreement with previous work in both dogs and other species, oral CBD
administration in this experiment was well-tolerated. No gastrointestinal or constitutional
adverse events were observed in dogs receiving CBD during this study. Additionally,
food consumption and body weight remained consistent throughout the experiment.
However, other studies evaluating the safety of oral CBD administration in dogs have
reported the potential for adverse events, including lethargy, gastrointestinal issues such
as vomiting or diarrhea, and hematological changes such as increases in liver enzymes
(Deabold et al., 2019; Gamble et al., 2018; McGrath et al., 2018; Vaughn et al., 2020).
However, aside from initial bloodwork evaluated upon animal intake from the shelter,
hematological changes were not evaluated during this experiment. As increases in liver
enzymes may be indicative of altered liver function, the potential effects of oral CBD
administration on clinical chemistry parameters should be monitored in future work.
Heart rate variability has been used as a measure of stress and anxiety in a number
of animal species, including dogs. In particular, considerable work has been done using
HRV as an indicator of canine fear and anxiety in response to stressful stimuli, in which
HRV generally decreases and HR increases when animals are under stress, indicating
impaired parasympathetic function and autonomic nervous system dysregulation (Craig
et al., 2017; Gácsi et al., 2013; Wormald et al., 2017). The results of this study concur,
showing increased HR and decreased HRV – AVNN, pNN50, LF, and HF – during the
fireworks stimulus compared to the Pre-Noise time point when no sound was played. As
AVNN represents the interval between heart beats, the decrease in AVNN was expected
alongside the increase in HR during the fireworks stimulus. The pNN50 is thought to
relate to parasympathetic activity and was also expected to decrease with increased stress
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from the fireworks stimulus (Kim et al., 2018; Shaffer and Ginsberg, 2017). The low
frequency band (LF) mainly reflects baroreceptor activity in the heart while at rest, but
can be generated by parasympathetic, sympathetic, or baroreceptor activity depending on
the situation. Unlike other HRV parameters, the LF band is expected to increase with
stress as an increase in baroreceptor activity would be expected to accompany a rise in
blood pressure (Kim et al., 2018; McCraty and Shaffer; 2015). This was not replicated in
this study, where LF actually decreased during the fireworks stimuli. The high frequency
band (HF), or respiratory band, corresponds to heart rate variations related to the
respiratory cycle. Unlike LF, HF only reflects parasympathetic activity, and lower HF is
correlated with stress and anxiety (Grossman and Taylor, 2007; Thayer et al., 2010).
Because LF can be influenced by both sympathetic and parasympathetic activity while
HF is only produced by parasympathetic activity, the LF/HF ratio has been used as a way
to estimate sympathetic versus parasympathetic activity (Shaffer et al., 2014). An
increased LF/HF ratio is thought to indicate higher sympathetic drive, which would be
expected when exposed to stressful stimuli and has been demonstrated in dogs exposed to
sound stimuli (Franzini de Souza et al., 2017; 2018; Maccariello et al., 2018). In this
study, however, the LF/HF ratio tended to be reduced during the fireworks track
compared to the Pre-Noise time point. This, combined with the reduction in LF, may
indicate that the fireworks track was not sufficient to cause a fearful or stress response.
Additionally, the fireworks tract did not alter SDNN nor RMSSD in this study.
The standard deviation of interbeat-intervals (SDNN) measures how interbeat-intervals
change over time and has been shown to be reduced by stress (Kim et al., 2018; Schaffer
and Ginsberg, 2017). As such, SDNN is generally measured over a 24 h collection
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period, though short-term periods have also been used to evaluate short-term variability
(Baek et al., 2015; Katayama et al., 2016). The RMSSD reflects beat-to-beat variance and
is used to estimate vagally mediated changes in HRV, which reflects self-regulatory
capacity (Shaffer et al., 2014). Reduced RMSSD has been associated with smoking, high
LDL cholesterol, and work stress in humans and has been shown to be reduced in soundsensitive dogs in response to sound exposure (Franzini de Souza et al., 2018; Thayer et
al., 2010). As some of the findings of this study concur with previous work and other
results conflict with what was expected upon exposure to fireworks, it is possible that the
fireworks test was not successful in generating the desired fearful response. However,
some of this conflicting evidence may be a result of the ultra-short time frame used for
recording HRV, particularly for some variables that are more commonly measured over
longer time periods. Future work should consider recording HRV over longer time
frames in order to better assess changes. Only HR and AVNN were affected by the period
of the experiment, where HR was reduced in period 4 and AVNN was increased in period
4 compared to all other periods. This may suggest that the dogs were acclimating to the
fireworks stimulus, a limitation to this study design. Future work should consider either
washout periods or a study design that does not require multiple noise-induced fear
response tests in order to avoid this problem.
To our knowledge, no work has been done to evaluate the effect of CBD or
trazodone administration on HRV in dogs, though there is some evidence that CBD may
improve HRV in healthy humans (Schmid et al., 2010). Since an increase in stress and
anxiety due to sound stimuli has been shown to increase HR, LF, and the LF/HF ratio
while decreasing RMSSD, and HF (Franzini et al., 2017; 2018; Maccariello et al., 2018),
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it was expected that both CBD and trazodone would attenuate these changes. In contrast
to these expectations, both LF and HF were decreased by CBD in this study compared to
control. Conversely, CBD tended to increase HR, while SDNN, RMSSD, and pNN50
were unaffected by treatment. While the reduction in LF would indicate that CBD
attenuated the increase in cardiac sympathetic modulation, the increase in HR and
decrease in HF suggest the opposite. Trazodone, again in contradiction to expectations,
reduced overall HF in this study, tended to increase the LF/HF ratio during the Pre-Noise
time point, and did not affect any other HRV parameters. The combination of CBD and
trazodone also reduced HF compared to control and tended to reduce the LF/HF ratio
compared to all other treatments during the Noise time point when the fireworks track
was playing. The lack of effect on other HRV parameters such as SDNN and RMSSD
may be due to the fireworks track not producing a change in these variables rather than a
lack of treatment effect. These conflicting results warrant further investigation,
particularly considering the lack of information available regarding the effects of both
CBD and trazodone on HRV in dogs.
When the fireworks track started, there was a visible change in the demeanor of
the dogs compared to both the open field test and the first 3-min block of the noiseinduced fear response tests (Pre-Noise). While this may indicate that the fireworks track
was able to generate the desired behavioral response, it is also possible that the change in
behavior was a result of the dogs’ interest in the noise rather than a fearful response.
However, the considerable variability in the type of observed responses makes it difficult
to elucidate whether the change was due to fear or if it was just a reflexive response. The
predominant response was a decrease in activity, which may or may not have been
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accompanied by a variety of other behaviors, such as a tucked tail, shaking, or nervous
vocalizations like whining. These fearful behaviors would have been a better
representation of the behavior changes due to the fireworks test as they have been used to
evaluate such changes in other work (Franzini de Souza, 2017; 2018; Landsberg et al.,
2015; Maccariello et al., 2018). However, these behaviors occurred too infrequently in
this study to allow for statistical analysis. This may be indicative of a lack of behavioral
response to the fireworks test. However, as all dogs were selected for this experiment
based on the presentation of one or more fearful behaviors during baseline testing, this
may simply highlight the variation in behavioral responses to sound exposure. Other
anxiolytic supplements and medications have been shown to increase activity or distance
travelled using this model (Araujo et al., 2013; Landsberg et al., 2015); however, neither
CBD nor trazodone treatment changed activity compared to control. This is particularly
surprising for the treatment groups receiving trazodone, which has previously been
shown to visibly reduce behaviors associated with a number of stressful situations
(Gilbert-Gregory et al., 2016; Gruen and Sherman, 2008; Herron and Shreyer, 2014).
However, several of these studies relied on owner-completed surveys rather than
objective data to assess effectiveness.
In contrast, CBD has been shown to reduce anxious behaviors in mouse, rat, and
human models, but at this time there is little to no literature regarding its effect on canine
behavior. In mouse and rat models, responses to threatening or unpleasant stimuli were
assessed by several methods, including the elevated plus-maze, Vogel-conflict test,
contextual fear conditioning, and elevated T maze (Campos et al., 2013; Marinho et al.,
2015; Moreira et al., 2006). The use of these models has shown that intraperitoneal
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administration of CBD in doses ranging from 1 to 20 mg/kg produced anxiolytic effects
with some responses being dose-dependent (Blessing et al., 2015; Lee et al., 2017).
Though different models of anxiety were used in rodents, this may indicate that a higher
dose is necessary to produce the desired behavioral changes associated with reduced
stress and anxiety, particularly if dosed orally due to the considerable first-pass effect on
CBD in the liver (Samara et al., 1988; Trevaskis et al., 2009). Future research should
investigate the effect of higher dosage of CBD for dogs above the dose tested in this
study. Another important consideration is the time of CBD administration prior to noise
exposure. As previously mentioned, oral CBD has been shown to have a half-life of less
than 4 hours (Bartner et al., 2018; Deabold et al., 2019; Gamble et al., 2018), but CBD
treats in this experiment were dosed between 4 and 6 hours of testing. Thus, it is possible
that the dose used in this study would be sufficient to generate an anxiolytic effect if
dosed closer to the fireworks test. Alternatively, CBD may need to be dosed for longer
than 7 days in order to produce anxiolytic effects. Future investigation into these
possibilities is warranted.
While there was no period effect on any behavioral variables, the lack of behavioral
response to treatment could also have been due to acclimation of some of the animals to
the firework track. While dogs were selected for inclusion into the study based on their
reaction to the baseline noise-induced fear response test, it is possible that the weekly
exposure to the stimulus diminished the reaction of some of the dogs during the later
tests. This hypothesis is supported by the effect of period on other variables measured in
this study, including plasma cortisol, HR, and AVNN. This highlights an important
limitation of this study design, where time constraints prevented washout periods. To
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avoid this issue in future work, dogs could be blocked by their reaction to the baseline
test and assigned to just one treatment for the duration of the study. This would eliminate
the need for multiple firework tests and would allow baseline and treatment tests to be
spaced out over time but would also require a much larger sample size. However,
considering the high level of variability in behavioral responses to the fireworks test, it
would be difficult to ensure even distribution of dogs even with blocking. If feasible, it
would be ideal to utilize the crossover design with longer washout periods to minimize
the potential for acclimation to the stressful stimulus. The variability in behavioral
responses also makes it difficult to quantify different fear responses. Several of the most
common fearful behaviors (shaking, cowering, panting, etc.) were measured, but could
not be analyzed due to insufficient occurrences, which may be accounted for in future
work by aggregating such behaviors together into one behavioral category. The inclusion
of a non-fearful control group should also be considered for future work as it would allow
for better evaluation of changes in fearful behaviors in reactive dogs.
Conclusions
The results of the current study do not provide strong support of an anxiolytic
effect of CBD in dogs when supplemented at 1.4 mg CBD/kg BW/d. Trazodone, but not
CBD, decreased plasma cortisol concentration. When combined with trazodone, CBD
appeared to attenuate the effects of trazodone on plasma cortisol. Cannabidiol decreased
LF and HF, tended to increase HR, and tended to decrease duration of Other Eyes.
Conversely, trazodone increased duration of Other Eyes, increased time spent with tail
relaxed, reduced HF, increased the LF/HF ratio.
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It would be beneficial in future studies to use increasing doses of CBD to clarify
any potential anxiolytic effect, if present, and the dose necessary to elicit that effect. This
study demonstrates the considerable variation in canine anxiety behaviors, which makes
it difficult to accurately measure the response to treatments. It may be inadvisable to
administer CBD concomitantly with other products or medications as the results from this
study highlight potential drug interactions associated with CBD use. Considering the
increased interest of CBD use in companion animals, continued research is essential to
understanding the mechanisms by which CBD may exert anxiolytic effects as well as
possible risks, like drug interactions, associated with CBD administration.

68

Tables and Figures
Table 4.1. Schedule of events.
Study Day

Key Event

-7 to -6

Animal intake, physical exam, and bloodwork (CBC/serum chemistry)

-5 to -3

Acclimation to diet, daily routine, and testing room

-2

Open Field Test

-1

Baseline Fireworks Test

1 to 4

Start of treatment 1 (Squares 1 – 4 started on consecutive days)

7 to 10

Period 1 Fireworks Test, start of treatment 2 evening after test

14 to 17

Period 2 Fireworks Test, start of treatment 3 evening after test

21 to 24

Period 3 Fireworks Test, start of treatment 4 evening after test

28 to 31

Period 4 Fireworks Test
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Table 4.2. Definition of heart rate (HR) and heart rate variability (HRV) variables.
Variable

Definition

HR

Heart rate, bpm

AVNN

Mean beat-to-beat intervals, ms

SDNN

Standard deviation of beat-to-beat intervals, ms

RMSSD

Square root of the mean squared difference of successive RRs or interbeat intervals, ms

pNN50

Percentage of successive RR intervals that differ by more than 50 ms, %

LF

Peak frequency of the low-frequency band (0.04 - 0.15 Hz)

HF

Peak frequency of the high-frequency band (0.15 - 0.40 Hz)

LF/HF

Ratio of LF-to-HF
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Table 4.3. Ethogram of behaviors tracked by a single trained observer blinded to
treatments using The Observer XT (Noldus Information Technology Inc., Leesburg, VA).
Behavioral
Category

Behavior

Definition Used

Movement

Inactive

Standing still, sitting, or laying down

Cowering

Sudden cessation of movement in response to
a stimulus

Pacing

Frantically moving back and forth, restlessness

Destruction

Scratching or chewing at room furnishings

Facing Door

Eyes are focused on the door of the room

Glancing
Around

Eyes are shifting back and forth, possibly
looking for the source of a sound

Other

Eyes are focused on something else in the
room

Ears Relaxed

Ears are held in natural position

Ears Erect

Ears raised in response to stimulus

Ears Moving

Ears moving back and forth

Tail Relaxed

Tail is not rigid and is lower than the top of the
body

Tail Stiff

Tail is rigid and horizontal

Tail Wagging

Tail is wagging back and forth

Tail Tucked

Tail is tucked between hind legs

Barking

Emitting a short, loud sound

Eyes

Ears

Tail Posture

Muzzle

Whining
Panting
Licking

Emitting a long, high pitch sound, often
repeated
Mouth open wide with tongue protruding
while breathing heavily
Using the tongue on own body or another
object

Yawning

Opening the mouth wide and inhaling

Biting

Using teeth on the door or object
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Figure 4.1. Cortisol concentration (ng/mL) for each treatment (n = 16), back transformed
after analysis. Error bars represent the standard error of the treatment mean (SEM), which
was calculated from the back-transformed confidence interval for each treatment: SEM =
(upper limit – lower limit)/3.92. Due to lack of effect of time (P = 0.189) and any
interactions with time (P > 0.05), all time points (Pre-Noise and Noise) have been
combined. Trazodone treatment reduced overall cortisol concentration compared to
control (P < 0.001), whereas there was no effect of CBD nor the CBD by trazodone
interaction (P = 0.104, and 0.238, respectively). *Bars with asterisk differ from control at
P < 0.001.
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Table 4.4. Effect of trazodone (T), CBD (C), CBD by trazodone (C*T) interaction, time (Pre-Noise and Noise), CBD by trazodone by
time (C*T*Time) interaction, and period on mean heart rate (HR) and heart rate variability (HRV) parameters for 1-minute
immediately prior to (Pre-Noise) and the first minute (Noise) of the noise-induced fear response tests administered after each 7-d
treatment period.
Treatment
P-value
Variable1

Control

Trazodone (T)

CBD (C)

T+C2

SE3

Trazodone

HR, bpm

118.03

118.02

124.20

124.07

10.968

AVNN,
ms

555.96

539.85

539.42

517.50

SDNN, ms

108.16

102.96

106.54

RMSSD,
ms

100.35

89.28

pNN50, %

41.19

LF, Hz

C*T

Time

C*T*Time

Period

0.985

0.093 0.987

<.001

0.637

0.005

25.988

0.276

0.266 0.850

0.040

0.807

0.046

88.18

7.129

0.200

0.359 0.450

0.977

0.419

0.695

91.70

69.71

12.649

0.130

0.189 0.538

0.366

0.654

0.538

36.99

36.88

33.73

5.774

0.180

0.168 0.847

0.032

0.773

0.306

0.090

0.062

0.050

0.048

0.0071

0.188

0.011 0.315

0.010

0.273

0.533

HF, Hz

0.142a

0.076b

0.059b

0.068b

0.0221

0.205

0.022 0.071

0.036

0.853

0.481

LF/HF
Ratio

0.729

0.803

0.711

0.540

0.1052

0.595

0.126 0.183

0.053

0.039

0.908

Pre-Noise

0.651a,b

0.992a*

0.907a,b

0.607b

0.1402

Noise

0.808a

0.615a

0.515a

0.474a* 0.1461

1

CBD

With the exception of HR, pNN50, and HF, variables were not normally distributed and were analyzed using the natural logarithm.
Data were back transformed for reporting purposes. In the event of a treatment by time interaction, parameters are given as their
treatment mean within each time point (Pre-Noise and Noise).
2
Treatment T+C indicates the combination treatment of CBD and trazodone
3
The standard error (SE) of the back transformed data was calculated from the confidence limits of the transformed data as follows:
SE = (back-transformed upper limit – back-transformed lower limit)/3.92.
ab*
Within rows, values with different letters differ at P ≤ 0.05 and asterisks indicate a trend at P < 0.10.
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Table 4.5. Effect of trazodone (T), CBD (C), CBD by trazodone interaction (C*T), time (Pre-Noise and Noise), CBD by trazodone by
time interaction (C*T*Time), and period on the duration of behavioral parameters (s) for 1-minute immediately prior to (Pre-Noise)
and the first minute (Noise) of the noise-induced fear response tests administered after each 7-d treatment period.
Treatment
P-value
1
2
3
Variable , s
Control Trazodone (T) CBD (C) T+C
SE
Trazodone CBD C*T Time C*T*Time Period
Inactive

55.35

56.33

55.21

56.26

1.214

0.329

0.918

0.971

0.011

0.092

0.993

Facing Door

37.45

33.90

34.96

37.70

4.198

0.872

0.796

0.217

0.561

0.556

0.786

Glancing
Around

16.90

15.65

17.93

15.91

3.460

0.396

0.736

0.841

<.001

0.142

0.819

5.10

13.33

4.10

5.48

1.885

0.044

0.072

0.182

<.001

0.469

0.792

Ears Relaxed

11.37

7.76

12.35

11.43

4.913

0.179

0.168

0.422

<.001

0.868

0.567

Ears Erect

29.33

34.29

29.93

29.80

5.614

0.304

0.408

0.279

<.001

0.747

0.982

Ears Moving

19.25

17.79

17.20

18.78

2.076

0.970

0.742

0.351

<.001

0.457

0.493

Tail Relaxed

37.90

49.86

38.93

50.96

4.857

0.001

0.753

0.992

0.611

0.898

0.990

Tail Stiff

18.45

5.55

16.39

6.65

4.582

0.002

0.887

0.644

0.010

0.757

0.896

Other Eyes

1

Variables were not normally distributed and were analyzed using the natural logarithm. Data were back transformed for reporting
purposes.
2
Treatment T+C indicates the combination treatment of CBD and trazodone
3
The standard error (SE) of the back transformed data was calculated from the confidence limits of the transformed data as follows:
SE = (back-transformed upper limit – back-transformed lower limit)/3.92.
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CHAPTER 5. FEEDING CANNABIDIOL-CONTAINING TREATS DID NOT
AFFECT CANINE DAILY VOLUNTARY ACTIVITY
Frontiers in Veterinary Science, 2021, 8:645667
Introduction
Pet owners and caretakers are increasingly interested in monitoring their animal’s
behavior and activity as indicators of health and well-being. While several subjective
measures like the canine brief pain inventory and the Hudson visual analog scale are
available for use (Brown et al., 2008; Hudson et al., 2004), the ability to measure activity
through objective, non-invasive means such as accelerometers is a potentially preferable
tool that can provide an impartial measure of animal activity (Dow et al., 2009; Eskander
et al., 2020; Hansen et al., 2007; Michel and Brown, 2011). The use of accelerometers,
kinesiology, and gait analysis are becoming popular methods by which to evaluate the
health status of an animal as well as response to treatment. Several triaxial accelerometers
have been validated for the measurement of canine activity and can be easily attached to
a collar or harness for home use (den Uijl et al., 2017; Griffies et al., 2018; Preston et al.,
2012; Yam et al., 2011). They have been used to evaluate the effectiveness of treatments
for osteoarthritis and pruritic behaviors (Brown et al., 2010; Meijia et al., 2019; Muller et
al., 2018; Wernimont et al., 2018), the effects of exercise and rest on the voluntary
activity of active sled dogs (Robinson et al., 2020; 2021), and to predict rest in dogs and
sleep in humans (Clarke and Fraser, 2015; Ladha and Hoffman, 2018; Nam et al., 2016).
Normal activity of healthy dogs is influenced by many factors, including breed,
age, degree of socialization, and amount of exercise (Pickup et al., 2017; Rosado et al.,
2012; Siwak et al., 2001). Additionally, canine activity may be negatively influenced by
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factors such as disease, chronic illnesses like osteoarthritis, or behavioral issues such as
anxiety (Brown et al., 2010; Overall et al., 2001; Tiira et al., 2016). There are also certain
circumstances where canine activity needs to be reduced as a result of normal activity in
high energy dogs, pruritic behaviors like scratching, or anxious behaviors like pacing and
destruction. Activity may also need to be prevented or reduced following an illness,
medical treatment or surgical procedure (Tiira et al., 2016; Wernimont et al., 2018). In
such instances, many turn to medications like sedatives or antidepressants that have been
shown to reduce canine activity (Gruen et al., 2014). However, some pet owners may be
hesitant to use such medications due to potential side effects, cost, or personal bias
against their use. Instead, they often investigate alternatives to conventional medications
such as CBD (Kogan et al., 2016; 2018).
There has been considerable interest in the use of CBD for both humans and
companion animals due to its reported benefits, such as analgesia, anti-inflammatory,
anxiolytic, and sedative effects (Andre et al., 2016; Bonini et al., 2018; Huchelmann et
al., 2017). The analgesic effect of CBD has been documented in rodent and human
models (Costa et al., 2007; van de Donk et al., 2018; Yassin and Robinson, 2017), and
the use of oral and transmucosal CBD oil formulations increased canine brief pain
inventory (CBPI) and Hudson scores in dogs with osteoarthritis, suggesting an increase in
activity and comfort with CBD use (Brioschi et al., 2020; Gamble et al., 2018). However,
despite evidence of an anxiolytic effect of CBD in both rodents and humans with doses
ranging from 2.5 to 10 mg/kg (Appian-Kusi et al., 2020; Campos et al., 2013; Crippa et
al., 2011), a recent report failed to demonstrate an anxiolytic effect of treats containing
1.4 mg CBD/kg BW in dogs exposed to a noise-induced fear response test (Morris et al.,
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2020). Other effects attributed to CBD, such as sedative effects, are thought to be
biphasic. Larger doses have been shown to exert sedative effects in both rats and humans,
whereas low doses of CBD may increase wakefulness (Babson et al., 2017; Chagas et al.,
2013; Nicholson et al., 2004). While the effect of CBD on sedation has not been
specifically investigated in a canine model, a preliminary investigation of the safety of
escalating CBD doses in 20 healthy dogs reported mild constitutional adverse events
recorded for dogs receiving 1.7-64.7 mg/kg CBD oil, which included both lethargy and
hyperesthesia (Vaughn et al., 2020). A similar investigation into the safety of a 1:20
THC:CBD herbal extract reported mild neurological adverse events, like ataxia and
delayed hopping, after single and multiple oral doses of 2 and 5 mg/kg CBD extract
(Chicoine et al., 2020). While adverse events in both studies were mild and rare, they do
highlight the potential for CBD to cause undesirable side effects as well as the need for
continuing research evaluating the safety and efficacy of CBD use in dogs.
Despite the lack of scientific evidence demonstrating the safety and efficacy of
CBD use in dogs, a recent survey of over 1000 dog owners recruited on social media
showed that almost 80% of owners surveyed had purchased hemp or marijuana products
for their dogs to provide pain relief, relieve anxiety, aid with sleep, and treating other
health conditions. Many also indicated that they believed hemp products were more
effective than conventional medications (Kogan et al., 2016; 2018). The study population
included owners of both healthy and diseased animals as well as owners that either had or
had not ever purchased hemp products for their dogs; however, this is likely an overestimation of overall hemp use in companion animals due to the surveys being shared
primarily within social media groups dedicated to cannabis use in pets. Nevertheless,
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these surveys provide insight on the overwhelmingly favorable perceptions of pet owners
on the safety and efficacy of CBD use in companion animals. Due to this interest in the
use of CBD in companion animals, there is a critical need for further evaluation of CBD
use in dogs and its potential effects on canine activity. Thus, the objective of the current
study was to determine the impact of CBD on the daily activity of healthy adult dogs with
the underlying hypothesis that CBD would reduce the overall daily activity of dogs
compared with control. This hypothesis was tested using triaxial accelerometers to
measure the activity of dogs receiving two levels of CBD administration compared to a
control.
Materials and Methods
This study was approved by the LMU IACUC (protocol 1911-RES) prior to the
start of the study. All housing and husbandry received were in accordance with the
Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals (8th ed.),
and all applicable LMU SOPs.
Subjects and Housing
Thirty neutered, adult dogs (15 male, 15 female, 9 months to 4 years old, 17.6 ±
3.4 kg) of various mixed breeds, including terrier, hound, Bassett, shepherd, Border
Collie, Husky, cur, Labrador, Boxer, and Pug mixes were received at the LMU DVTC
from a local shelter for inclusion in this study. The shelter was asked to provide dogs
weighing 16 ± 4 kg. Additionally, the shelter was informed and gave consent for the use
of the dogs for research purposes before their arrival. Before beginning the experiment,
each dog had a complete blood count (CBC) and serum chemistry analysis (IDEXX
Laboratories, Inc., Westbrook, ME) performed, along with a physical evaluation by a
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veterinarian and a fecal examination to rule out any underlying disease that might
preclude enrollment. Dogs were excluded if they demonstrated serious behavioral issues,
such as extreme fear or aggression that would endanger research personnel, were severely
emaciated or obese, classified as a body condition score < 3.5 or > 7.5 on a 9-point scale
(where 1 is emaciated and 9 is obese; Laflamme, 1997), or if initial evaluations revealed
an underlying disease that required more than routine treatments, such as heartworm
infection, metabolic or infectious disease, and mobility issues. Three dogs were excluded
due to positive heartworm tests and another three dogs were excluded for behavioral
concerns. The remaining 24 dogs (12 male, 12 female, 9 months to 4 years old, 18.0 ± 3.4
kg) were selected for inclusion in the study. Dogs were individually housed in 1.2 x 1.8
m kennels within one of two dog wards at the LMU DVTC for the duration of the study.
Diets and Treatments
Dogs were fed Purina Pro Plan EN Gastroenteric Fiber Balance Dry Dog Food
(Nestle Purina Inc., St. Louis, MO) to meet the daily metabolizable energy requirements
of neutered adult dogs at maintenance, calculated as (70 * BW0.75) * 1.6 and split into two
meals per day fed between 0700 and 0900 h in the morning and between 1700 and 1900 h
in the evening each day. Dogs were weighed and body condition scored (5-point scale)
weekly and diets adjusted accordingly. Treatments were arranged in a randomized
complete block design and consisted of 0 (placebo treats; CON), 34.0 ± 1.16 (LOW), or
75.6 ± 5.86 (HIGH) mg CBD/d. The CBD was the primary constituent of a proprietary
industrial hemp isolate (AgTech Scientific, Paris, KY) that was incorporated into treats
and administered in the form of 2 treats daily, each containing half the daily dose. Both
control and CBD treats were composed of the following ingredients: chicken, chicken
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liver, Asian carp, catfish, and – in the case of CBD treats – industrial hemp extract. While
CBD was the primary constituent of the industrial hemp extract, trace ∆9tetrahydrocannabinol (THC) was present in both LOW and HIGH treatments (1.1 ± 0.37
and 2.9 ± 0.22 mg THC/d, respectively). Treats were formulated to target CBD at doses
of 2.5 and 5.0 mg/kg BW/d for LOW and HIGH treatments, respectively, based on an
estimation that dogs would weigh an average of 16 kg. The LOW dose was selected
based on previous literature that utilized a similar dose in dogs to assess single-dose
pharmacokinetics of CBD and to evaluate its potential to alleviate pain in dogs with
osteoarthritis (Gamble et al., 2018). That dose was then doubled to achieve the HIGH
dosage. However, based on the mean BW of dogs included in the study and analysis of
the treats, mean doses of CBD were 1.8 and 4.5 mg CBD/kg BW/d for LOW and HIGH
treatments, respectively. Treats were offered solely as a reward upon kennel re-entry
following twice-daily exercise, which occurred within 30 min of meals.
Experimental Design and Data Collection
Upon completion of intake exams, dogs underwent a 7-d acclimation period for
adjustment to environment, diet, collars, and daily routine (Table 5.1). Kennels were
maintained on a 12-h light schedule. Dogs received two 15-min exercise periods each
day, with morning exercise occurring between 0700 and 0900 h and evening exercise
occurring between 1700 and 1900 h. During exercise periods, dogs that were aggressive
towards other dogs were individually hand-walked by research personnel; all other dogs
were allowed to exercise freely in playgroups of 2 – 4 dogs in one of two grassy
enclosures. The number of dogs being hand-walked and in playgroups was balanced
across all treatments. Four hours each day – 1000 to 1200 h (AM) and 1330 to 1530 h
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(PM) – were designated as the time when no persons were allowed to enter the kennels.
Two of those hours were designated as Quiet time, and the other two as Music time
where calming classical music was played over speakers in each kennel. Quiet and Music
sessions were randomly allotted to either AM or PM times each day. All dogs started
receiving control treats (0 mg CBD) twice daily as a reward for kennel re-entry after the
twice-daily exercise.
After the acclimation period, Vetrax® activity sensors (AgLogica Holdings,
Norcross, GA) were fitted to dogs’ collars using the attachment provided by the
manufacturer and placed ventral to the mandible. These triaxial accelerometers were used
for the continuous collection of activity variables – activity points, activity duration
(min), duration of no activity (h), duration of resting (h), running duration (min), walking
duration (min), scratching duration (s), head shaking duration (s), and sleep quality
(Table 5.2). Data collected by the sensors was automatically uploaded to the Vetrax®
server via Wi-Fi once an hour for behavior algorithm processing, which has been
previously validated (Griffies et al., 2018). Except for a weekly consistent 2-3 h charging
period, sensors remained on the dogs at all times. Before the start of the experiment, data
were collected over a 14-d baseline period to block dogs by mean daily activity – high
(mean 118.6 min; range 88.6-157.5 min) or low (mean 59.3 min, range 30.2-85.1 min) –
before stratifying dogs by age, weight and sex and randomly assigning dogs within each
block to treatments. Dogs were stratified by treatment and sex, evenly distributed
between the two wards, and adapted to treatments for 7 d before another 14-d collection
of activity via Vetrax® sensors (Table 5.1).

81

Consumption of food and treats, consistency of stool, frequency of elimination,
subjective assessment of activity during exercise, mucus membrane color, and other
indicators of general health status were monitored twice daily by research personnel.
Evidence of any adverse event – defined as any symptom occurrence that would not be
expected in normal dogs – was also monitored. However, no adverse events were
observed in any dogs following the administration of CBD treats during this study.
Statistical Analysis
Based on variation in activity and behaviors reported in previous work using these
sensors (Griffies et al., 2018; Wernimont et al., 2018), it was calculated that n = 8
dogs/treatment was sufficient to detect a 25% change with a 16% CV (Berndtson, 1991).
Activity monitors for two of the dogs in the control group (one in the high activity block
and one in the low activity block) spontaneously stopped transmitting halfway through
the treatment period, and activity data from the last 7 d of the experiment for those two
dogs were lost.
The normality of the residuals was tested using the UNIVARIATE procedure in
SAS 9.4 (SAS Institute, Cary, NC). In instances where data did not meet normality
assumptions, statistical analysis was performed on transformed data. However, data were
then back-transformed for reporting purposes. The standard error of the back-transformed
data was calculated from the confidence limits of the transformed data as follows: SEM =
(back-transformed upper limit – back-transformed lower limit)/3.92. The denominator
relates to the Z-value of a 95% confidence interval (± 1.96). For the baseline period,
activity duration, running, scratching, and head shaking were not normally distributed
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and were log-transformed for statistical analysis. Activity points and walking were not
normally distributed and were transformed into the square root for statistical analysis.
During the baseline period, dogs allotted to CBD treatments tended (P = 0.061) to
run more than control; thus, the mean duration of running from the baseline period was
utilized as a covariate for the duration of running in the treatment period. All other
variables were similar across treatments in the baseline period. For overall daily activity
during the treatment period, running, scratching, and head shaking were not normally
distributed and were log-transformed for statistical analysis. For Quiet and Music session
activity periods, all variables – except for No Activity and Resting – were not normally
distributed and were log-transformed for statistical analysis. For exercise activity periods,
activity points, activity duration, and scratching were not normally distributed and were
log-transformed for statistical analysis, whereas running and head shaking were not
normally distributed and were transformed to the cube root for statistical analysis.
From the treatment period, overall daily activity and activity during exercise
periods (0700-0900 h and 1700-1900 h) were analyzed using the MIXED procedure in
SAS including the fixed effects of treatment, day, and the treatment by day interaction.
Dog nested within activity block (high or low) was included as a random effect and day
was included as a repeated measure with dog nested within treatment as the subject.
Activity during the Quiet and Music sessions were analyzed using the MIXED procedure
in SAS including the fixed effects of treatment, day, session (Quiet or Music), time of
day (AM or PM), and all accompanying interactions. Dog nested within the activity block
was again included as a random effect. Time (AM or PM) was included as a repeated
measure with dog nested within treatment as the subject. Treatment effects are described
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as the contrast between CON and both CBD treatments and the contrast between LOW
and HIGH CBD treatments. Results are presented as the mean ± SE. Effects were
considered significant when P ≤ 0.05 and considered a tendency when P < 0.10.
Results
Total Daily Activity
CBD did not alter total activity points, activity duration, no activity, resting,
running, walking, head shaking, or sleep quality compared to CON (Table 5.3; P > 0.05).
However, CBD tended to reduce scratching compared with CON (P = 0.071) but was not
different between LOW and HIGH treatments (P = 0.209). Level of CBD inclusion
(LOW vs. HIGH) did not affect any variables measured (P > 0.05). With the exceptions
of activity duration, running, walking, and scratching, all variables were affected by day
of treatment (P < 0.05), but no treatment by day interactions were observed (P > 0.05).
Quiet and Music Session Activity
Overall, dogs were more active in the PM sessions than the AM, with all variables
affected by the time of day (Table 5.4; P < 0.001). Activity points, activity duration,
running, walking, and resting increased in the PM compared to the AM (P < 0.001) while
the duration of No Activity decreased in the PM compared to AM (P < 0.001). During
these sessions, the Music session tended to reduce activity points (P = 0.055) and running
(P = 0.098) compared to the Quiet session. The Music session reduced activity duration
(P = 0.002), walking (P < 0.001), and resting (P = 0.045) while increasing duration of no
activity (P = 0.014) compared to the Quiet session.
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Session by time interactions were observed for activity points, no activity, and
resting (Table 5.4; P < 0.05), and a trend for session by time interactions was observed
for activity duration, running, and walking (P = 0.076, 0.078, and 0.084, respectively).
Type of session (Quiet or Music) did not alter activity points or duration of activity
during the AM session (P = 0.502 and 0.522, respectively). When the Quiet session was
allotted to the PM, however, activity points (P = 0.002), duration of activity (P < 0.001),
resting (P < 0.001), running (P < 0.001), and walking (P < 0.001) were increased
compared to when the Music session was allotted to the PM. Duration of No Activity was
similar between Quiet and Music sessions when allotted to the AM (P = 0.230) but was
increased in the Music session compared to the Quiet session when allotted to the PM (P
< 0.001).
Activity points, running, and head shaking were unaffected by treatment, and all
treatment interactions during the Quiet and Music sessions (Table 5.4; P > 0.05).
Scratching was reduced by CBD during Quiet and Music sessions compared to CON (P =
0.030), but the level of CBD inclusion did not affect time spent scratching (P = 0.612).
A treatment by time interaction was observed for No Activity and resting (Table
5.4; P = 0.013 and 0.006, respectively) and a trend for a treatment by time interaction was
observed for activity and walking duration (P = 0.079 and 0.060, respectively).
Regardless of Quiet or Music session, activity duration was similar across treatments in
the AM (P > 0.05), but dogs receiving HIGH CBD tended (1.44 ± 0.172 min; P = 0.091)
to be less active than CON (2.64 ± 0.324 min) in the PM and tended (1.37 ± 0.162 min; P
= 0.059) to walk less than CON (2.60 ± 0.326 min) in the PM. Similarly, duration of No
Activity was unaffected by treatment in the AM (P > 0.05) but in the PM tended to
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increase in the HIGH CBD treatment (1.13 ± 0.060 h) compared to both CON (0.95 ±
0.063 h) and LOW (0.97 ± 0.060 h) treatments (P = 0.054 and 0.068, respectively).
Conversely, resting duration increased in the LOW treatment (0.96 ± 0.051 h) compared
to the HIGH treatment (0.80 ± 0.051 h) in the PM (P = 0.038), but was similar across all
other time points and treatments (P > 0.05). No treatment by session nor treatment by
session by time interactions were observed (P > 0.05) for any variables measured. All
activity variables were affected by day of treatment period (P < 0.05), but no treatment
by day interactions were observed (P > 0.05).
Exercise Activity
Neither CBD treatment nor inclusion level affected any variables measured during
the exercise periods (Table 5.5; P > 0.05). Day of treatment period tended (P = 0.066) to
affect scratching and affected head shaking (P = 0.003), but no other variables were
impacted by day of treatment (P > 0.05). Additionally, no treatment by day interactions
were observed (P > 0.05).
Discussion
Triaxial accelerometer sensors were used in this study to determine the effect of
daily CBD dosing on activity in healthy adult dogs by measuring daily activity, pruritic
behaviors, and an assessment of rest and sleep quality. The objective of this study was to
evaluate the impact of CBD on the daily activity of healthy adult dogs with the
hypothesis that CBD would reduce overall daily activity compared to control. However,
results showed that oral CBD administration did not alter the overall daily activity of
healthy adult dogs. The lack of effect on overall daily activity and sleep quality was
unexpected based on previous reports of sedative and hypnogenic effects of CBD in
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rodent, human, and canine models. In humans and rats, CBD doses ranging from
approximately 2 to 40 mg/kg BW/d have been reported to induce sedative effects,
improve sleep quality, and increase total sleep time (Chagas et al., 2013; Carlini and
Cunha, 1981; Zuardi et al., 1993). However, more recent work has reported CBD to have
no influence on the sleep cycle in humans, (Linares et al., 2018) and others argue that
CBD by itself does not produce sedative effects but rather modulates the sedative effect
of ∆9-tetrahydrocannabinol (THC), even if THC is only present in minute amounts
(Kesner and Lovinger, 2020; Nicholson et al., 2004; Spindle et al., 2020).
The potential for the sedative effect of CBD to be caused by the presence of THC
may be supported by an escalating dose study in dogs where placebo, CBD-predominant,
THC-predominant, and CBD/THC combination oils were administered to dogs to
evaluate the occurrence and severity of adverse events after administration (Vaughn et
al., 2020). Doses for the CBD-predominant oil started at 1.7 mg CBD/kg BW/d and was
incrementally increased to a maximum of 64.7 mg CBD/kg BW/d over 30 days. Lethargy
was reported with the CBD-predominant oil formulation, however, that oil was not THCfree; it was reported to contain 0.7 mg/mL THC (Vaughn et al., 2020). The industrial
hemp extract included in the CBD treats used in this experiment contained similar THC
content as the oil reported in Vaughn et al. (2020) but did not produce a similar effect.
The reason for these conflicting results remains unclear. These differences could be due
to the difference in animals utilized for the study – shelter vs. research-bred dogs – or the
different modes of delivery – eating a treat versus oral gavage of an oil. There have been
reports of variation in the pharmacokinetics of CBD depending on the mode of delivery.
In one experiment, CBD-infused oil demonstrated increased maximum plasma CBD
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concentration than the same dose administered as microencapsulated oil beads and a
CBD-infused transdermal cream (Bartner et al., 2018). Other reports using similar doses
of oral CBD oil and chews report an increased maximum plasma CBD concentration
when administered as a chew compared to an oil; however, this has yet to be investigated
in a single, controlled experiment (Deabold et al., 2019; Gamble et al., 2018)
Additionally, dogs used in Vaughn et al. (2020) fasted before administration of the CBD
oil whereas dogs in the current experiment consumed CBD treats within 30 min of a
meal. It has been suggested that administering cannabinoids with a fat-meal increased
bioavailability (Zgair et al., 2017). Since the CBD used in Vaughn et al. (2020) was
mixed in a lipid-based formulation, it is unclear if these differences in methodology
would lead to the difference in sedative effects observed between their report and the
current study. Additional investigation using THC-free CBD is needed to evaluate the
potential for CBD to exert a sedative effect in dogs.
While there was no observed effect on overall daily activity with CBD treatment,
it tended to influence activity during different times of the day. Dogs in the current study
were more active in the PM than the AM regardless of treatment and type of session.
Playing calming music in the kennels (Music session) did reduce activity compared to
when no music was played (Quiet session), which supports previous work showing that
playing music can reduce stress and increase relaxed behaviors in kenneled dogs (Amaya
et al., 2020; Bowman et al., 2017; Engler and Bain, 2017). This effect, however, appears
to be independent of the effect of CBD as there was no interaction between treatment and
session nor a treatment by session by time interaction. The tendency for dogs in the
HIGH CBD treatment to be less active than CON dogs in the PM may indicate that CBD
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exerted some sedative or calming effect on the dogs. However, this potential sedative
effect was expected to be observed in the AM as previous pharmacokinetic reports
showed a half-life for CBD of 1-4 h (Deabold et al., 2019; Bartner et al., 2018; Gamble et
al., 2018; Wakshlag et al., 2020). As this effect was not observed during the AM
sessions, exercise periods, nor overall daily activity, these collective results do not
support a sedative or calming effect of CBD in dogs. Thus, the claim that CBD exerts a
sedative or calming effect in dogs remains unsubstantiated, but further investigation may
provide clarification to these results.
In the present study, dogs were necessarily regimented into a strict schedule of
daily activities. It is possible that in a setting where dogs were entirely free to choose
their activities, such as a home, the outcome could have been different. The strict,
consistent schedule of the kennel environment did not allow for much activity outside of
scheduled exercise periods, which may have prevented normally high-energy dogs from
being as active as they might be with consistent free access to more space. Conversely,
shelter environments have been shown to increase activity in dogs compared to a home
environment and may prevent dogs from resting due to increased stress (Hoffman et al.,
2019; Part et al., 2014). This may have artificially increased activity in dogs that would
have otherwise been less active. As a result, it may be preferable to evaluate the effect of
these treatments in familiar environments that have more space for dogs to exhibit normal
activity and rest behaviors. Additionally, the small sample size and use of healthy adult
dogs were limitations of this study. The dogs included in this study exhibited high
variability in voluntary activity despite being blocked by baseline activity and having no
known mobility or behavioral issues. These limitations may preclude extrapolation of
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these results to other canine populations. Since CBD is often used to increase comfort
and activity in dogs with mobility issues like osteoarthritis or to decrease the activity of
anxious or hyperactive dogs (Kogan et al., 2018), future work should evaluate voluntary
activity in animals with mobility or behavioral issues like osteoarthritis or anxiety.
Results from this study suggest a potential antipruritic effect of CBD.
Phytocannabinoids like CBD act on the body through the endocannabinoid system (ECS),
which is a signaling system including endocannabinoids like anandamide and 2arachidonylglycerol, their receptors, and regulatory enzymes (Pacher et al., 2006). The
ECS helps regulate metabolic homeostasis, thermoregulation, epidermal homeostasis, and
more (Avila et al., 2020; Bellocchio et al., 2008). While CBD has little to no affinity for
CB1 and CB2 ECS receptors, it is a known agonist for the transient receptor potential
vanilloid family of receptors (TRPV1-4), which are known ECS receptors widely
expressed in the skin and plays a role in itch sensation (Avila et al., 2020; Bisogno et al.,
2001; Caterina and Pang, 2016; Tóth et al., 2019). As TRPV1 is rapidly desensitized after
activation, it is thought that CBD may exert antipruritic effects by keeping TRPV1
desensitized, thus preventing neuronal activation by irritants (Imamachi et al., 2009;
Muller et al., 2019; Xie and Hu, 2018).
Additionally, CBD has been shown to be an antagonist for transient receptor
potential melastatin 8 (TRPM8) receptors (De Petrocellis et al., 2008; Muller et al.,
2019). In the skin, TRPM8 is responsible for environmental cold detection and has been
suggested to contribute to the perception of pain and itch, which may indicate it is
another target for the potential antipruritic effect of CBD (Caterina and Pang, 2016;
Jankowski et al., 2017). The antipruritic effect of cannabinoids has been observed in

90

humans (Dvorak et al., 2003; Visse et al., 2017; Yuan et al., 2014), but this is the first
report of a potential antipruritic effect of CBD in dogs as a reduction in scratching
duration was observed in dogs. While this experiment was not designed to assess the
antipruritic effect of CBD, these results may suggest a potential for CBD to be beneficial
in the treatment of skin conditions and pruritic behaviors in dogs. To investigate this
potential effect, it would be beneficial for future work to specifically examine the effect
of CBD in dogs with skin issues such as allergies, atopic dermatitis, or unexplained
pruritus.
Conclusions
The results of the current study indicate that when supplemented with up to 4.5
mg/kg BW/d, CBD does not impact the overall daily activity of adult dogs. Total daily
activity including duration of the activity, sleep quality, and resting were unaffected by
CBD. Similarly, activity during exercise periods was also unaffected by CBD. During
Quiet and Music session periods, 4.5 mg CBD/kg BW/d tended to reduce activity in dogs
compared to both 1.8 mg CBD/kg BW/d and CON, but this did not translate to an overall
daily effect. Playing classical music in the kennels reduced activity compared to having
no music played but did not alter the response to CBD. Cannabidiol reduced total daily
scratching as well as scratching during Quiet and Music sessions, which may indicate a
possible antipruritic effect. Future work examining the effect of CBD on activity is
warranted, particularly in dogs with mobility and behavioral issues like osteoarthritis and
anxiety. Additionally, the potential antipruritic effect of CBD should be investigated
using dogs with dermatological issues like skin allergies or atopic dermatitis.
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Tables and Figures
Table 5.1 Schedule of events for monitoring activity in dogs receiving cannabidiol
containing treats.
Day of
Event
Data Collection
Treats
Study
-2 and -1

Intake and initial health exams

None

Control

1 to 7

Acclimation

None

Control

8 to 21

Baseline Period Activity Collection

Vetrax activated

Control

22 to 28

Treatment Adaptation

None

Treatment

29 to 43

Treatment Period Activity Collection

Vetrax activated

Treatment
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Table 5.2. Activity variables measured by Vetrax® activity sensors (AgLogica Holdings,
Inc., Norcross, GA).
Variable

Definition

Activity Points

Total activity of dogs weighted by each individual activity (ex.
running worth more points than walking), calculated using a
proprietary algorithm.

Activity, min

Duration of total activity including running and walking.

No Activity, h

Duration of complete inactivity.

Resting, h

Duration of time not actively walking or running, but not
completely inactive.

Running, min

Duration of running.

Walking, min

Duration of walking.

Scratching, s

Time spent scratching.

Head Shaking, s

Time spent shaking head.

Sleep

Scale of sleep quality measured using a proprietary algorithm
based on absence of night-time disturbance; scaled 0-100 with
100 being undisturbed sleep.
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Table 5.3. Effect of treatment (TRT), day, and TRT*day interaction on total daily activity variables collected via Vetrax® activity
sensors (AgLogica Technology, Norcross, GA). Treatment effects are shown as the contrast between control (CON) and both CBD
treatments (CBD) and the contrast between CBD treatments (LOW v. HIGH).
Treatment

P-value

Control
(CON)

1.8 mg CBD/kg
BW/d (LOW)

4.5 mg CBD/kg
BW/d (HIGH)

SE

CON v.
CBD

LOW v.
HIGH

Day

TRT*Day

56834

57079

56634

4952.5

0.985

0.950

0.017

0.857

Activity, min

80.1

82.7

82.0

11.90

0.882

0.966

0.421

0.773

No Activity, h

13.6

13.9

14.3

0.58

0.496

0.652

0.002

0.394

Resting, h

8.8

8.5

8.1

0.43

0.364

0.513

<.001

0.389

Running, min

5.8

5.6

6.9

0.36

0.612

0.172

0.172

0.447

Walking, min

76.2

76.5

71.8

10.94

0.878

0.760

0.531

0.749

Scratching, s

69.6

35.8

51.9

7.33

0.071

0.209

0.162

0.485

Head Shaking, s

32.4

27.3

42.4

5.49

0.878

0.229

0.006

0.194

Sleep Quality

77.2

76.1

75.1

2.21

0.500

0.722

0.029

0.679

Variable

1

Activity Points

1

2

Running, Scratching, and Shaking were not normally distributed and were transformed for statistical analysis. Data were backtransformed for reporting purposes.
2
Standard error (SE) of the back-transformed data was calculated as follows: SE = (back-transformed upper limit – back-transformed
lower limit)/3.92.
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Table 5.4. Effect of treatment (TRT), day, session (Quiet or Music), time of day (AM or PM), and all relevant interactions on activity
variables collected via Vetrax® activity sensors (AgLogica Technology, Norcross, GA) from 1000-1200 h (AM) and 1330-1530 h
(PM) each day. Treatment effects are shown as the contrast between control (CON) and both CBD treatments (CBD) and the contrast
between CBD treatments (LOW v. HIGH).
Treatment

P-value

Control
(CON)

1.8 mg
CBD/kg
BW/d
(LOW)

4.5 mg
CBD/kg
BW/d
(HIGH)

Activity Points

2884

2509

Activity, min

1.23

No Activity, h

SE

CON
vs.
CBD

LOW
vs.
HIGH

Time
of
Day

2308

148.6

0.152

0.550

0.87

0.85

0.144

0.204

1.21

1.25

1.34

0.059

Resting, h

0.71

0.70

0.62

Running, min

0.04

0.03

Walking, min

1.29

Scratching, s
Head Shaking, s

Variable

1

Session

Session
*Time

TRT*
Time

TRT*
Session

Day

<.001

0.055

0.014

0.287

0.465

<.001

0.937

<.001

0.002

0.076

0.079

0.257

<.001

0.273

0.327

<.001

0.014

<.001

0.013

0.443

0.002

0.050

0.384

0.234

<.001

0.045

<.001

0.006

0.203

0.002

0.04

0.006

0.602

0.544

<.001

0.098

0.078

0.369

0.834

0.223

0.87

0.82

0.148

0.138

0.857

<.001

<.001

0.084

0.060

0.217

<.001

4.18

2.29

2.62

0.413

0.030

0.612

<.001

0.930

0.274

0.326

0.886

0.730

1.78

1.65

1.82

0.128

0.882

0.600

<.001

0.926

0.305

0.319

0.212

0.375

2

1

Except for No Activity and Resting, variables were not normally distributed and were transformed for statistical analysis. Data were
back-transformed for reporting purposes. There was no effect of the treatment by day nor the Session by time by treatment interactions
on any variable (P > 0.05) and thus are not shown.
2
Standard error (SE) of the back-transformed data was calculated as follows: SE = (back-transformed upper limit – back-transformed
lower limit)/3.92.
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Table 5.5. Effect of treatment (TRT), day, and TRT*day interactions on activity parameters collected via Vetrax® activity sensors
(AgLogica Technology, Norcross, GA) during the 2 periods of daily exercise, which included all data from 0700-0900 h and 17001900 h each day. Treatment effects are shown as the contrast between control (CON) and both CBD treatments (CBD) and the
contrast between CBD treatments (LOW v. HIGH).
Treatment
P-value
Control
(CON)

1.8 mg/kg BW/d
CBD (LOW)

4.5 mg/kg BW/d
CBD (HIGH)

SE

CON v.
CBD

LOW v.
HIGH

Day

TRT*Day

Activity Points

21736

25735

26122

2096.8

0.143

0.910

0.117

0.283

Activity, min

37.66

48.09

48.07

3.213

0.143

0.998

0.528

0.305

No Activity, h

0.82

0.75

0.77

0.132

0.708

0.899

0.359

0.842

Resting, h

2.47

2.24

2.31

0.116

0.312

0.838

0.338

0.847

Running, min

4.9

4.5

5.3

0.31

0.940

0.298

0.258

0.531

Walking, min

35.0

43.8

40.7

0.12

0.207

0.446

0.958

0.576

Scratching, s

21.1

14.1

20.3

2.53

0.442

0.267

0.066

0.875

Head Shaking, s

17.8

14.7

25.8

0.27

0.682

0.167

0.003

0.273

Variable

1

1

2

Except for No Activity and Resting, variables were not normally distributed and were transformed for statistical analysis. Data were
back-transformed for reporting purposes.
2
Standard error (SE) of the back-transformed data was calculated as follows: SE = (back-transformed upper limit – back-transformed
lower limit)/3.92.
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CHAPTER 6. ALTERATION OF THE CANINE METABOLOME AFTER A THREEWEEK SUPPLEMENTATION OF CANNABIDIOL-CONTAINING TREATS
Frontiers in Veterinary Science, 2021, 8:685606;
Journal of Animal Science and Research, 2021, 5(2)
Introduction
Mass spectrometry-based metabolomics has been increasingly used to assess the
health and status of animals and to analyze metabolic alterations caused by diet, disease,
or other factors (Sethi and Brietzke, 2015; Ogunade et al., 2018; Yang et al., 2018).
Targeted metabolomics can be used to quantify defined groups of metabolites, whereas
untargeted metabolomics provides a comprehensive analysis of all measurable analytes in
a sample, including any unknowns (Adeyemi et al., 2019; Roberts et al., 2012). In
instances where the specific metabolites of interest are unknown, untargeted
metabolomics can also be used to discover specific biomarkers for later use in targeted
metabolomics studies as well as pathway analysis (Xia et al., 2013; Goldansaz et al.,
2020). In recent years, Chemical isotope labeling (CIL) liquid chromatography mass
spectrometry (LC–MS)-based untargeted metabolomics has provided an opportunity to
analyze metabolites based on chemical groups, including metabolites containing
amine/phenol chemical groups, which are common intermediate products of amino acid
metabolism; metabolites containing carbonyl groups, which are common intermediate
products of energy metabolism; metabolites containing carboxyl groups, including fatty
acids and their derivatives; and metabolites containing hydroxyl groups, which include
important biological compounds like homones (Ogunade et al., 2021; Zhao et al., 2016;
2019).
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To date, there has been no evaluation of the effect of CBD on the canine
metabolome. Therefore, the objective of this explorative study was to evaluate the impact
of CBD supplementation on the canine metabolome with the underlying hypothesis that
after 3 weeks of supplementation, CBD would alter the canine metabolome compared
with control. This was accomplished through the use of untargeted metabolomics and
biomarker analysis of amine/phenol-, carbonyl-, carboxyl-, and hydroxyl-containing
metabolites.
Materials and Methods
This study was approved by the LMU IACUC (protocol 1911-RES) before the
start of the study. All housing and husbandry received were in accordance with the
Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals (8th ed.),
and all applicable LMU SOPs.
Subjects and Housing
Sixteen dogs (8 male, 8 female, 9 months to 4 years of age, 18.2 ± 3.4 kg BW) of
various mixed breeds, including terrier, hound, Bassett, shepherd, Border Collie, Husky,
cur, Labrador, Boxer, and Pug mixes were received from a local shelter for inclusion in
this study. The shelter was asked to provide dogs weighing 16 ± 4 kg. Additionally, the
shelter informed of and gave consent for the use of the dogs for research purposes before
their arrival. Prior to beginning the experiment, each dog had a CBC and serum chemistry
analysis (IDEXX Laboratories, Inc., Westbrook, Maine) performed, along with physical
evaluation by the attending veterinarian and a fecal examination to rule out any
underlying disease that might preclude enrollment. Dogs were excluded if they
demonstrated serious behavioral issues, such as aggression that would endanger research
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personnel, were severely emaciated, classified as a body condition score < 3.5 or > 7.5 on
a 9-point scale (where 1 is emaciated and 9 is obese; Laflamme, 1997), or if their initial
evaluations revealed an underlying disease that required more than routine treatments
(such as heartworm positive dogs). Dogs were individually housed in 1.2 x 1.8 m kennels
within one of two dog wards at the LMU DVTC. Dogs were stratified by treatment and
sex and evenly distributed between the two wards. Dogs were fed Purina Pro Plan EN
Gastroenteric Fiber Balance Dry Dog Food to meet the daily metabolizable energy
requirements of neutered adult dogs at maintenance, calculated as (70 * BW0.75) * 1.6 and
split into two meals per day. Dogs were weighed and body condition scored (5-point
scale) weekly for the adjustment of diets. Dogs arrived from the shelter and were started
on the study diet more than 37 days prior to starting treatments and 58 days before
collecting samples for this study.
Experimental Design and Treatments
These dogs were participating in a concurrent study evaluating the impact of CBD
on canine voluntary activity (Morris et al., 2021) with treatments consisting of 0 (placebo
treats; CON) or 75.6 ± 5.86 mg CBD/d (CBD). Dogs were blocked by baseline activity
before being stratified by age, weight, and sex and randomly assigned to treatments
within each block. The CBD was the primary constituent of a proprietary industrial hemp
isolate (AgTech Scientific, Paris, KY) that was incorporated into treats and administered
in the form of 2 treats daily, each containing half the daily dose. Both CON and CBD
treats were composed of the following ingredients: chicken, chicken liver, Asian carp,
catfish, and in the case of the CBD treats, industrial hemp extract. Cannabidiol was the
primary constituent of the industrial hemp extract; however, trace THC was present in the
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CBD treatment (2.9 ± 0.22 mg THC/d). Based on the mean BW of dogs included in the
study and analysis of the treats, mean dose of CBD was 4.5 ± 0.77 mg CBD/kg BW/d.
Treats were offered solely as a reward upon kennel re-entry following twice-daily
exercise, which was within 30 min of meals.
Blood Sample Collection
After 21 d of treatment administration, approximately 6 mL of blood was
collected via cephalic catheter or jugular venipuncture approximately 2 hours after the
final treat administration. The selection of this time point was based on previous work
demonstrating the half-life of elimination of CBD to be between 1 and 4 hours after oral
administration (Bartner et al., 2018; Deabold et al., 2019; Gamble et al., 2018). Blood
samples were collected into tubes containing sodium heparin and were immediately
centrifuged at 1645 x g for 10 min. Plasma was collected after centrifugation then stored
at -20°C (<12 hours) before long-term storage at -80°C.
CIL/LC-MS-Based Untargeted Metabolomics Analysis
Untargeted metabolomic profiling was done using a CIL/LC-MS-based technique
with an Agilent 1100 LC system (Palo Alto, CA) connected to a Bruker Impact HD
quadrupole time-of-flight (QTOF) MS (Billerica, MA). This technique uses a differential
isotope labelling (12C and 13C-labelling) to separate metabolites based on chemical
groups followed by LC-MS analysis (Zhao et al., 2019). Detailed information regarding
sample preparation, labeling, normalization, LC-UV and LC-MS setup, and metabolite
quantification have been reported elsewhere (Wu and Li, 2012; Mung and Li, 2017).
Typical coefficient of variation for this high-performance chemical isotope labeling LC-
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MS method for metabolome analysis is in the range of 5–10% for individual metabolites
(Guo and Li, 2009; Zhao et al., 2016; Zhao et al., 2017). In this study, the amine/phenol-,
carbonyl-, carboxyl-, and hydroxyl-containing metabolites were analyzed. A total of 19
LC-MS data files were generated (3 quality control samples, 8 CBD samples, and 8 CON
samples).
Metabolite Data Processing
Raw data processing on the 19 LC-MS data files was performed using ISOMS
Pro 1.0 according to procedures described by Mung and Li (2017). Peak pairs whose
mean (sample) / mean (blank) was ≤ 4.0 were filtered out. Peak pairs with no data present
in at least 80% of the samples were filtered out. The final metabolite-intensity table was
generated using IsoMS-Quant (Huan and Li, 2015).
Metabolite Identification
A two-tier identification approach was used to perform metabolite identification.
In tier 1, peak pairs were searched against a chemical isotope labeled metabolite library
(CIL Library) based on accurate mass and retention time (Huan and Li, 2015). In tier 2, a
linked identity library (LI Library) was used for identification of the remaining peak
pairs. The LI Library includes over 2000 human endogenous metabolites from 68
metabolic pathways, providing high-confidence putative identification results based on
accurate mass and predicted retention time matches (Li et al., 2013).
Statistical Analysis
The final metabolite intensity tables for the amine/phenol-, carbonyl-, carboxyl-,
and hydroxyl-containing metabolome were imported separately into MetaboAnalyst 5.0
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software package (www.metaboanalyst.ca; Chong et al., 2019) for statistical analysis.
Prior to statistical analysis, the data were log-transformed, normalized by median, and
auto-scaled. Median scaling was performed to eliminate unwanted inter-sample variations
to make the individual samples more comparable to each other. Auto-scaling was used to
make the metabolites more comparable in magnitude to each other.
Univariate (volcano plot) and multivariate analysis (Partial least squares
discriminant analysis [PLS-DA] scores plot) were then generated to identify overall
treatment differences across the multivariate dataset. The volcano plot was constructed by
plotting the fold change (FC; CBD/CON) of each metabolite against its P-value. The
volcano plot was constructed by plotting the FC (CBD/CON) of each metabolite against
its adjusted P-value. Metabolites with FC ≥ 1.2 or ≤ 0.83 having a false discovery ratio
(FDR) ≤ 0.05 were considered to be differentially increased or decreased relative to
CON, respectively.
The utility of the metabolites with FC ≥ 1.2 or ≤ 0.83 and FDR ≤ 0.05 to serve as
potential biomarkers of the effects of CBD was tested using receiver operating
characteristic (ROC) curves as calculated by the ROCCET web server using
MetaboAnalyst 5.0 software package. Metabolites with an area under ROC (AUROC) ≥
0.90 and a P ≤ 0.05 were considered excellent biomarkers as defined in Xia et al. (2013).
Results
Amine/Phenol Metabolites
Within the amine/phenol analysis, a total of 2681 unique peak pairs (representing
different compounds) were detected. Of those peak pairs, 134 metabolites were positively
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identified in tier 1 (CIL Library; Supplementary Table 6.1) and 103 metabolites were
putatively identified with high confidence in tier 2 (LI Library; Supplementary Table
6.2). The PLS-DA scores plot (Figure 6.1A) shows clear separation between CON and
CBD samples, and the permutation test (P < 0.01) confirms the validity of the PLS-DA
model (Supplementary Figure 6.1).
Volcano plot analysis showed that 32 metabolites were differentially altered (FC
≥ 1.2 or ≤ 0.83, FDR ≤ 0.05) by CBD (Table 6.1; Figure 6.1B). Eighteen of those
metabolites – pyrimidodiazepine, 4-amino-4-deoxychorismate, isoferulic acid, an isomer
of D-glucosamine, 7-carboxy-7-carbaguanine, 2,4-dihydroxyhept-2-enedioate, ascorbate,
2’-deamino-2’-hydroxy-6’-dehydroparomamine, trans-2,3-dihydroxycinnamate, gammaglutamyl-gamma-aminobutyraldehyde, 1,4-diaminobutane, tyramine, an isomer of 2deoxy-scyllo-inosamine, isoleucyl-alanine, 3,4-hydroxyphenylpyruvate, aspartylthreonine, vanillic acid, and D-lysopine – were differentially increased (FC ≥ 1.2, FDR ≤
0.05) by CBD. The other 14 metabolites – N-acetyl-L-asparagine, alanyl-proline,
asparaginyl-aspartic acid, seryl-aspartic acid, phenylalanyl-glycine, prolyl-glutamine, otyrosine, N-acetyl-L-adrenaline, L-threo-3-methylaspartate, Z-3-peroxyaminoacrylate, Lglutamate-5-semialdehyde, 2-methyl-3-hydroxy-5-formylpyridine-4-carboxylate,
gamma-aminobutyric acid, and aspartyl-glutamine – were differentially reduced (FC ≤
0.83, FDR ≤ 0.05) by CBD compared to CON.
Univariate ROC analysis of the 32 identified amine/phenol-containing metabolites
that were differentially increased or decreased by CBD revealed 24 metabolites –
aspartyl-glutamine, gamma-aminobutyric acid, gamma-glutamyl-gammaaminobutyraldehyde, L-glutamate-5-semialdehyde, prolyl-glutamine, pyrimidodiazepine,
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4-amino-4-deoxychorismate, trans-2,3-dihydroxycinnamate, alanyl-proline, N-acetyl-Lasparagine, (Z)-3-peroxyaminoacrylate, 1,4-diaminobutane, 2’-deamino-2’-hydroxy-6’dehydroparomamine, ascorbate, D-lysopine, o-tyrosine, phenylalanyl-glycine, 2,4dihydroxyhept-2-enedioate, asparaginyl-aspartic acid, isoferulic acid, 7-carboxy-7carbaguanine, 3-(4-hydroxyphenyl)pyruvate, aspartyl-threonine, and isoleucyl-alanine –
that appear to be highly predictive of the metabolomic changes between CBD and CON
(AUROC ≥ 0.90; P < 0.001; Figure 6.2).
Carbonyl Metabolites
Within the carbonyl analysis, a total of 612 unique peak pairs were detected. Of
those peak pairs, 6 peak pairs were positively identified in tier 1 (CIL Library;
Supplementary Table 6.1) and 15 peak pairs were putatively identified with high
confidence in tier 2 (LI Library; Supplementary Table 6.2). The PLS-DA scores plot
(Figure 6.3A) shows clear separation between CON and CBD samples, and the
permutation test (P < 0.01) confirms the validity of the PLS-DA model (Supplementary
Figure 6.2).
Volcano plot analysis showed that 5 metabolites were differentially altered (FC ≥
1.2 or ≤ 0.83, FDR ≤ 0.05) by CBD (Figure 6.3B; Table 6.2). Glucose and 2formylglutarate were differentially increased (FC ≥ 1.2, FDR ≤ 0.05) by CBD, while
glyceraldehyde, isomer of glyceraldehyde, and 4-oxoglutaramate were differentially
reduced (FC ≤ 0.83, FDR ≤ 0.05) by CBD compared to control.
Univariate ROC analysis of the 5 carbonyl metabolites positively and putatively
identified that were differentially altered by CBD revealed that plasma glucose appears to
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be highly predictive of the metabolomic changes between CBD and CON (AUROC =
0.91; P = 0.020; Figure 6.4).
Carboxyl Metabolites
Within the carboxyl analysis, a total of 2943 unique peak pairs were detected. Of
those peak pairs, 29 peak pairs were positively identified in tier 1 (CIL Library;
Supplementary Table 6.1) and 144 peak pairs were putatively identified with high
confidence in tier 2 (LI Library; Supplementary Table 6.2). The PLS-DA scores plot
(Figure 6.5A) shows clear separation between CON and CBD samples, and the
permutation test (P = 0.02) confirms the validity of the PLS-DA model (Supplementary
Figure 6.3).
Volcano plot analysis showed that 42 metabolites were differentially altered (FC
≥ 1.2 or ≤ 0.83, FDR ≤ 0.05) by CBD (Figure 6.5B; Table 6.3) Twenty-eight metabolites
– 2,5-dioxopentanoate, isomer of hydroxypropionic acid, 4-cumarate, isomer of Dglycerate, acetic acid, D-glycerate, isomer of glycolate, isomer of threonate, 5-deoxy-Dglucuronate, citramalic acid, glycolate, 3-oxopropanoate, ethyl malonate, isomer of 4oxopropanoate, isomer of 3-hydroxybutyric acid, 2-hydroxy-3-oxopropanoate,
hydroxyisobutyric acid, isovaleric acid, butyric acid, glyoxylate, nicotinate, 3hydroxybutyric acid, (S)-5-amino-3-oxohexanoic acid, hydroxypropionic acid, lactic
acid, isomer of lactic acid, and isovanillic acid – were differentially increased (FC ≥ 1.2,
FDR ≤ 0.05) by CBD. Fourteen metabolites – 4-oxoproline, 2-aminomuconate
semialdehyde, isomer of 9-oxononanoic acid, L-1-pyrroline-3-hydroxy-5-carboxylate,
(S)-4-amino-5-oxopentanoate, isomer of 1-aminocyclopropane-1-carboxylate, Lallothreonine, arginine, isomer of aspartate, isomer of jasmonic acid, isojasmonic acid, 2105

oxo-4-phenylbutyric acid, 9,10-12,13-diepoxyoctadecanoate, jasmonic acid, and isomer
of 1-pyrroline-2-carboxylate – were differentially reduced (FC ≤ 0.83, FDR ≤ 0.05) by
CBD compared to control.
Univariate analysis of the 42 carboxyl metabolites positively and putatively
identified that were differentially increased or decreased by CBD revealed that 23
metabolites – jasmonic acid, (S)-4-amino-5-oxopentanoate, 3,4-dihydroxymandelic acid,
isomer of 1-aminocyclopropane-1-carboxylate, isomer of hydroxypropionic acid, L-1pyrroline-3-hydroxy-5-carboxylate, L-allothreonine, 2-oxo-4-phenylbutyric acid,
arginine, citramalic acid, 4-oxoproline, 5-deoxy-D-glucuronate, 9,10-12,13diepoxyoctadecanoate, isomer of 1-pyrroline-2-carboxylate, isomer of aspartate, 2aminomuconate semialdehyde, isomer of 9-oxononanoic acid, acetic acid, ethyl
malonate, isomer of jasmonic acid, 3-oxopropanoate, D-glycerate, and isomer of Dglycerate – appear to be highly predictive of the metabolomic changes between CBD and
CON (AUROC ≥ 0.90; P < 0.001; Figure 6.6).
Hydroxyl Metabolites
Within the hydroxyl analysis, a total of 3759 unique peak pairs were detected. Of
those peak pairs, 141 peak pairs were positively identified in tier 1 (CIL Library;
Supplementary Table 6.1) and 65 peak pairs were putatively identified with high
confidence in tier 2 (LI Library; Supplementary Table 6.2). The PLS-DA scores plot
(Figure 6.7A) shows clear separation between CON and CBD samples, and the
permutation test (P < 0.01) confirms the validity of the PLS-DA model (Supplementary
Figure 6.4).
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Volcano plot analysis showed that 32 metabolites were differentially altered (FC
≥ 1.2 or ≤ 0.83, FDR ≤ 0.05) by CBD (Figure 6.7B; Table 6.4). Fifteen metabolites –
17α,20α-dihydroxypregn-4-en-3-one, D-tagatose, 3,4-dihydroxyphenylpropanoate, Lrhamnono-1,4-lactone, L-rhamnofuranose, isomer of L-rhamnofuranose, 6-deoxy-Lgalactose, D-galactosamine, sepiapterin, isomer of sepiapterin, L-fuculose, isomer of
deoxyadenosine, deoxyadenosine, and 3-hydroxy-L-proline – were differentially
increased (FC ≥ 1.5, FDR ≤ 0.05) by CBD. Eighteen metabolites – N-acetyl-trans-3hydroxy-L-proline, ethanolamine, 2,3-dihydroxyindole, N2’-acetyl-3’hydroxykynurenamine, cyanate, isomer of cyanate, glycerol, alpha-ribazole, isomer of 3phenoxybenzyl alcohol, dihydroshikonofuran, glycoaldehyde, N-acetyl-2-carboxy-2,3dihydro-5,6-dihydroxyindole, allotetrahydrodeoxycorticosterone 3-O-glucuronide,
phenethyl alcohol, propane-1,3-diol, cortolone, arabitol, and cortisol 21-O-sulfate – were
differentially reduced (FC ≤ 0.83, FDR ≤ 0.05) by CBD compared to control.
Univariate analysis of the 35 hydroxyl metabolites positively and putatively
identified that were differentially increased or decreased by CBD revealed that 15
metabolites – L-fuculose, glyceraldehyde, L-rhamnofuranose, L-rhamnono-1,4-lactone,
arabitol, D-tagatose, propane-1,3-diol, 6-deoxy-L-galactose, D-galactosamine, phenethyl
alcohol, isomer of L-rhamnofuranose, isomer of 3-phenoxybenzyl alcohol, 3,4dihydroxyphenylpropanoate, cortolone, and isomer of deoxyadenosine – appear to be
highly predictive of the metabolomic changes between CBD and CON (AUROC ≥ 0.90;
P < 0.001; Figure 6.8).
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Discussion
Amino Acid Metabolism
Increased concentrations of tyramine, 3-(4-hydroxyphenyl)pyruvate, 2,4dihydroxyhept-2-enedioate, gamma-glutamyl-gamma-aminobutyraldehyde, 1,4diaminobutane, 2,5-dioxopentanoate, 3-hydroxy-L-proline, D-lysopine, D-glycerate,
isomer of D-glycerate, glycolate, isomer of glycolate, glyoxylate, 2-hydroxy-3oxopropanoate, glycolaldehyde 3,4-dihydroxymandelic acid, hydroxyisobutyric acid,
isovaleric acid, butyric acid, S-5-amino-3-oxohexanoic acid, 3-hydroxypropionic acid,
and isomer of hydroxypropionic acid indicate that CBD altered amino acid metabolism.
Tyramine, 3-(4-hydroxyphenyl)pyruvate, and 2,4-dihydroxyhept-2-enedioate are
intermediates in tyrosine and phenylalanine metabolism (Lehmann and Pollmann, 2009;
Miller and Litwack, 1971; Wang et al., 2010). Tyramine, in particular, is also involved in
the biosynthesis of many secondary metabolites in plants, such as isoquinoline alkaloids,
flavonoids, and hydroxycinnamic acid amines (Leonard et al., 2020; Sato et al., 2007).
Gamma-glutamyl-gamma-aminobutyraldehyde, 2,5-dioxopentanoate, 3-hydroxyL-proline, and 1,4-diaminobutane (i.e. putrescene) are intermediates in arginine, proline,
hydroxyproline, and ornithine degradation pathways (Kurihara et al., 2005; Jo et al.,
2008; Visser et al., 2012; Watanabe et al., 2012). Putrescene is also known to play a role
in the regulation of cell growth, protein synthesis, apoptosis, and other cellular processes
(Igarashi and Kashiwagi, 2010; Larqué et al., 2007). 2,5-dioxopentanoate can be
converted into 2-oxoglutarate, by which it can enter the citric acid cycle through
conversion into succinyl-CoA in several prokaryotic organisms, including several species
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of Pseudomonas, Escherichia coli, and Haloferax volcanii (Brouns et al., 2006; Johnsen
et al., 2009; Watanabe et al., 2006).
D-lysopine is an amino opine derivative of L-lysine found in crown gall tumors
produced by pathogenic bacteria that infect plants, including C. sativa. While not known
to be produced in mammalian systems, other opines like saccharopine are known
intermediates in the metabolism of lysine in mammals (Darling and Larsen, 1961;
Lippincott et al., 1972; Moore et al., 1997). 3,4-Dihydroxymandelic acid is a metabolite
of norepinephrine with potent antioxidant activity (Ley et al., 2002). If the increase in
3,4-dihydroxymandelic acid, it is possible that its increase may contribute to the
antioxidant effect of CBD, which warrants further investigation.
Hydroxyisobutyric acid is an intermediate in valine degradation that in humans is
used as a biomarker of 3-hydroxyisobutyric aciduria and methylmalonic semialdehyde
dehydrogenase deficiency, rare metabolic diseases (Podebrad et al., 2000). In dogs,
alpha-hydroxyisobutyric acid was shown to be upregulated in a small group of dogs with
diabetes compared to healthy controls (O’Kell et al., 2017), though it was not identified
as a potential CBD biomarker in this study. Isovaleric acid is a branched-chain fatty acid
intermediate in leucine catabolism (Parimoo and Tanaka, 1993), and S-5-Amino-3oxohexanoic acid is an intermediate in lysine degradation (Bellinzoni et al., 2011;
Kreimeyer et al., 2007).
D-glycerate is an essential intermediate in the catabolism of glycine, serine, and
threonine in plants. Once formed, D-glycerate can then feed into either glyoxylate
metabolism via hydroxypyruvate or be converted into 3-phospho-D-glycerate and fed
into glycolysis (Bartsch et al., 2008; Randall and Tolbert, 1971). In humans with a
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glycerate kinase mutation, D-glycerate levels are elevated to the point of acidemia which,
if left untreated, can lead to progressive neurological impairment, hypotonia, seizures,
failure to thrive, and metabolic acidosis (Guo et al., 2006; Sass et al., 2010). In plants,
glycolate is an intermediate in glyoxylate metabolism, converting hydroxypyruvate into
glyoxylate for further metabolism in the glyoxylate cycle (Kisaki and Tolbert, 1969). In
mammalian systems, glyoxylate is produced either through oxidation of glycolate in
peroxisomes or the catabolism of hydroxyproline before being converted into glycine via
alanine-glyoxylate aminotransferases present in peroxisomes (Belostotsky et al., 2012;
Salido et al., 2012). The glyoxylate cycle, a pathway that converts fatty acids into glucose
once believed to be absent in mammalian systems, may be present in the liver (Davis and
Goodman, 1992; Song, 2000). Genetic defects in glyoxylate metabolic enzymes have
been attributed to metabolic diseases like primary hyperoxalurias and insulin resistance,
though this has not been investigated in canine models (Salido et al., 2012; Song, 2000).
Additionally, plasma glyoxylate has been indicated as an early marker for type II diabetes
development in humans (Nikiforova et al., 2014; Padberg et al., 2014). 2-Hydroxy-3oxopropanoate and glycolaldehyde are additional intermediates in glyoxylate metabolism
(Barkulis and Krakow, 1956; Gupta and Vennesland, 1964). Glycolaldehyde is also
precursor to pyridoxine synthesis and is an intermediate in folate synthesis in bacteria
(Vella et al., 1980). The increase in these metabolites may suggest that CBD enhanced
amino acid degradation.
Decreased concentrations of N-acetyl-L-asparagine, o-tyrosine, N-acetyl-Ladrenaline, L-threo-3-methylaspartate, L-glutamate-5-semialdehyde, 4-oxoglutaramate,
4-oxoproline, L-1-pyrroline-3-hydroxy-5-carboxylate, isomer of 1-pyrroline-2-
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carboxylate, N-acetyl-trans-3-Hydroxy-L-proline, arginine, 2-aminomuconate
semialdehyde, isomer of 1-aminocyclopropane-1-carboxylate, L-allothreonine, isomer of
aspartate, 2-oxo-4-phenylbutyric acid, 2,3-dihydroxyindole, N2’-acetyl-3'hydroxykynurenamine, cyanate, isomer of cyanate, and N-acetyl-2-Carboxy-2,3-dihydro5,6-dihydroxyindole may also suggest that CBD altered amino acid metabolism. Nacetyl-L-asparagine is a derivative of asparagine that is N-acetylated by N‐
acetyltransferase 1 (NAT1), one of several acetyltransferases known to play a role in drug
metabolism (Carlisle et al., 2018). This enzyme has been suggested to play a role in the
regulation of mTOR complex I activation, cancer cell proliferation, and mitochondrial
function (Butcher and Minchin, 2012; Camporez et al., 2017; Carlisle et al., 2018). As
CBD is suspected to exert an anti-cancer effect, it may be prudent in future work to
investigate if CBD supplementation alters NAT1 activity.
o-Tyrosine is a structural isomer of tyrosine and a phenylalanine derivative. It is
considered a marker for oxidative stress as it is produced through free-radical
hydroxylation of phenylalanine (Molnar et al., 2005; 2016). If the decrease in o-tyrosine
was due to CBD supplementation, this may contribute to the suspected antioxidative
effects of CBD. N-acetyl-L-adrenaline is a methylated form of epinephrine, an adrenal
hormone involved in the regulation of visceral functions (Malenka et al., 2015; Smith et
al., 1992). 2-Aminomuconate semialdehyde, 2,3-dihydroxyindole, and N2’-acetyl-3’hydroxykynurenamide are intermediates in tryptophan metabolism. 2-Aminomuconate is
part of the kynurenine pathway, a metabolic pathway used for NAD biosynthesis
(Colabroy et al., 2005; Nishizuka et al., 1965). Kynurenine pathway metabolites like 2aminomuconate are thought to help regulate processes like immune cell response,
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neuronal excitability, and host-microbiome signaling (Cervenka et al., 2017). N2’Acetyl-3'-Hydroxykynurenamine is an acetylated intermediate in tryptophan metabolism
(Thiele et al., 2013). 2-3-Dihydroxyindole is an intermediate in an indole degradation
pathway present in several bacterial species but is not known as a mammalian metabolite
(Ma et al., 2018). 2-Oxo-4-phenylbutyric acid is an intermediate in phenylalanine,
tyrosine, and tryptophan metabolism that, in microbial species, is a precursor to
homophenylalanine (Koketsu et al., 2013); however, this pathway is not known to be
present in mammalian species. N-Acetyl-2-Carboxy-2,3-dihydro-5,6-dihydroxyindole
(i.e. leucodopachrome) is an intermediate in tyrosine metabolism and in betalain
melanogenesis pathway (Land et al., 2003; Olivares et al., 2001). While these results
would suggest an alteration of phenolic-containing amino acid metabolism by CBD, the
implications remain unclear as the relative concentrations of phenylalanine, tyrosine, and
tryptophan remained unchanged by treatment.
L-Glutamate-5-semialdehyde is a non-proteinogenic amino acid that is an
intermediate in both proline and arginine biosynthesis from glutamate (Fons et al., 1991;
Ginguay et al., 2017). L-1-pyrroline-3-hydroxy-5-carboxylate, and 1-pyrroline-2carboxylate are intermediates in arginine and proline metabolism (Abaskharon et al.,
2019; Hu et al., 1996; Watanabe et al., 2016). N-Acetyl-trans-3-hydroxy-L-proline (i.e.
oxaceprol) is a derivative of L-proline that is an established anti-inflammatory drug used
in the treatment of osteoarthritis (Durg et al., 2019). Combined with the decrease in
arginine, these results suggest an impact of CBD on arginine and proline metabolism;
however, since the relative concentration of proline was unaffected by treatment, the
biological significance is unclear. 4-oxoglutaramate is an intermediate in one of the
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histidine catabolism pathways that leads to the production of 2-oxoglutarate (i.e. αketoglutarate), which then feeds into the citric acid cycle (Brown and Kies, 1959; Hassall
and Greenberg, 1963).
L-threo-3-methylaspartate is an amino acid formed by glutamate mutase and can
be metabolized by methylaspartate ammonia-lyase. It is found in the structures of the
antibiotics friulimicin and vicenistatin and in carbon metabolism of haloarchaea
(Khomyakova et al., 2011; Raj and Poelarends, 2013). Cyanate is an intermediate in
nitrogen metabolism that can be produced spontaneously from urea. It has been suggested
to improve insulin sensitivity and potentially exert antioxidative effects (Kang et al.,
2018). Aspartyl-glutamine, aspartyl-threonine, alanyl-proline, asparaginyl-aspartic acid,
isoleucyl-alanine, phenylalanyl-glycine, prolyl-glutamine, and seryl-glycine are products
of the incomplete breakdown of protein digestion or catabolism. While some dipeptides
are known to have physiological or cell-signaling effects, none of the affected dipeptides
have been identified as one of these bioactive molecules (Naka et al., 2015; Nakato et al.,
2019).
The altered concentrations of these metabolites suggest an effect of CBD on
amino acid metabolism. However, since the relative concentrations of the individual
amino acids like glutamate and proline were unaffected by treatment, the biological
significance of the changes in these metabolites is unclear. Additional research is needed
to assess the potential for CBD to alter amino acid metabolism.
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Carbohydrate Metabolism
The increase in glucose, lactic acid, acetic acid, an isomer of glucosamine, 2’deamino-2’-hydroxy-6’-dehydroparomamine, an isomer of 2-deoxy-schyllo-inosamine,
D-glycerate, D-tagatose, D-galactosamine, L-rhamnono-1,4-lactone, L-rhamnofuranose,
L-fuculose, 6-deoxy-L-galactose, and 5-deoxy-D-glucuronate may suggest that
carbohydrate metabolism was altered by CBD. The endocannabinoid system (ECS) – by
which CBD and other cannabinoids exert physiological effects – plays a well-established
role in glucose and energy metabolism, marking it as a target for the treatment of
metabolic diseases like type 2 diabetes (Bielawiec et al., 2020). Cannabinoids like CBD
and THC have been suggested to reduce hyperglycemia and increase insulin production
in rodents (Jadoon et al., 2016; Zorzenon et al., 2019), but this has yet to be investigated
in a canine model. Lactic acid is generated from pyruvate during anaerobic conditions in
the muscle and red blood cells. The Cori cycle, or lactic acid cycle, removes lactate from
tissues and transports lactate via blood to the liver where it can be converted back into
glucose (Katz and Tayek, 1998; Nuttall et al., 2008). As both this cycle and lactic acid
play vital roles in glucose homeostasis, the increase in plasma lactic acid indicates
alteration of glucose metabolism by CBD. Similarly, acetic acid plays a role as an
intermediate in several essential energetic pathways, including glycolysis, pyruvate
metabolism, and glyoxylate metabolism via acetyl-CoA.
Glucosamine is an amino sugar that is readily synthesized in the body from
glucose and glutamine. It is an essential component of mucopolysaccharides that are
incorporated into connective tissue, mucous secretions, skin, tendons, ligaments, and
cartilage. Additionally, it helps regulate the synthesis of collagen in cartilage (Anderson
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et al., 2005; Beale, 2004; Bhathal et al., 2017). Because of its high concentration in joint
tissues, glucosamine is commonly used as a dietary supplement in humans, horses, and
dogs as a support for joint health and function and to relieve symptoms of osteoarthritis,
though there is little scientific evidence supporting these effects (Henroitin et al., 2012).
Both 2-deoxy-scyllo-inosamine and 2’-deamino-2’-hydroxy-6’-dehydroparomamine are
intermediates in the biosynthesis of aminoglycoside antibiotics, like kanamycin, from
glucose in Streptomyces bacterial species (Kudo et al., 2005; Park et al., 2011). However,
since these metabolites are not known to be generated in mammalian systems, the
biological significance of their changes is unclear.
D-glycerate is an intermediate in several metabolic pathways. Regarding
carbohydrate metabolism, D-glycerate is an intermediate in the conversion of other Dsugars and glyoxylate to 2-phosphoglycerate, which can then feed into glycolysis
(Dawkins and Dickens, 1965; Heinz et al., 1968). D-tagatose is a monosaccharide often
found in fruit or dairy products that is commonly used as an artificial sweetener due to its
low glycemic index (Mu et al., 2018). It can also be produced as an intermediate in the
catabolism of D-sugars like D-galactose prior to entry into the pentose phosphate
pathway (Bohren et al., 1989). D-galactosamine is an amino sugar derived from galactose
that is a constituent of glycoprotein hormones like luteinizing hormone and folliclestimulating hormone (Saracyn et al., 2015; Wu et al., 2014). L-rhamnono-1,4-lactone, Lrhamnofuranose, L-fuculose, and 6-deoxy-L-galactose (i.e. fucose) are intermediates in
fructose and mannose metabolism (Becker and Lowe, 2003; Rigo et al., 1985; Wen et al.,
2016). Fucose, in particular, is a common N-linked glycan that has been shown to play an
important role in mammalian health, with disruption of fucosylated glycan expression
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implicated in a number of disease mechanisms (Becker and Lowe, 2003; Vanhooren and
Vandamme et al., 1999).
5-deoxy-D-glucuronate is an intermediate in the catabolism of myo-inositol in
bacterial species like Bacillus subtilis, a common species found in the gastrointestinal
tract of humans and ruminants (Hong et al., 2009; Yoshida et al., 2008). While not known
to be produced in canine metabolic pathways, production of 5-deoxy-D-glucuronate in
the gastrointestinal tract by microflora may have been absorbed into the body. The
increase in this metabolite may suggest CBD supplementation affected gastrointestinal
microflora populations. Decreased concentrations of arabitol may also support an impact
of CBD on the microbiome. Arabitiol is a sugar alcohol commonly produced by several
yeast species (Kordowska-Wiater, 2015). Elevated levels of arabitol in urine have been
suggested as a biomarker of fungal infections (Salonen et al., 2001), and elevated plasma
arabitol has been linked to other diseases like congenital liver cirrhosis and acute
mountain sickness in humans (Verhoeven et al., 2001; Zhu et al., 2015). While CBD is
believed to be beneficial in an assortment of gastrointestinal conditions (McCabe and
Cital, 2021), little work has been done regarding its influence on microbial populations in
the canine gastrointestinal tract, highlighting a potential avenue for future investigation of
CBD supplementation.
The decrease in gamma-aminobutyric acid (GABA), glyceraldehyde, and an
isomer of glyceraldehyde may also indicate that CBD altered carbohydrate metabolism.
Best known as the primary inhibitory neurotransmitter in the central nervous system,
GABA is also produced by insulin-producing β cells of the pancreas, endothelial cells,
gut microbiota, and immune cells (Bansal et al., 2011; Franklin and Wollheim, 2004). In
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the pancreas, GABA inhibits glucagon secretion from neighboring α cells and modulates
glucose homeostasis (Bansal et al., 2011; Purwana et al., 2014; Rorsman et al., 1989).
This action of GABA in the pancreas has highlighted its potential as a target for diabetes
treatment (Wan et al., 2015). It has also been shown to regulate cytokine secretion from
PBMCs and CD4+ T cells and is thought to exert anti-inflammatory effects (Bhandage et
al., 2018; Jin et al., 2013; Prud'homme et al., 2013). Glyceraldehyde, a triose
monosaccharide, is an intermediate in glycolysis in its phosphorylated form (GAP).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), the enzyme that catalyzes the
conversion of GAP into 1,3-bisphosphoglycerate, is a major regulator of carbon flux in
the body (Hildebrandt et al., 2015). It is also known to play a role in other cellular
functions such as redox sensing, membrane fusion, iron homeostasis, and cell death
(White and Garcin, 2017). The decrease in glyceraldehyde might lend support to the
suspected anti-obesity and anti-diabetic effects of CBD; however, the relative increase in
glucose and decrease in GABA would appear to be incongruous with this potential effect.
These results highlight a relatively unexplored avenue of CBD research that warrants
further investigation.
Lipid Metabolism
Increased concentrations of 17alpha,20alpha-dihydroxypregn-4-en-3-one, ethyl
malonate, 3-hydroxybutyric acid, an isomer of 3-hydroxybutyric acid, 3hydroxypropionic acid, an isomer of hydroxypropionic acid, and butyric acid may
indicate an alteration of lipid metabolism with CBD supplementation. Primarily known as
a steroid hormone elevated in late pregnancy in mammals, 17alpha,20alphadihydroxypregn-4-en-3-one is also thought to play a role in progesterone homeostasis in
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non-pregnant animals (Mahajan et al., 1983; Shikita et al., 1967). Ethyl malonate is a
branched fatty acid associated with several fatty acid metabolism disorders in humans,
including short-chain acyl-CoA dehydrogenase deficiency and ethylmalonic
encephalopathy (Tiranti et al., 2004; Wolfe et al., 2011), and has also been identified as a
potential biomarker for the detection of human breast cancer (Wang et al., 2018). 3hydroxybutyric acid is a ketone body and a typical intermediate in the partial breakdown
of branched-chain amino acids like valine in muscles (Miyazaki et al., 2015). 3Hydroxypropionic acid is an intermediate in beta-alanine, propanoate, and uracil
metabolism (Den et al., 1959; Hawes et al., 1996). Butyric acid is an intermediate in
butanoate metabolism, which is often formed by bacterial fermentation in the gut (Louis
and Flint, 2009; Macfarlane and Macfarlane, 2003).
Additionally, decreased concentrations of propane-1,3-diol, glycerol,
ethanolamine, isomer of 9-oxononanoic acid, 9,10-12,13-diepoxyoctadecanoate,
allotetrahydrodeoxycorticosterone 3-O-glucuronide, cortolone, and cortisol 21-O-sulfate
may also suggest that CBD altered lipid metabolism. Propane-1,3-diol is a product of
glycerol fermentation in bacterial species but is not known as a mammalian metabolite
(Marçal et al., 2020). Glycerol is the backbone of glycerides and plays an essential role in
lipid metabolism, carbohydrate metabolism, and other metabolic processes (Blötz and
Stülke, 2017). Blood glycerol is also a biomarker for liver disease, hyperglycemia, and
type II diabetes (Jin et al., 2018; Johnston et al., 1982; Mahendran et al., 2013).
Additionally, glycerol is involved in endocannabinoid signaling as a product of
endocannabinoid 2-arachidonylglycerol (2-AG) hydrolysis (Baggelaar et al., 2018).
Ethanolamine, an amino alcohol, is an intermediate in glycerophospholipid metabolism.
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It is also involved in retrograde endocannabinoid signaling as a product of arachidonoyl
ethanolamide (AEA) degradation by fatty acid amide hydrolase (FAAH) (Giang and
Cravatt, 1997). These results may suggest CBD inhibited AEA degradation, which
supports previous work showing inhibition of cellular uptake and breakdown of AEA by
CBD via inhibition of fatty acid binding proteins (Elmes et al., 2015; Leweke et al., 2012;
Schroeder et al., 2016). However, as the relative concentrations of plasma AEA and 2AG were unaffected by treatment, the physiological significance of the changes in these
metabolites is unclear. Future work using targeted metabolomics and pathway analysis
may further elucidate this potential effect.
9-Oxononanoic acid is a medium chain fatty acid product of alpha-linoleic acid
oxidation in plants (Otte et al., 2013). Early studies showed elevated lipid peroxides and
reduced lipogenesis in rat livers after oral administration of 9-oxononanoic acid
(Kanazawa et al., 1986; Minamoto et al., 1988); more recent work indicates this is a
result of arachidonic cascade induction by 9-oxononanoic acid through its activation of
phospholipase A2 (Ren et al., 2013). If the decrease in 9-oxononanoic acid is a result of
CBD supplementation, this may be one potential mechanism contributing to the
suspected anti-inflammatory effects of CBD. Jasmonic acid is a plant stress hormone
synthesized from linolenic acid that serves as a natural pesticide and promotes plant
growth (Behr et al., 2019). Additionally, jasmonic acid has been suggested to exhibit
anti-cancer and anti-inflammatory properties in vitro (Henriet et al., 2017). 9,10-12,13Diepoxyoctadecanoate is an intermediate in the conversion of linoleic acid into
tetrahydrofurandiols (THF-diols) (Falck et al., 2007).
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Allotetrahydrodeoxycorticosterone (THDOC) 3-O-glucuronide is an endogenous
neurosteroid that acts as a potent positive allosteric modulator of the GABAA receptor
and exhibits sedative, anxiolytic, and anticonvulsant effects (Reddy, 2006; Reddy and
Rogawski, 2002). Cortolone and cortisol 21-O-sulfate are metabolites in steroid hormone
catabolism (Kornel et al., 1995). Cortolone is often linked to a glucuronide to help in its
excretion (Hosoda et al., 1984; Yang et al., 2017), and cortisol 21-O-sulfate may be used
as a biomarker for Cushing’s syndrome (Kornel et al., 1995).
Altogether, these results support an effect of CBD on lipid metabolism and may
indicate potential mechanisms for its suspected anti-inflammatory effect. However, as the
animals on this study were healthy, it is unclear how this would translate to a diseased
population in which these metabolomic changes might be more influential, such as
animals with Cushing’s disease. Further studies are needed in unhealthy or diseased
populations of dogs to determine the potential physiological applications of these
potential effects of CBD.
Hydroxycinnamic Acid Derivatives
The increase in plasma isoferulic acid (IFA), trans-2,3-dihydroxycinnamate, and
vanillic acid may suggest that CBD altered the metabolism of hydroxycinnamic acid
derivatives. Isoferulic acid is a naturally occurring hydroxycinnamic acid derivative
commonly found in Lobelia and Cimicifuga species. It is an isomer of ferulic acid, a
phenolic compound that is a component of lignin, which is commonly found in cell walls
of plants, including C. sativa (Zimniewska et al., 2018). Ferulic acid has also been
isolated from hemp seed meal, a byproduct of hemp oil processing (Pojić et al., 2014).
Both ferulic acid and IFA have been reported to have anti-inflammatory, anti-viral, anti120

oxidative, and anti-diabetic properties and are commonly used as ingredients in herbal
medicines in Japan and China (Meeprom et al., 2013; Zhao et al., 2008). Isoferulic acid
has been shown to reduce plasma glucose in diabetic rats and to inhibit IL-8 production
in mice (Liu et al., 2000; Hirabayashi et al., 1994). Additionally, IFA has been suggested
to act as an anti-glycation compound. Protein glycation is a non-enzymatic reaction
associated with oxidative stress and reactive oxygen species (ROS) production; it is
thought to be a contributor to age-related diseases (Meeprom et al., 2015). In several
studies, IFA protected against fructose- and glucose-mediated glycation and inhibited
ROS production in vitro (Meeprom et al., 2013; Arfin et al., 2018). In humans, IFA has
been shown to be an intermediate in the metabolism of plant-derived phenolic
compounds like caffeic acid (Clifford et al., 2019), with humans obtaining the majority
from dietary consumption.
Trans-2,3-dihydroxycinnamate is a derivative of cinnamic acid, which is an
intermediate in the biosynthesis of lignin, flavonoids, and other secondary metabolites
produced by plants like C. sativa (Vogt, 2010). Cinnamic acid and its derivatives, like
trans-2,3-dihydroxycinnamate, possess antioxidizing activity (Santos and Vieira, 2013).
Vanillic acid is a dihydroxybenzoic acid derivative commonly used as a flavoring agent.
It is also an intermediate in the synthesis of vanillin from ferulic acid and a phenolic
compound that, like IFA, is a component of lignin present in the secondary cell wall of
plants, including C. sativa (Civolani et al., 2000; Khan et al., 2014). Like other ligninassociated aromatic acids, vanillic acid has been reported to exert antimicrobial properties
(Yemiş et al., 2011). If the increase in these metabolites is a result of CBD
supplementation, it is possible that these compounds may contribute to the suspected
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anti-microbial, anti-inflammatory, and antioxidative effects of hemp; however, additional
work is warranted to further investigate these potential effects.
Vitamin and Nucleotide Metabolism
Increased concentrations of pyrimidodiazepine, 4-amino-4-deoxychorismate, 7carboxy-7-carbaguanine, 2-formylglutarate, ascorbate, an isomer of threonate, 2hydroxy-3-oxopropanoate, nicotinate, 3-oxopropanoate, an isomer of 3-oxopropanoate,
deoxyadenosine, and an isomer of deoxyadenosine may indicate an alteration of vitamin
and nucleotide metabolism. Pyrimidodiazepine is a derivative of uracil and a substrate for
pyrimidodiazepine synthase, an enzyme that can contribute to glutathione synthesis.
Uracil derivatives like pyrimidodiazepine are also thought to possess antimicrobial and
antioxidant properties (El-Kalyoubi et al., 2017). 3-Oxopropanoate is an intermediate in
uracil and beta-alanine metabolism that can then be converted into malonate and enter
fatty acid biosynthetic pathways (Scholem and Brown, 1983). Deoxyadenosine is a
derivative of adenosine and an intermediate in purine metabolism. In the absence of
adenosine deaminase in humans, deoxyadenosine will accumulate in and kill T
lymphocytes, leading to the development of adenosine deaminase severe combined
immunodeficiency disease (Bradford et al., 2017). Nicotinate, or vitamin B3, is required
for the formation of coenzymes NAD and NADP. While it can be synthesized from
tryptophan in humans and dogs, the process is inefficient and is thus considered an
essential nutrient (Kirkland, 2009; Krehl and Torbet, 1946). 4-amino-4-deoxychorismate
is a precursor for para-aminobenzoic acid (pABA) biosynthesis, which is a precursor for
folic acid (vitamin B9) synthesis in plants and microorganisms (Sahr et al., 2006;
Wegkamp et al., 2007). While vitamin B9 is an essential cofactor that facilitates methyl
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transfers, mammals do not possess the enzymes to produce folic acid and instead rely on
dietary consumption of the vitamin (Sahr et al., 2006). 7-carboxy-7-carbaguanine is
pyrrolopyrimidine that, like 4-amino-4-deoxychorismate, is involved in the biosynthesis
of vitamin B9 (McCarty et al., 2009). 2-formylglutarate is an intermediate in
nicotinamide metabolism in several bacterial species (Alhapel et al., 2006; Kress et al.,
2008). Threonate is an intermediate in ascorbate metabolism that is thought to play a role
in bone mineralization, prevent androgen-driven balding, and improve learning and
memory when combined with magnesium (Kwack et al., 2010; Sun et al., 2016; Wang
and Jiang, 2011). Ascorbate, or vitamin C, can be synthesized in dogs from glucose or
ingested in the diet (Linster and Schaftingen, 2007; Meister, 1994). Vitamin C serves as a
cofactor in several essential reactions, including collagen synthesis and wound healing, as
well as an antioxidant. If the increase in ascorbate was due to CBD supplementation, this
may contribute to the suspected antioxidative effects of CBD.
Decreased concentrations of 2-methyl-3-hydroxy-5-formylpyridine-4-carboxylate
(Z)-3-peroxyaminoacrylate, and alpha-ribazole may also support an effect of CBD on
vitamin and nucleotide metabolism. 2-methyl-3-hydroxy-5-formylpyridine-4-carboxylate
is an intermediate in the pyridoxine (vitamin B6) degradation pathway (Yokochi et al.,
2009). Vitamin B6 is an essential cofactor in several enzymatic reactions, including the
synthesis of glutathione, an important antioxidant (Dalto and Matte, 2017). alphaRibazole is an intermediate in vitamin B12 synthesis in plants and bacterial species that
can be used as a marker for vitamin B12 content in foodstuffs (Gray and EscalanteSemerena, 2010; Pakin et al., 2005). (Z)-3-peroxyaminoacrylate is an intermediate in
bacterial pyrimidine degradation pathway known as the Rut pathway. However, this
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pathway and intermediate are not known to play a role in mammalian pyrimidine
metabolism (Knapik et al., 2012).
Since the relative concentrations of pyridoxine, uracil, and folate were not
affected by treatment, and since several of these metabolites are not known to be
generated in mammalian systems, the biological significance of these changes is unclear.
However, increased pyrimidodiazepine and ascorbate, along with decreased 2-methyl-3hydroxy-5-formylpyridine-4-carboxylate, may indicate an influence of CBD on
antioxidant status. Further studies are needed to determine the roles of these metabolites
and the potential effects of CBD on these pathways.
Additional Metabolites
Increased relative concentrations of 4-coumarate, 3,4dihydroxyhpenylpropanoate, isovanillic acid, citramalic acid, sepiapterin, and an isomer
of sepiapterin may further suggest an alteration of metabolism by CBD supplementation.
4-Coumarate, or 4-hydroxycinnamate, is a hydroxycinnamic acid derivative and an
intermediate in several plant metabolic pathways, including phenylpropanoid
biosynthesis, isoquinoline alkaloid biosynthesis, tyrosine metabolism, and more (Li et al.,
2005; Schneider et al., 2005). 3,4-Dihydroxyphenylpropanoate, or dihydrocaffeic acid, is
an intermediate in tyrosine metabolism, specifically the conversion of L-DOPA to
rosmarinate, and is suspected to possess antioxidant and anti-inflammatory properties
(Ranjith et al., 2007; Wang et al., 2018). Isovanillic acid is a metabolite of isovanillin
with suspected antibacterial properties (Panoutsopoulos and Beedham, 2005; Strand and
Scheline, 1975). While not known as a mammalian metabolite, it can be found in plasma
after consumption of flavonoid consumption (Loke et al., 2009). Citramalic acid is most
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commonly produced by yeast or anaerobic bacteria as an intermediate in C5-branched
dibasic acid metabolism (Zarzycki et al., 2009). As it is not a mammalian metabolite,
citramalic acid is most commonly found as a urine metabolite in cases of yeast or
bacterial overgrowth (Shaw et al., 1995). Sepiapterin is an intermediate in folate
biosynthesis that in mammals can be metabolized into tetrahydrobiopterin, which is an
essential cofactor in mammals for the metabolism of aromatic amino acids and
biosynthesis of neurotransmitters (Smith et al., 2019; Wang et al., 2011). It has been
suggested as a treatment for atherosclerosis and tetrahydropterin deficiencies in humans
(Smith et al., 2019; Tarpey, 2002; Vásquez-Vivar et al., 2002).
Decreased concentrations of L-glutamate-1-semialdehyde, 1-aminocyclopropane1-carboxylate, L-allothreonine, an isomer of 3-phenoxybenzyl alcohol,
dihydroshikonofuran, and phenethyl alcohol also indicate an effect of CBD on
metabolism. L-Glutamate-1-semialdehyde, 1-aminocyclopropane-1-carboxylate, and Lallothreonine are plant metabolites. L-Glutamate-1-semialdehyde is produced as an
intermediate in porphyrin and chlorophyll synthesis (Campanini et al., 2013). 1Aminocyclopropane-1-carboxylate is the direct precursor of the plant hormone ethylene
and plays a role in the regulation of plant development (Polko and Kieber, 2019). LAllothreonine is a stereoisomer of threonine and an intermediate in plant glycine, serine,
and threonine metabolism (Fiehn et al., 2000). 3-Phenoxybenzyl alcohol is a mammalian
metabolite of the insecticide permethrin produced by carboxylesterases (Crow et al.,
2007; Stok et al., 2004). Dihydroshikonofuran is a monoterpenoid product of ubiquinone
and other terpenoid-quinone biosynthesis from the same metabolic pathway that produces
shikonin, a plant pigment with anti-inflammatory, antibacterial, and wound-healing
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properties (Boehm et al., 2000; Yazaki et al., 1987). Phenethyl alcohol is a natural
fragrance produced by rose, carnation, and other plants (Guterman et al., 2006; Politano
et al., 2013).
Limitations, Strengths, and Weaknesses
This study is the first to evaluate the impact of CBD supplementation on the
canine metabolome. This analysis was not intended to be all-encompassing but rather a
first look into the potential for CBD supplementation to alter the canine metabolome.
Thus, this study was limited by the relatively short duration of CBD supplementation,
lack of baseline sampling, small sample size, and the use of only a single CBD dosage.
Even so, identifying potential changes in the metabolome is essential for directing future
investigation into both the physiological relevance of these changes as well as elucidating
potential mechanisms leading to these observed effects.
Conclusions
This study demonstrated the canine metabolome was altered with 4.5 mg CBD/kg
BW/d supplementation for 3 weeks. Altered metabolites may suggest a potential for CBD
to influence glucose, carbohydrate, lipid, amino acid, vitamin, and nucleotide
metabolism. Additionally, the difference in relative concentrations of metabolites like 9oxononanoic acid, o-tyrosine, IFA, glucosamine, pyrimidodiazepine, 9-oxononanoic acid,
and 3,4-dihydroxymandelic acid may indicate potential pathways by which CBD may
exert suspected anti-inflammatory, antioxidant, anti-obesity, and antimicrobial effects.
Several metabolites were identified as potential biomarkers for changes in the canine
metabolome by CBD. Further studies with larger sample sizes, longer supplementation
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periods and baseline comparisons to refine metabolites are necessary to elucidate the
physiological relevance of these changes.
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Tables and Figures
A.

B.

Figure 6.1. A. Partial least squares discriminant analysis (PLS-DA) scores plot and B.
volcano plot showing the differential amine/phenol-containing metabolites. Fold change
(FC) ≥ 1.2 (in red) or ≤ 0.83 (in blue) with false discovery ratio (FDR) ≤ 0.05 are
differentially increased or reduced by cannabidiol (CBD) relative to control (CON).
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Table 6.1. Identified amine/phenol-containing metabolites affected by cannabidiol (CBD)
compared to control (CON). Metabolites with a fold change (FC) ≥ 1.2 relative to CON
and a false discovery ratio (FDR) ≤ 0.05 considered increased in the CBD compared to
CON. Metabolites with a FC ≤ 0.83 and an FDR ≤ 0.05 considered reduced in CBD
compared to CON.
Normalized
Identification
Metabolite
FC
FDR
RT1
Level2
Pyrimidodiazepine

1029.2

2.89

0.002

Tier 2

504.2

2.38

0.004

Tier 2

1075.1

1.91

0.005

Tier 1

Isomer of D-Glucosamine

152.6

1.85

0.045

Tier 2

7-Carboxy-7-carbaguanine

369.6

1.64

0.019

Tier 2

2,4-Dihydroxyhept-2-enedioate

680.1

1.64

0.004

Tier 2

Ascorbate

530.4

1.62

0.023

Tier 2

2'-Deamino-2'-hydroxy-6'dehydroparomamine

761.9

1.57

0.026

Tier 2

trans-2,3-Dihydroxycinnamate

856.8

1.53

0.001

Tier 2

gamma-Glutamyl-gammaaminobutyraldehyde

337.7

1.52

0.010

Tier 2

1,4-Diaminobutane

1281.7

1.50

0.007

Tier 1

Tyramine

1538.7

1.50

0.007

Tier 1

Isomer of 2-Deoxy-scylloinosamine

208.1

1.47

0.031

Tier 2

Isoleucyl-Alanine

586.8

1.45

0.026

Tier 1

1068.7

1.31

0.019

Tier 2

236.0

1.31

0.019

Tier 1

Vanillic acid

1026.1

1.26

0.012

Tier 1

D-Lysopine

999.8

1.20

0.019

Tier 2

N-Acetyl-L-Asparagine

492.6

0.83

0.023

Tier 2

Alanyl-Proline

477.2

0.82

0.026

Tier 1

Asparaginyl-Aspartic acid

149.6

0.79

0.026

Tier 1

4-Amino-4-deoxychorismate
Isoferulic acid

3-(4-Hydroxyphenyl)pyruvate
Aspartyl-Threonine
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Seryl-Aspartic acid

162.3

0.78

0.045

Tier 1

Phenylalanyl-Glycine

569.9

0.78

0.026

Tier 1

Prolyl-Glutamine

335.6

0.78

0.012

Tier 1

o-Tyrosine

1313.2

0.77

0.023

Tier 1

N-Acetyl-L-Adrenaline

1650.1

0.75

0.041

Tier 2

L-threo-3-Methylaspartate

491.9

0.74

0.045

Tier 2

Z-3-Peroxyaminoacrylate

666.3

0.72

0.024

Tier 2

L-Glutamate 5-semialdehyde

367.9

0.72

0.004

Tier 2

2-Methyl-3-hydroxy-5formylpyridine-4-carboxylate

652.3

0.66

0.032

Tier 2

Aspartyl-Glutamine

194.8

0.65

0.001

Tier 1

Gamma-Aminobutyric acid

466.3

0.55

0.049

Tier 1

1

Normalized RT (retention time) shows the corrected retention time of the peak pair with
Universal RT Calibrant data.
2
Tier 1 indicates positive metabolite identification within the chemical isotope labeling
(CIL) metabolite library whereas Tier 2 indicates high confidence putative identification
within the linked identity (LI) library.
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Figure 6.2. Candidate amine/phenol-containing biomarkers altered by cannabidiol (CBD;
in blue) compared to control (CON; in yellow) included A. aspartyl-glutamine (AUROC
= 1.00; P < 0.001); B. gamma-aminobutyric acid (AUROC = 1.00; P = 0.005); C.
gamma-glutamyl-gamma-aminobutyraldehyde (AUROC = 1.00; P < 0.001); D. Lglutamate-5-semialdehyde (AUROC = 1.00; P < 0.001); E. prolyl-glutamine (AUROC =
1.00; P < 0.001); F. pyrimidodiazepine (AUROC = 1.00; P < 0.001); G. 4-amino-4deoxychorismate (AUROC = 0.98; P < 0.001); H. trans-2,3-dihydroxycinnamate
(AUROC = 0.98; P < 0.001); I. alanyl-proline (AUROC = 0.97; P = 0.002); J. N-acetylL-asparagine (AUROC = 0.97; P < 0.001); K. (Z)-3-peroxyaminoacrylate (AUROC =
0.95; P < 0.001); L. 1,4-diaminobutane (AUROC = 0.95; P < 0.001); M. 2’-deamino-2’hydroxy-6’-dehydroparomamine (AUROC = 0.95; P = 0.004); N. ascorbate (AUROC =
0.95; P = 0.003); O. D-lysopine (AUROC = 0.95; P = 0.004); P. o-tyrosine (AUROC =
0.95; P = 0.001); Q. phenylalanyl-glycine (AUROC = 0.95; P = 0.002); R. 2,4dihydroxyhept-2-enedioate (AUROC = 0.94; P < 0.001); S. asparaginyl-aspartic acid
(AUROC = 0.94; P = 0.003); T. isoferulic acid (AUROC = 0.94; P < 0.001); U. 7carboxy-7-carbaguanine (AUROC = 0.92; P = 0.001); V. 3-(4-hydroxyphenyl)pyruvate
(AUROC = 0.91; P = 0.004); W. aspartyl-threonine (AUROC = 0.91; P = 0.005); and X.
isoleucyl-alanine (AUROC = 0.91; P = 0.007).
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A.

B.

Figure 6.3. A. Partial least squares discriminant analysis (PLS-DA) scores plot and B.
volcano plot showing the differential carbonyl-containing metabolites. Fold change (FC)
≥ 1.2 (in red) or ≤ 0.83 (in blue) with false discovery ratio (FDR) ≤ 0.05 are differentially
increased or reduced by cannabidiol (CBD) relative to control (CON).
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Table 6.2. Identified carbonyl-containing metabolites affected by cannabidiol (CBD)
compared to control (CON). Metabolites with a fold change (FC) ≥ 1.2 relative to CON
and a false discovery ratio (FDR) ≤ 0.05 considered increased in the CBD compared to
CON. Metabolites with a FC ≤ 0.83 and an FDR ≤ 0.05 considered reduced in CBD
compared to CON.
Normalized
RT1

FC

FDR

Identification
Level2

2-Formylglutarate

569.3

1.99

0.021

Tier 2

Glucose

371.2

1.54

0.018

Tier 1

4-Oxoglutaramate

394.4

0.62

0.050

Tier 2

Isomer of Glyceraldehyde

471.1

0.42

0.035

Tier 1

Glyceraldehyde

453.2

0.38

0.040

Tier 1

Metabolite

1

Normalized RT (retention time) shows the corrected retention time of the peak pair with
Universal RT Calibrant data.
2
Tier 1 indicates positive metabolite identification within the chemical isotope labeling
(CIL) metabolite library whereas Tier 2 indicates high confidence putative identification
within the linked identity (LI) library.

134

Figure 6.4. Candidate carbonyl-containing biomarker – Glucose (AUROC = 0.91; P =
0.020) – altered by cannabidiol (CBD; in blue) compared to control (CON; in yellow).
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A.

B.

Figure 6.5. A. Partial least squares discriminant analysis (PLS-DA) scores plot and B.
volcano plot showing the differential carboxyl-containing metabolites. Fold change (FC)
≥ 1.2 (in red) or ≤ 0.83 (in blue) with false discovery ratio (FDR) ≤ 0.05 are differentially
increased or reduced by cannabidiol (CBD) relative to control (CON).
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Table 6.3. Identified carboxyl-containing metabolites affected by cannabidiol (CBD)
compared to control (CON). Metabolites with a fold change (FC) ≥ 1.2 relative to CON
and a false discovery ratio (FDR) ≤ 0.05 considered increased in the CBD compared to
CON. Metabolites with a FC ≤ 0.83 and an FDR ≤ 0.05 considered reduced in CBD
compared to CON.
Normalized
Identification
Metabolite
FC
FDR
RT1
Level2
2,5-Dioxopentanoate

741.4

3.70

0.047

Tier 2

Isomer of Hydroxypropionic acid

380.9

2.56

<.001

Tier 1

4-Coumarate

802.6

2.42

0.043

Tier 2

Isomer of D-Glycerate

255.0

2.31

0.009

Tier 2

Acetic acid

560.5

2.21

<.001

Tier 1

D-Glycerate

299.4

2.14

0.007

Tier 2

Isomer of Glycolate

282.4

2.09

0.008

Tier 2

Isomer of Threonate

272.2

2.09

0.088

Tier 2

5-Deoxy-D-glucuronate

361.4

2.04

0.002

Tier 2

Citramalic acid

449.1

2.04

0.001

Tier 1

3,4-Dihydroxymandelic acid

493.9

2.04

<.001

Tier 1

Glycolate

299.4

2.03

0.046

Tier 2

3-Oxopropanoate

361.4

1.95

0.002

Tier 2

Ethyl Malonate

739.7

1.89

<.001

Tier 1

Isomer of 3-Oxopropanoate

332.4

1.88

0.007

Tier 2

Isomer of 3-Hydroxybutyric acid

474.9

1.86

0.005

Tier 1

2-Hydroxy-3-oxopropanoate

389.2

1.81

0.080

Tier 2

Hydroxyisobutyric acid

548.8

1.60

0.012

Tier 1

Isovaleric acid

1039.8

1.60

0.030

Tier 1

Butyric acid

870.3

1.58

0.009

Tier 1

Glyoxylate

528.3

1.55

0.083

Tier 2

Nicotinate

574.9

1.54

0.007

Tier 2
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3-Hydroxybutyric acid

501.4

1.43

0.047

Tier 1

S-5-Amino-3-oxohexanoic acid

596.0

1.38

0.025

Tier 2

Hydroxypropionic acid

424.8

1.38

0.015

Tier 1

Lactic acid

452.2

1.37

0.012

Tier 1

Isomer of Lactic acid

471.2

1.36

0.009

Tier 1

Isovanillic acid

739.5

1.33

0.009

Tier 1

4-Oxoproline

798.3

0.80

0.017

Tier 2

2-Aminomuconate semialdehyde

799.6

0.79

0.032

Tier 2

Isomer of 9-Oxononanoic acid

1048.9

0.74

0.093

Tier 2

L-1-Pyrroline-3-hydroxy-5carboxylate

372.5

0.74

0.012

Tier 2

S-4-Amino-5-oxopentanoate

439.3

0.70

0.007

Tier 2

Isomer of 1-Aminocyclopropane-1carboxylate

272.2

0.67

0.013

Tier 2

L-Allothreonine

439.3

0.64

0.007

Tier 2

Arginine

279.8

0.60

0.012

Tier 2

Isomer of Aspartate

574.6

0.58

0.098

Tier 2

Isomer of Jasmonic acid

1525.6

0.55

0.030

Tier 2

2-Oxo-4-phenylbutyric acid

1150.3

0.53

0.007

Tier 2

9,10-12,13-Diepoxyoctadecanoate

1333.8

0.50

0.009

Tier 2

Jasmonic acid

1437.0

0.44

<.001

Tier 2

Isomer of 1-Pyrroline-2-carboxylate

1160.7

0.15

0.009

Tier 2

1

Normalized RT (retention time) shows the corrected retention time of the peak pair with
Universal RT Calibrant data.
2
Tier 1 indicates positive metabolite identification within the chemical isotope labeling
(CIL) metabolite library whereas Tier 2 indicates high confidence putative identification
within the linked identity (LI) library.
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Figure 6.6. Biomarker analysis of carboxyl metabolites for cannabidiol (CBD) and
control (CON) treatments identified A. jasmonic acid (AUROC = 1.00; P < 0.001); B.
(S)-4-amino-5-oxopentanoate (AUROC = 1.00; P < 0.001); C. 3,4-dihydroxymandelic
acid (AUROC = 1.00; P < 0.001); D. isomer of 1-aminocyclopropane-1-carboxylate
(AUROC = 1.00; P < 0.001); E. isomer of hydroxypropionic acid (AUROC = 1.00; P <
0.001); F. L-1-pyrroline-3-hydroxy-5-carboxylate (AUROC = 1.00; P < 0.001); G. Lthreonine/L-allothreonine (AUROC = 1.00; P < 0.001); H. 2-oxo-4-phenylbutyric acid
(AUROC = 0.98; P < 0.001); I. Arginine (AUROC = 0.98; P < 0.001); J. citramalic acid
(AUROC = 0.97; P < 0.001); K. 4-oxoproline (AUROC = 0.95; P < 0.001); L. 5-deoxyD-glucuronate (AUROC = 0.95; P < 0.001); M. 9,10-12,13-diepoxyoctadecanoate
(AUROC = 0.95; P < 0.001); N. isomer of 1-pyrroline-2-carboxylate (AUROC = 0.95; P
< 0.001); O. isomer of aspartate (AUROC = 0.95; P < 0.001); P. 2-aminomuconate
semialdehyde (AUROC = 0.94; P < 0.001); Q. isomer of 9-oxononanoic acid (AUROC =
0.94; P < 0.001); R. acetic acid (AUROC = 0.92; P < 0.001); S. ethyl malonate (AUROC
= 0.92; P < 0.001); T. isomer of jasmonic acid (AUROC = 0.92; P < 0.001); U. 3oxopropanoate (AUROC = 0.91; P < 0.001); V. D-glycerate (AUROC = 0.91; P <
0.001); and W. isomer of D-glycerate (AUROC = 0.91; P < 0.001) as candidate
biomarkers.
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A.

B.

Figure 6.7. A. Partial least squares discriminant analysis (PLS-DA) scores plot and B.
volcano plot showing the differential hydroxyl-containing metabolites. Fold change (FC)
≥ 1.2 (in red) or ≤ 0.83 (in blue) with false discovery ratio (FDR) ≤ 0.05 are differentially
increased or reduced by cannabidiol (CBD) relative to control (CON).
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Table 6.4. Identified hydroxyl-containing metabolites affected by cannabidiol (CBD)
compared to control (CON). Metabolites with a fold change (FC) ≥ 1.2 relative to CON
and a false discovery ratio (FDR) ≤ 0.05 considered increased in the CBD compared to
CON. Metabolites with a FC ≤ 0.83 and an FDR ≤ 0.05 considered reduced in CBD
compared to CON.
Normalized
Identification
Metabolite
FC FDR
1
RT
Level2
17alpha,20alpha-Dihydroxypregn-4-en-31618.8
6.19 0.001
Tier 2
one
D-Tagatose

235.4

2.35 0.001

Tier 2

3,4-Dihydroxyphenylpropanoate

678.7

2.09 0.011

Tier 2

L-Rhamnono-1,4-lactone

280.5

1.91 0.001

Tier 2

L-Rhamnofuranose

198.0

1.67 0.008

Tier 2

Isomer of L-Rhamnofuranose

735.3

1.66 0.008

Tier 2

6-Deoxy-L-galactose

649.6

1.66 0.008

Tier 2

D-Galactosamine

162.8

1.48 0.008

Tier 2

Sepiapterin

240.1

1.48 0.014

Tier 2

Isomer of Sepiapterin

182.5

1.46 0.028

Tier 2

L-Fuculose

128.6

1.43 0.001

Tier 2

Isomer of Deoxyadenosine

261.6

1.42 0.019

Tier 2

Deoxyadenosine

243.3

1.40 0.035

Tier 2

3-Hydroxy-L-proline

211.6

1.23 0.016

Tier 2

N-Acetyl-trans-3-Hydroxy-L-proline

602.8

0.82 0.080

Tier 2

Ethanolamine

398.0

0.82 0.045

Tier 2

2,3-Dihydroxyindole

578.9

0.81 0.044

Tier 2
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N2'-Acetyl-3'-Hydroxykynurenamine

425.7

0.79 0.087

Tier 2

Cyanate

469.9

0.79 0.014

Tier 2

Isomer of Cyanate

505.6

0.77 0.008

Tier 2

Glycerol

447.9

0.76 0.051

Tier 2

alpha-Ribazole

894.1

0.74 0.014

Tier 2

Isomer of 3-Phenoxybenzyl alcohol

538.1

0.73 0.008

Tier 1

Dihydroshikonofuran

1341.0

0.73 0.018

Tier 2

Glycolaldehyde

613.0

0.71 0.018

Tier 2

N-Acetyl-2-Carboxy-2,3-dihydro-5,6dihydroxyindole

404.7

0.69 0.014

Tier 2

Allotetrahydrodeoxycorticosterone 3-Oglucuronide

1167.4

0.69 0.027

Tier 2

Phenethyl alcohol

653.4

0.63 0.002

Tier 1

Propane-1,3-diol

945.6

0.56 0.001

Tier 2

Cortolone

1011.9

0.46 0.092

Tier 2

Arabitol

238.7

0.42 0.001

Tier 2

Cortisol 21-O-sulfate

875.1

0.40 0.088

Tier 2

1

Normalized RT (retention time) shows the corrected retention time of the peak pair with
Universal RT Calibrant data.
2
Tier 1 indicates positive metabolite identification within the chemical isotope labeling
(CIL) metabolite library whereas Tier 2 indicates high confidence putative identification
within the linked identity (LI) library.
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Figure 6.8. Biomarker analysis of hydroxyl metabolites for cannabidiol (CBD) and
control (CON) treatments identified A. L-fuculose/L-rhamulose (AUROC = 1.00; P <
0.001); B. glyceraldehyde (AUROC = 1.00; P < 0.001); C. L-rhamnofuranose (AUROC
= 1.00; P < 0.001); D. L-rhamnono-1,4-lactone (AUROC = 1.00; P < 0.001); E.
Xylitol/Arabitol/Ribitol (AUROC = 1.00; P < 0.001); F. D-tagatose/L-sorbose (AUROC
= 0.98; P < 0.001); G. propane-1,3-diol (AUROC = 0.98; P < 0.001); H. 6-deoxy-Lgalactose/L-rhamnose (AUROC = 0.97; P = 0.002); I. D-glucosamine (AUROC = 0.95;
P = 0.001); J. phenethyl alcohol (AUROC = 0.94; P = 0.002); K. isomer of Lrhamnofuranose (AUROC = 0.92; P = 0.001); L. 3-phenoxybenzyl alcohol (AUROC =
0.91; P = 0.003); M. 3,4-dihydroxyphenylpropanoate (AUROC = 0.91; P = 0.003); N.
cortolone (AUROC = 0.91; P = 0.073); and O. isomer of deoxyadenosine (AUROC =
0.91; P = 0.008) as candidate biomarkers.
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CHAPTER 7. FEEDING TREATS CONTAINING CANNABIDIOL DID NOT ALTER
CANINE IMMUNE RESPONSE TO IMMUNIZATION WITH KEYHOLE
LIMPET HEMOCYANIN
Introduction
While there have been preliminary investigations into the safety of its use in dogs
(Deabold et al., 2019; Gamble et al., 2018; Vaughn et al., 2020), concerns remain
regarding the safety of CBD use as it poses potential risks of hepatoxicity and drug
interactions (Ewing et al., 2019; Morris et al., 2020; Yamaori et al., 2011). An additional
concern regarding the safety of CBD is its effects on the immune system. It has been
proposed to exert anti-inflammatory effects by enhancing adenosine signaling via the A2A
receptor, which may protect tissues from inflammation by down-regulating over-reactive
immune cells (Carrier et al., 2006; Ohta and Sitkovsky, 2001). Although these actions of
CBD have been pursued as potential treatments against chronic inflammatory conditions,
CBD may also negatively impact other functions of the immune system, such as
responses to vaccination, through the same mechanisms. In several human case studies,
the use of marijuana was associated with a decrease in serum IgG and IgM, B and T
lymphocytes, and natural killer cells compared to non-smokers (El-Gohary and Eid,
2004; Huemer et al., 2007). The production of these cells and immunoglobulins is
essential to the generation of a proper immune response to infection or immunization.
Thus, the potential for CBD to inhibit these processes poses a potential risk to the health
of animals supplemented with CBD. However, this effect has yet to be tested in a canine
model.
Keyhole limpet hemocyanin (KLH) is considered an ideal antigen to assess
primary and secondary immune responses to vaccination because it is harmless, has a low
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risk of cross-reactivity, and produces an adequate immune response that allows for
measureable differences between treatments (Swaminathan et al., 2014). The use of KLH
as an antigen in immunotoxicology studies has been validated for use in dogs to evaluate
both primary and secondary responses to KLH immunization (Finco-Kent and Kawabata,
2005; Kawai et al., 2013) and has also been used to detect immunosuppressive effects of
cyclophosphamide and cyclosporine in dogs (Legrand et al., 2012).
The primary objective of this study was to determine the effect of industrial
hemp-derived CBD on the immune response to immunization with a novel antigen in
dogs. A secondary objective was to determine if CBD altered the overall health indices of
dogs receiving immunization. The underlying hypothesis was that CBD would not
negatively impact health indices, nor would it alter or negatively affect and KLH-specific
antibody production of dogs receiving CBD.
Materials and Methods
This study was approved by the LMU IACUC (protocol 2005-RES) prior to the
start of the study. All housing and husbandry received were in accordance with the
Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals (8th ed.),
and all applicable LMU SOPs.
Subjects and Housing
Forty adult dogs (20 intact male, 17 female, 3 spayed females; 2.0 ± 1.3 years old;
21.9 ± 6.7 kg) of various mixed breeds were received from several local shelters for
inclusion in this study. The shelters were informed and gave consent for the use of the
dogs for research purposes before their arrival. Before beginning the experiment, each
dog had a hematology and serum chemistry analysis (IDEXX Laboratories, Inc.,
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Westbrook, ME) performed, along with a physical evaluation by a veterinarian and a
fecal examination to rule out any underlying disease that might preclude enrollment.
Dogs were excluded if they demonstrated serious behavioral issues such as aggression
that would endanger research personnel; were severely emaciated, classified as a body
condition score < 3.5 or > 7.5 on a 9-point scale (where 1 is emaciated and 9 is obese;
Laflamme, 1997); or if initial evaluations revealed an underlying disease that required
more than routine treatments (i.e. heartworm infection, metabolic or infectious disease,
and mobility issues). Thirty-two dogs (16 intact males, 13 intact females, 3 spayed
females; 2.1 ± 1.3 years old; 22.4 ± 6.3 kg) were selected for inclusion in the study. Dogs
were individually housed in 1.2 x 1.8 m kennels within one of two dog wards at the LMU
DeBusk Veterinary Teaching Center. Dogs were stratified by treatment and sex and
evenly distributed between the two wards.
Diets and Treatments
Dogs were fed Purina Pro Plan EN Gastroenteric Dry Dog Food (Nestle Purina
Inc., St. Louis, MO) to meet the daily metabolizable energy requirements of intact adult
dogs at maintenance, calculated as (70 * BW0.75) * 1.8 and split into two meals at
approximately 0800 h and 1800 h each day. Dogs were weighed and body condition
scored (5-point scale) weekly and diets adjusted accordingly. Dogs were stratified by BW
and sex before being randomly assigned to treatments arranged in a completely
randomized design consisting of 0 (placebo treats; CON) or 114.5 ± 6.6 mg CBD/d
(CBD). Based on the mean BW of dogs included in the study and analysis of the treats,
mean dose of CBD was 5.0 ± 3.7 mg CBD/kg BW/d. No other cannabinoids were
detected in the treats. The CBD was the primary constituent of a proprietary industrial
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hemp isolate (AgTech Scientific, Paris, KY) that was incorporated into treats
administered twice daily with each treat containing half the daily dose. Both control and
CBD treats were composed of the following ingredients: chicken, chicken liver, Asian
carp, catfish, and – in the case of CBD treats – industrial hemp extract. Treats were
offered within 30 min of meals solely as a reward upon kennel re-entry following twicedaily exercise. Research personnel administering the treats were blinded as to the
treatments administered.
Experimental Design
Upon intake, all dogs underwent a 7-d acclimation period for adjustment to
treatments, environment, diet, and daily routine (Table 7.1). Following the initial 7-d
acclimation to treatments, dogs were immunized with 10 mg KLH/dog (product #:
H7017-5X20MG; Sigma-Aldrich, St. Louis, MO) via intramuscular injection into the
semimembranosus muscle region. The KLH was dissolved in physiological saline at a
concentration of 10 mg/mL with a total injection volume of 1 mL/dog. This dosage of
KLH was selected based on previous work in dogs (Kawai et al., 2013). The solution was
filtered using a sterile 0.02 µm membrane filter before injection. The second
immunization of KLH was administered in the same manner on d 14 in the contralateral
leg immediately after collection of blood samples.
Sample Collection and Analysis
Blood samples (~6 mL) were collected via jugular or cephalic venipuncture upon
intake (d -9 and -8) and on d 7, 14, 21, and 28 (Table 7.1). Blood samples were split
between serum (~5 mL) and EDTA plasma (~1 mL) tubes. Whole blood samples in

148

EDTA plasma tubes from each time point were used for hematology analysis using a
ProCyte Dx Hematology Analyzer (Table 7.2; IDEXX Laboratories, Inc., Westbrook,
ME). Serum samples were allowed to clot for 1 h before centrifugation at 1645 x g for 10
min. Approximately 0.5 mL of serum was then used for serum chemistry analysis using a
Catalyst Dx Chemistry Analyzer (IDEXX Laboratories, Inc., Westbrook, ME) while the
remaining serum was temporarily (24-48 hr) stored at -20°C before being stored at -80°C
for later immunoglobulin analysis.
Serum IgG and IgM (mg/dL) were measured using a commercially available
enzyme-linked immunosorbent assay (ELISA) kit (Dog IgG and IgM; Immunology
Consultants Laboratory, Inc., Portland, OR) with inter- and intra-assay coefficients of
variation of 7.2% and 6.7%, respectively for IgG and 6.4% and 4.1%, for IgM. Anti-KLH
IgG and IgM immunoglobulins (kU/L) was analyzed using commercially available
ELISA kits (Canine Anti-KLH IgG and IgM; Alpha Diagnostic Intl. Inc., San Antonio,
TX) with inter- and intra-assay coefficients of variation of 8.4% and 3.6%, respectively
for IgG and 6.86% and 5.43%, for IgM assays.
Consumption of food and treats, stool consistency, frequency of elimination,
mucus membrane color, subjective assessment of activity during exercise, and other
indicators of general health status were monitored twice daily by research personnel.
Body temperature and injection sites were also monitored immediately and 12 h after
KLH immunization for evidence of any reaction to the immunization. Evidence of any
adverse event – defined as any symptom occurrence that would not be expected in normal
dogs – was also monitored. However, no adverse events were observed in any dogs
following KLH immunization nor the administration of CBD treats during this study.
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Statistical Analysis
The normality of the residuals was first tested using the UNIVARIATE procedure
in SAS 9.4 (SAS Institute, Cary, NC). In instances where data did not meet normality
assumptions, statistical analysis was performed on transformed data. Data were then
back-transformed for reporting purposes. The standard error of the back-transformed data
was calculated from the confidence limits of the transformed data as follows: SEM =
(back-transformed upper limit – back-transformed lower limit)/3.92 where the
denominator relates to the Z-value of a 95% confidence interval (± 1.96). HGB,
RETIC%, RETIC, MONO%, LYM, MONO, MPV, PDW, total protein, alanine
aminotransferase, and total IgM were not normally distributed and were log-transformed
for statistical analysis. BASO%, the blood urea nitrogen-to-creatinine ratio, alkaline
phosphatase, and anti-KLH IgG were not normally distributed and were transformed to
the square root for statistical analysis. Glucose and creatinine were not normally
distributed and were transformed to the cube root for statistical analysis. Lastly, EOS%,
EOS, and BASO were not normally distributed and were transformed to the fourth root
for statistical analysis. At baseline, blood urea nitrogen and globulin were increased while
albumin and the albumin-to-globulin ratio were decreased in CON compared with CBD;
thus, baseline values were utilized as a covariate for the remaining measurements.
Data were then analyzed using the MIXED procedure in SAS including the fixed
effects of treatment, day, and the treatment by day interaction. Day was included as a
repeated measure with dog nested within treatment as the subject. Results are presented
as the mean ± SE. Effects were considered significant when P ≤ 0.05 and considered a
tendency when P ≤ 0.10.
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Results
Hematology and Serum Chemistry
Hematological variables were generally normal for dogs across both treatments
throughout the study (Table 7.3). While there were differences or trends in RBC (P =
0.065), hematocrit (P = 0.013), hemoglobin (P = 0.027), mean corpuscular hemoglobin
concentration (P = 0.068), and platelets (P = 0.071) between treatments, all were within
IDEXX normal reference ranges. Effects of experiment day were observed for almost all
variables apart from red cell distribution width, reticulocyte %, and reticulocytes (P =
0.260, 0.285, and 0.309, respectively). Treatment by day interactions were observed for
platelet distribution width (P = 0.027) and a trend observed for monocytes (P = 0.065).
No other treatment by day interactions were observed (P > 0.05). Monocytes were similar
across treatments on each day of the experiment (P > 0.05) except for d 28, where CON
tended to be lower than CBD (P = 0.085); platelet distribution width was similar across
treatments on each individual day of the experiment (P > 0.05). Again, despite these
minor differences between treatments, all remained within the laboratory’s normal
reference ranges.
With respect to the serum chemistry, again the variables were generally normal
for dogs across both treatments (Table 7.4). Day of experiment affected concentrations of
all serum chemistry variables (P < 0.05). Blood urea nitrogen and the ratio of blood urea
nitrogen to creatinine were increased in CBD compared to CON (P = 0.027 and 0.016,
respectively), but both treatments were within normal reference range and no treatment
by day interactions were observed (P = 0.105 and 0.689, respectively). A treatment effect
and treatment by day interaction were observed for serum albumin (P = 0.017 and 0.044,
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respectively), where CON albumin tended to increase compared with CBD on d 14 (P =
0.057) and increased on d 21 and 28 (P < 0.05). Again, despite the differences, serum
albumin remained within normal reference range in all dogs for the duration of the study.
Treatment by day interactions were observed for both globulin (P = 0.047) and the
albumin to globulin ratio (P < 0.001). However, both were similar across treatments on
each individual day of the experiment (P > 0.05). Both a treatment effect and a treatment
by day interaction were observed for alkaline phosphatase (P = 0.045 and 0.014,
respectively). While similar between treatments at baseline and on d 7 (Figure 7.1; P =
0.994 and 0.183, respectively), alkaline phosphatase was elevated in CBD compared with
CON on d 14, 21, and 28 (P = 0.006, 0.027, and 0.014, respectively). Again, despite the
treatment differences, all stayed within laboratory reference ranges for the duration of the
study; however, alkaline phosphatase did increase 2-fold in the CBD group from baseline
to d 21.
Total Immunoglobulins
Total IgG was unaffected by both treatment and treatment by day interaction (P =
0.930 and 0.897, respectively) but increased over time (Figure 7.2A; P < 0.001). Total
IgM was unaffected by treatment (P = 0.817) but was affected by day (P < 0.001) and a
treatment by day interaction (Figure 7.2B; P = 0.047). The CON IgM peaked 7 days after
initial KLH immunization and returned to baseline levels by day 21, whereas CBD IgM
did not peak until day 21 and returned to baseline levels on day 28.
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Anti-KLH Immunoglobulins
Anti-KLH immunoglobulins were undetectable in all samples on day 0. AntiKLH IgG was affected by day (Fig. 7.3A; P < 0.001), peaking on day 21 (218.45 ± 8.743
kU/L), but was unaffected by both treatment and treatment by day interaction (P = 0.422
and 0.510, respectively). Similarly, anti-KLH IgM was unaffected by treatment and
treatment by day interaction (Fig. 7.3B; P = 0.879 and 0.927, respectively) but an effect
of day was observed (P < 0.001). Anti-KLH IgM peaked in both treatments 7 d after the
initial KLH immunization (354.27 ± 15.130 kU/L) before declining each subsequent
week.
Discussion
Due to the potential impact of CBD on the immune system, the purpose of this
investigation was to determine if CBD would alter the humoral immune response of dogs
to immunization with KLH and to assess its potential to alter overall health indices.
Acute toxicity studies in mice and monkeys have demonstrated the potential for CBD to
cause liver injury at extremely high doses (mouse equivalent dose of 200-300 mg/kg)
(Ewing et al., 2019; Rosenkrantz et al., 1981). While those doses are not applicable to
most real-life scenarios, they do demonstrate the potential risk of CBD use if proper
dosing is not established. For example, a dog may get into a box of CBD treats and
consume all treats at once. In sub-acute studies in mice, mouse equivalent doses of 15
mg/kg produced only hepatocyte cytoplasmic swelling, but repeated doses of 50 mg/kg
elevated several liver enzymes and caused hepatocyte cytoplasmic swelling (Ewing et al.,
2019). This demonstrates the potential risk of liver injury at both lower doses and
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repeated dosing regimens. The need for continued investigation is evident, particularly
since neither toxicity nor long-term dosing studies have been performed in dogs.
Several studies have evaluated changes in hematology and serum chemistry in
response to short-term CBD supplementation in dogs. At doses ranging from 2 to 65
mg/kg, CBD has been shown to increase serum alkaline phosphatase in dogs as early as
14 d after treatment initiation (Gamble et al., 2018; McGrath et al., 2018; Vaughn et al.,
2020). Results from this study concur with these previous findings as serum alkaline
phosphatase, though remaining within the IDEXX normal reference range, was increased
in the CBD treatment compared with control on 14 d and remained elevated throughout
the study. Whether this increase presents any potential detriment remains uncertain,
particularly considering that other serum chemistry variables were similar between
treatments. It would be beneficial for future work to investigate the potential for
hepatoxic effects in dogs over long-term CBD supplementation as well as the use of
multiple CBD doses.
The anti-inflammatory actions of CBD have most often been suggested as
potential treatments against chronic inflammatory conditions like multiple sclerosis and
osteoarthritis; however, there is also evidence from in vitro work suggesting CBD may
negatively impact other functions of the immune system. Notably, CBD has been shown
to inhibit IL-2, IL-10, and IFNγ production in mice (Condie et al., 1996; Jan et al., 2007),
which are essential for both the activation and differentiation of T and B cells in response
to an immune challenge (Arenas-Ramirez et al., 2015; Jeurissen et al., 2004). The
suppression of antibody production has been demonstrated in mice after a single
intraperitoneal dose of CBD (Jan et al., 2007) and is associated with marijuana use in
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humans (El-Gohary and Eid, 2004; Huemer et al., 2007). There is, however, conflicting
evidence on the immunomodulatory effects of CBD. Jenny et al. (2009) reported a
biphasic response in human peripheral blood mononuclear cells (PBMCs), with CBD
exhibiting a stimulatory effect at lower doses and inhibitory effects at higher doses.
Collectively, these studies highlight the possibility of CBD acting negatively on the
immune system and the need for work evaluating this potential risk.
The present study is one of the first to describe the potential effect of CBD on the
immune response of dogs after immunization. Despite a minor shift in the timing of total
IgM peak between control and CBD, the IgG and IgM responses of both groups were
similar throughout the study. Anti-KLH immunoglobulin responses were similar to
previous studies using this model in dogs (Finco-Kent and Kawabata, 2005; Kawai et al.,
2013), and CBD did not appear to exhibit immunosuppressive effects such as those seen
with known immunosuppressants cyclophosphamide and cyclosporine (Legrand et al.,
2012). While these results suggest CBD does not negatively impact the immune response
of dogs to immunization, the work is preliminary. This work utilized healthy, adult dogs
receiving no concommittant medication that might futher impact the immune response;
CBD may affect aged or diseased populations differently. Future work should investigate
the possibility of different responses to CBD supplementation in diseased, young, or aged
populations compared to healthy adults using common canine vaccines rather than KLH.
Additionally, our study utilized a single dose (mg/kg) of CBD supplemented over 5
weeks; longer-term CBD dosing using multiple CBD doses is necessary as well as futher
investigation into potential drug interactions. It would be beneficial for future work to
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evaluate B and T cell population changes with CBD supplementation as this will better
describe any potential impact on the immune system.
Conclusions
Results of the current study provide initial evidence that CBD does not negatively
impact the normal canine immune response to immunization when supplemented at 5
mg/kg BW/d. Neither total nor KLH-specific immunoglobulin production was reduced
by CBD supplementation. However, this work does highlight, alongside several other
studies in dogs, the potential for CBD to alter liver function and need for further safety
evaluations of CBD use in dogs. Considering these concerns and the increased use of
CBD in companion animals, continued investigation into the safety of CBD use in
companion animals is critical.
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Tables and Figures
Table 7.1. Schedule of events for evaluating immune response to immunization with a
novel antigen in dogs receiving cannabidiol containing treats compared to control.
Day of
Study

Event

-9 & -8

Intake Exams Baseline blood draw

Control

-7 – -1

Acclimation

None

Treatment

0

Primary
None
immunization

Treatment

7

Blood Draw

14
21
28

Data Collection

Day 7 post-primary immunization blood
draw

Blood Draw;
Day 14 post-primary immunization blood
Secondary
draw prior to secondary immunization
immunization
Day 7 post-secondary immunization blood
Blood Draw
draw
Blood Draw

Day 14 post-secondary immunization blood
draw
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Treats

Treatment
Treatment
Treatment
Treatment

Table 7.2. Complete blood count variables and their abbreviations.
Abbreviation

Variable

RBC, M/µL

Red blood cells

HCT, %

Hematocrit

HGB, g/dL

Hemoglobin

MCV, fL

Mean corpuscular volume

MCH, pg

Mean corpuscular hemoglobin

MCHC, g/dL

Mean corpuscular hemoglobin concentration

RDW, %

Red cell distribution width

RETIC %

Reticulocyte percentage

RETIC, K/µL

Reticulocytes

RETIC-HGB, pg

Reticulocyte/Hemoglobin ratio

WBC, K/µL

White blood cells

NEU, %

Percentage neutrophils

LYM, %

Percentage lymphocytes

MONO, %

Percentage monocytes

EOS, %

Percentage eosinophils

BASO, %

Percentage basophils

NEU, K/µL

Neutrophils

LYM, K/µL

Lymphocytes

MONO, K/µL

Monocytes

EOS, K/µL

Eosinophils

BASO, K/µL

Basophils

PLT, K/µL

Platelets

MPV, fL

Mean platelet volume

PDW, fL

Platelet distribution width

PCT, %

Plateletcrit
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Table 7.3. Effect of cannabidiol (CBD) treatment (Trt), day, and the treatment by day
(Trt*Day) interaction on hematology variables in dogs compared to control (CON).

CON

RBC, M/µL

IDEXX
Reference
Interval
5.65-8.87

6.98

HCT, %

37.3-61.7

HGB, g/dL

Variable

P-value
SEM

Trt

Day

Trt*Day

7.34

0.135

0.065

<.001

0.657

44.35

47.75

0.943

0.013

<.001

0.710

13.1-20.5

16.12

17.12

0.183

0.027

<.001

0.684

MCV, fL

61.6-73.5

63.56

64.92

0.655

0.141

<.001

0.717

MCH, pg

21.2-25.9

23.16

23.44

0.229

0.384

0.070

0.600

MCHC, g/dL

32.0-37.9

36.46

35.97

0.189

0.068

0.004

0.323

RDW, %

13.6-21.7

18.39

18.06

0.308

0.437

0.260

0.929

0.43

0.39

0.027

0.654

0.285

0.610

10.0-110.0

28.79

28.79

2.014

0.972

0.309

0.637

22.3-29.6

25.83

26.57

0.375

0.164

<.001

0.781

5.05-16.76

12.05

12.75

0.809

0.528

0.001

0.316

NEU, %

55.89

60.13

1.881

0.111

<.001

0.629

LYM, %

27.25

25.73

1.650

0.506

<.001

0.451

MONO, %

6.23

6.17

0.161

0.884

<.001

0.187

EOS, %

7.78

5.62

0.684

0.205

<.001

0.795

BASO, %

0.60

0.57

0.028

0.754

0.037

0.140

RETIC %
RETIC,
K/µL
RETICHGB, pg
WBC, K/µL

CBD

NEU, K/µL

2.95-11.64

6.39

7.41

0.292

0.231

<.001

0.493

LYM, K/µL
MONO,
K/µL
EOS, K/µL

1.05-5.10

2.97

2.92

0.132

0.883

<.001

0.100

0.16-1.12

0.72

0.76

0.023

0.582

<.001

0.065

0.06-1.23

0.89

0.72

0.087

0.403

<.001

0.551

BASO, K/µL

0.00-0.10

0.07

0.07

0.004

0.754

0.008

0.152

PLT, K/µL

148-484

259.5

225.1

13.346

0.071

0.040

0.755

MPV, fL

8.7-13.2

12.06

12.18

0.133

0.895

0.012

0.972

PDW, fL

9.1-19.4

12.06

12.18

0.202

0.800

0.006

0.027

PCT, %
0.14-0.46
0.31
0.27
0.015 0.044
0.104
0.730
RBC, red blood cells; HCT, hematocrit; HGB, hemoglobin; MCV, mean corpuscular
volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin
concentration; RDW, red cell distribution width; RETIC, reticulocyte; WBC, white blood
159

cells; NEU, neutrophils; LYM, lymphocytes; MONO, monocytes; EOS, eosinophils;
BASO, basophils; PLT, platelets; MPV, mean platelet volume; PDW, platelet distribution
width; PCT, plateletcrit
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Table 7.4 Effect of cannabidiol (CBD) treatment (Trt), day, and the treatment by day
(Trt*Day) interaction on serum chemistry variables indicative of liver function in dogs
compared to control (CON).
IDEXX
Reference
Interval

CON

CBD

SEM

Trt

Day

Trt*Day

Glucose, mg/dL

74-143

88.72

88.12

1.116

0.941

<.001

0.280

Creatinine, mg/dL

0.5-1.8

1.12

1.09

0.018

0.495

<.001

0.643

7-27

16.29

18.73

0.777

0.027

<.001

0.103

14.71

17.53

0.808

0.016

0.082

0.689

Variable

BUN, mg/dL
BUN/CREA

P-value

Total Protein, g/dL

5.2-8.2

6.75

6.69

0.066

0.667

0.003

0.996

Albumin, g/dL

2.3-4.0

3.44

3.24

0.066

0.017

<.001

0.044

Globulin, g/dL

2.5-4.5

3.46

3.29

0.072

0.455

<.001

0.047

1.00

0.99

0.045

0.818

<.001

<.001

ALB/GLOB
ALT, U/L

10-125

56.83

55.70

2.729

0.874

<.001

0.387

ALP, U/L

23-212

57.61

93.32

7.099

0.045

<.001

0.014

BUN, blood urea nitrogen; BUN/CREA, blood urea nitrogen/creatinine ratio;
ALB/GLOB, albumin/globulin ratio; ALT, alanine aminotransferase; ALP, alkaline
phosphatase
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Figure 7.1. Serum alkaline phosphatase (U/L) of control (CON) and cannabidiol (CBD)
treatments over time. Data were not normally distributed and were transformed by the
square root for statistical analysis, then back-transformed for reporting purposes.
Standard error (SE) of the back-transformed data was calculated as follows: SE = (backtransformed upper limit – back-transformed lower limit)/3.92. Alkaline phosphatase
levels remained within IDEXX normal reference range throughout the study and were
similar between treatments at baseline (day 0, P = 0.994) and day 7 (P = 0.183), but were
increased in CBD treatment on days 14, 21, and 28 compared to control (P = 0.006,
0.027, and 0.014, respectively). Asterisks (*) Indicate differences between treatments (P
< 0.05) on that day.

162

A.

B.
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Figure 7.2. Total serum A) IgG and B) IgM (mg/dL) of control (CON) and cannabidiol
(CBD) treatments over the 28-d experiment. Dogs were challenged with keyhole limpet
hemocyanin on days 0 and 14 after collection of blood samples. Both total IgG and total
IgM concentrations were altered by day (P < 0.001). Day of experiment altered both total
IgG and total IgM concentrations (P < 0.001). Total IgG was unaffected by both
treatment and the treatment by day interaction (P = 0.930 and 0.897, respectively). Total
IgM was not normally distributed and was log-transformed for statistical analysis, then
back-transformed for reporting purposes. Standard error (SE) of the back-transformed
data was calculated as follows: SE = (back-transformed upper limit – back-transformed
lower limit)/3.92. Total IgM was unaffected by treatment (P = 0.817) but a treatment by
day interaction was observed (P = 0.047).
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A.

B.
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Figure 7.3. Anti-Keyhole Limpet Hemocyanin (KLH) A) IgG and B) IgM (kU/mL) of
control (CON) and cannabidiol (CBD) treatments over the 28-d experiment. Dogs were
challenged with KLH on days 0 and 14 after collection of blood samples. Anti-KLH IgG
was not normally distributed and was transformed to the square root for statistical
analysis, then back-transformed for reporting purposes. Standard error (SE) of the backtransformed data was calculated as follows: SE = (back-transformed upper limit – backtransformed lower limit)/3.92. Day of experiment altered both anti-KLH IgG and IgM (P
< 0.001). Both anti-KLH IgG and IgM were unaffected by treatment (P = 0.422 and
0.879, respectively) and the treatment by day interaction (P = 0.510 and 0.927,
respectively).
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CHAPTER 8. SUMMARY AND CONCLUSIONS
Interest and use of CBD in companion animals is increasing due to suspected
benefits like antioxidant, anti-inflammatory, and anxiolytic effects. Yet despite increased
use and favorable public opinion, scientific literature detailing mechanisms of action are
inconsistent, and evidence of safety and efficacy of CBD use in dogs is shockingly
limited. Therefore, the primary goal of this dissertation was to investigate the potential
impact of industrial hemp-derived CBD treat supplementation on the health and wellbeing of dogs. This objective was accomplished through assessments of canine anxiety,
voluntary activity, metabolome, overall health indices, and immune response during CBD
supplementation.
To study the effect of oral CBD on canine health and well-being, industrial hempderived CBD extract was included in a dog treat formulation for supplementation.
Palatability of treats was first assessed when dogs were fed a variety of diet types.
Neither food consumption nor treat acceptance were altered by increasing CBD inclusion
in treats. These treats provide a simple, palatable method of administering oral CBD at
precise dosages for research, which is an improvement from use of oils that must either
be top-dressed or dosed via syringe.
Despite the lack of evidence regarding efficacy of CBD as an anxiolytic, canine
anxiety and noise aversion are some of the most common reasons that pet owners
administer CBD to their dogs (Kogan et al., 2019a). The second part of this series of
experiments was the first to investigate the potential anxiolytic effect of CBD in dogs
with noise aversion through the use of a noise-induced fear response test. Cannabidiol
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supplemented at 1.4 mg CBD/kg BW/d did not demonstrate an anxiolytic effect in this
model. The positive control, trazodone, decreased plasma cortisol, increased heart rate
variability variables, and increased duration of the relaxed behaviors, Other Eyes and tail
relaxed. Cannabidiol by itself decreased duration of relaxed behavior Other Eyes and did
not alter plasma cortisol. When supplemented in combination with trazodone, however,
CBD appeared to attenuate the effects of trazodone on plasma cortisol, which may be
indicative of cytochrome P450 inhibition by CBD that could lead to drug interactions.
Instead of decreasing heart rate and increasing heart rate variability as expected from an
anxiolytic, CBD increased heart rate and decreased some heart rate variability variables.
The lack of anxiolytic effect by CBD may have been a result of the low dose, short
duration of supplementation, or use of Latin square design.
The next study in this series of experiments did not show a change in voluntary
daily activity in dogs supplemented with 1.8 or 4.5 mg CBD/kg BW/d. The higher dose
tended to reduce voluntary activity during Quiet and Music periods, but this did not
translate to an overall daily effect. As this experiment utilized healthy animals to examine
voluntary daily activity, this effect may be more evident in dogs with mobility and
behavioral issues like osteoarthritis or anxiety. Unexpectedly, CBD reduced scratching,
which may indicate a possible antipruritic effect warranting investigation in dogs with
dermatological issues like skin allergies or atopic dermatitis.
Using the same cohort of dogs from the previous study, alteration of the plasma
metabolome was observed after 21 d of 4.5 mg CBD/kg BW/d supplementation.
Metabolites altered by CBD may suggest a potential influence on glucose, carbohydrate,
lipid, amino acid, vitamin, and nucleotide metabolism. Potential biomarkers identified
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may indicate potential pathways by which CBD may exert suspected anti-inflammatory,
antioxidant, anti-obesity, and antimicrobial effects. The identification of these metabolic
changes will help direct future research into the elucidation of potential mechanisms and
evaluation of the physiological relevance of these changes.
The last experiment in this series was one of the first to assess the potential risk
for CBD to diminish the normal immune response to immunization. When supplemented
to healthy dogs at 5 mg CBD/kg BW/d, both total and KLH-specific immunoglobulin
production were unaffected by CBD. While CBD demonstrated no immunosuppressive
effects after 5 weeks of supplementation, alkaline phosphatase was elevated in dogs
receiving CBD, highlighting the potential for CBD to alter liver function and need for
further safety and hepatoxicity evaluations of CBD use in dogs, particularly in aged or
diseased populations that may have compromised immune function.
While concerns of long-term safety remain as potential drug interactions and
altered liver function were observed, the potential therapeutic applications of CBD make
further investigation into these effects critical. Future work utilizing larger sample sizes
and several doses is needed to assess long-term safety and proper dosing of CBD in dogs.
Additionally, as our work utilized only healthy dogs, additional investigation is needed to
evaluate these potential therapeutic benefits in aged populations, dogs with diabetes, dogs
with atopic dermatitis, or other specific disorders.
In conclusion, this work provides initial evidence that industrial hemp-derived
CBD may impact the health and well-being of dogs. Formulating dog treats to include
CBD extract was shown to be a simple and palatable means of administering CBD that
can be used by both researchers and pet owners. Although CBD did not appear to
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influence behavioral measures in this work, it may have the potential to improve the wellbeing of dogs. As the use of CBD in companion animals continues to increase, increasing
our understanding of physiological mechanisms by which CBD exerts these effects is
crucial to further elucidate how CBD may improve animal health and well-being.
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